1	EDITORIALS	NNS	O	editorial	_	0	SENT_1	[p1l977t81r1179b100],

1	10	CD	NUMBER	10	_	0	SENT_2	[p1l237t177r270b199],
2	.	.	O	.	_	0	SENT_2	[p1l237t177r270b199],

1	Muscedere	NNP	O	Muscedere	nn	3	SENT_3	[p1l285t175r461b203],
2	]	CD	NUMBER	]	num	3	SENT_3	[p1l285t175r461b203],
3	G	NN	O	g	_	0	SENT_3	[p1l285t175r461b203],
4	,	,	O	,	_	0	SENT_3	[p1l285t175r461b203],
5	Mullen	JJ	PERSON	mullen	amod	7	SENT_3	[p1l469t175r594b203],
6	]	NN	O	]	nn	7	SENT_3	[p1l469t175r594b203],
7	B	NN	O	b	appos	3	SENT_3	[p1l469t175r594b203],
8	,	,	O	,	_	0	SENT_3	[p1l469t175r594b203],
9	Gan	NNP	LOCATION	Gan	nn	10	SENT_3	[p1l602t177r653b198],
10	K	NNP	LOCATION	K	appos	3	SENT_3	[p1l659t177r685b203],
11	,	,	O	,	_	0	SENT_3	[p1l659t177r685b203],
12	Slutsky	NNP	PERSON	Slutsky	nn	13	SENT_3	[p1l694t175r782b205],
13	AS	NNP	O	AS	appos	3	SENT_3	[p1l786t177r826b198],
14	.	.	O	.	_	0	SENT_3	[p1l786t177r826b198],

1	Tidal	JJ	MISC	tidal	amod	2	SENT_4	[p1l833t175r896b198],
2	ventilation	NN	O	ventilation	nsubj	17	SENT_4	[p1l901t175r1033b199],
3	at	IN	O	at	_	0	SENT_4	[p1l1039t180r1062b198],
4	expira	NN	O	expira	nn	5	SENT_4	[p1l1099t175r1174b205],
5	pressure	NN	O	pressure	prep_at	2	SENT_4	[p1l1234t183r1339b205],
6	on	IN	O	on	_	0	SENT_4	[p1l1353t183r1384b199],
7	regional	JJ	O	regional	amod	8	SENT_4	[p1l1397t175r1498b205],
8	distribution	NN	O	distribution	prep_on	5	SENT_4	[p1l1512t175r1657b199],
9	of	IN	O	of	_	0	SENT_4	[p1l1670t175r1700b199],
10	tidal	JJ	O	tidal	amod	11	SENT_4	[p1l1708t175r1761b199],
11	volume	NN	O	volume	prep_of	8	SENT_4	[p1l1773t175r1864b199],
12	and	CC	O	and	_	0	SENT_4	[p1l1877t175r1923b199],
13	low	JJ	O	low	amod	15	SENT_4	[p1l236t212r281b236],
14	airway	NN	O	airway	nn	15	SENT_4	[p1l286t212r366b242],
15	pressures	NNS	O	pressure	conj_and	11	SENT_4	[p1l371t220r488b242],
16	can	MD	O	can	aux	17	SENT_4	[p1l496t220r538b235],
17	augment	VB	O	augment	_	0	SENT_4	[p1l544t217r654b242],
18	lung	NN	O	lung	nn	19	SENT_4	[p1l659t212r716b242],
19	injury	NN	O	injury	dobj	17	SENT_4	[p1l721t212r795b242],
20	.	.	O	.	_	0	SENT_4	[p1l721t212r795b242],

1	Am	VBP	O	be	dep	7	SENT_5	[p1l802t214r861b239],
2	]	CD	NUMBER	]	num	7	SENT_5	[p1l802t214r861b239],
3	Respir	NNP	O	Respir	nn	7	SENT_5	[p1l866t212r947b242],
4	Crit	NNP	O	Crit	nn	7	SENT_5	[p1l952t212r999b236],
5	Care	NNP	O	Care	nn	7	SENT_5	[p1l1004t214r1060b236],
6	recrui	NN	O	recruus	nn	7	SENT_5	[p1l1098t212r1170b236],
7	ent	NN	O	ent	_	0	SENT_5	[p1l1205t217r1244b235],
8	in	IN	O	in	prep	7	SENT_5	[p1l1250t212r1274b235],
9	adult	JJ	O	adult	amod	11	SENT_5	[p1l1280t212r1344b236],
10	respiratory	JJ	O	respiratory	amod	11	SENT_5	[p1l1349t212r1483b242],
11	distress	NN	O	distress	dep	8	SENT_5	[p1l1489t212r1582b236],
12	syndrome	NN	O	syndrome	dep	11	SENT_5	[p1l1590t212r1718b242],
13	.	.	O	.	_	0	SENT_5	[p1l1590t212r1718b242],

1	Am	VBP	O	be	cop	2	SENT_6	[p1l1726t214r1785b239],
2	]	CD	NUMBER	]	dep	5	SENT_6	[p1l1726t214r1785b239],
3	Respir	NNP	O	Respir	nn	4	SENT_6	[p1l1791t212r1871b242],
4	Crit	NNP	O	Crit	nsubj	5	SENT_6	[p1l1877t212r1924b236],
5	Med	VBD	O	med	_	0	SENT_6	[p1l235t249r290b272],
6	1994	CD	DATE	1994	dobj	5	SENT_6	[p1l298t251r529b277],
7	;	:	O	;	_	0	SENT_6	[p1l298t251r529b277],
8	149:1327	CD	NUMBER	149:1327	num	9	SENT_6	[p1l298t251r529b277],
9	-34	CD	NUMBER	-34	dep	6	SENT_6	[p1l298t251r529b277],
10	.	.	O	.	_	0	SENT_6	[p1l298t251r529b277],

1	Care	NNP	O	Care	nn	2	SENT_7	[p1l1098t251r1154b272],
2	Med	NNP	O	Med	_	0	SENT_7	[p1l1160t249r1215b272],
3	1995	CD	DATE	1995	num	2	SENT_7	[p1l1223t251r1455b277],
4	;	:	O	;	_	0	SENT_7	[p1l1223t251r1455b277],
5	151:1807	CD	NUMBER	151:1807	number	6	SENT_7	[p1l1223t251r1455b277],
6	-14	CD	NUMBER	-14	dep	2	SENT_7	[p1l1223t251r1455b277],
7	.	.	O	.	_	0	SENT_7	[p1l1223t251r1455b277],

1	11	CD	NUMBER	11	_	0	SENT_8	[p1l237t289r270b309],
2	.	.	O	.	_	0	SENT_8	[p1l237t289r270b309],

1	Gattinoni	NNP	PERSON	Gattinoni	nn	2	SENT_9	[p1l286t286r404b309],
2	L	NNP	PERSON	L	_	0	SENT_9	[p1l411t288r432b314],
3	,	,	O	,	_	0	SENT_9	[p1l411t288r432b314],
4	D’Andrea	NNP	O	D’Andrea	nn	5	SENT_9	[p1l440t286r555b309],
5	L	NNP	O	L	appos	2	SENT_9	[p1l562t288r583b314],
6	,	,	O	,	_	0	SENT_9	[p1l562t288r583b314],
7	Pelosi	NNP	PERSON	Pelosi	nn	8	SENT_9	[p1l591t286r664b309],
8	P	NN	O	p	appos	5	SENT_9	[p1l670t288r689b314],
9	,	,	O	,	_	0	SENT_9	[p1l670t288r689b314],
10	Vitale	NNP	PERSON	Vitale	nn	11	SENT_9	[p1l696t286r767b309],
11	G	NNP	PERSON	G	appos	5	SENT_9	[p1l774t288r801b314],
12	,	,	O	,	_	0	SENT_9	[p1l774t288r801b314],
13	Pesenti	NNP	PERSON	Pesenti	nn	14	SENT_9	[p1l809t286r898b309],
14	A	NNP	O	A	appos	5	SENT_9	[p1l903t288r929b314],
15	,	,	O	,	_	0	SENT_9	[p1l903t288r929b314],
16	Fumagalli	NNP	PERSON	Fumagalli	appos	5	SENT_9	[p1l937t286r1060b316],
17	13	CD	NUMBER	13	num	16	SENT_9	[p1l1099t289r1133b309],
18	.	.	O	.	_	0	SENT_9	[p1l1099t289r1133b309],

1	Amato	NNP	ORGANIZATION	Amato	nn	2	SENT_10	[p1l1147t288r1229b309],
2	MBP	NN	ORGANIZATION	mbp	_	0	SENT_10	[p1l1236t288r1298b314],
3	,	,	O	,	_	0	SENT_10	[p1l1236t288r1298b314],
4	Barbas	NNP	ORGANIZATION	Barbas	nn	5	SENT_10	[p1l1307t286r1390b309],
5	CSV	NNP	ORGANIZATION	CSV	appos	2	SENT_10	[p1l1398t288r1451b314],
6	,	,	O	,	_	0	SENT_10	[p1l1398t288r1451b314],
7	Medeiros	NNP	PERSON	Medeiros	nn	8	SENT_10	[p1l1459t286r1574b309],
8	DM	NN	O	dm	appos	2	SENT_10	[p1l1581t288r1634b314],
9	,	,	O	,	_	0	SENT_10	[p1l1581t288r1634b314],
10	et	FW	O	et	nn	11	SENT_10	[p1l1643t291r1665b309],
11	al.	FW	O	al.	appos	2	SENT_10	[p1l1671t286r1698b309],
12	.	.	O	.	_	0	SENT_10	[p1l1671t286r1698b309],

1	Effect	NN	O	effect	_	0	SENT_11	[p1l1707t286r1779b309],
2	of	IN	O	of	_	0	SENT_11	[p1l1785t286r1814b309],
3	a	DT	O	a	det	4	SENT_11	[p1l1816t294r1829b309],
4	protecR	NN	O	protecr	prep_of	1	SENT_11	[p1l1835t291r1922b316, p1l235t325r260b348],
5	.	.	O	.	_	0	SENT_11	[p1l1835t291r1922b316, p1l235t325r260b348],

1	Regional	NNP	O	Regional	nn	2	SENT_12	[p1l269t323r379b353],
2	eﬂects	NNS	O	eﬂects	nsubj	12	SENT_12	[p1l387t323r466b346],
3	and	CC	O	and	_	0	SENT_12	[p1l474t323r519b347],
4	mechanism	NN	O	mechanism	conj_and	2	SENT_12	[p1l527t323r670b346],
5	of	IN	O	of	_	0	SENT_12	[p1l678t323r708b347],
6	positive	JJ	O	positive	amod	7	SENT_12	[p1l709t323r804b353],
7	end	NN	O	end	prep_of	4	SENT_12	[p1l812t323r895b347],
8	—	CD	NUMBER	—	num	11	SENT_12	[p1l812t323r895b347],
9	ex	FW	O	ex	nn	11	SENT_12	[p1l812t323r895b347],
10	iratory	JJ	O	iratory	amod	11	SENT_12	[p1l911t323r992b353],
11	pres	NNS	O	pre	dep	4	SENT_12	[p1l998t331r1060b353],
12	—	VBP	O	—	_	0	SENT_12	[p1l998t331r1060b353],
13	tive	JJ	O	tive	amod	16	SENT_12	[p1l1099t323r1281b347],
14	—	NN	O	—	nn	16	SENT_12	[p1l1099t323r1281b347],
15	ventilation	NN	O	ventilation	nn	16	SENT_12	[p1l1099t323r1281b347],
16	strategy	NN	O	strategy	dobj	12	SENT_12	[p1l1288t328r1384b353],
17	on	IN	O	on	_	0	SENT_12	[p1l1390t331r1421b347],
18	mortality	NN	O	mortality	prep_on	16	SENT_12	[p1l1427t323r1540b353],
19	in	IN	O	in	_	0	SENT_12	[p1l1545t323r1569b346],
20	the	DT	O	the	det	23	SENT_12	[p1l1575t323r1613b346],
21	acute	JJ	O	acute	amod	23	SENT_12	[p1l1619t328r1683b347],
22	respiratory	JJ	O	respiratory	amod	23	SENT_12	[p1l1689t323r1823b353],
23	distress	NN	O	distress	nn	30	SENT_12	[p1l1829t323r1922b347],
24	sure	JJ	O	sure	amod	30	SENT_12	[p1l236t368r287b384],
25	in	IN	O	in	_	0	SENT_12	[p1l297t360r321b383],
26	earl	NN	O	earl	nn	28	SENT_12	[p1l331t360r376b383],
27	adult	JJ	O	adult	amod	28	SENT_12	[p1l398t360r461b384],
28	respirato	NN	O	respirato	prep_in	24	SENT_12	[p1l470t360r579b390],
29	istress	NN	O	istress	nn	30	SENT_12	[p1l628t360r706b383],
30	syndrome	NN	O	syndrome	prep_in	18	SENT_12	[p1l717t360r845b390],
31	.	.	O	.	_	0	SENT_12	[p1l717t360r845b390],

1	J	NNP	O	J	_	0	SENT_13	[p1l854t362r865b387],
2	1993	CD	DATE	1993	num	1	SENT_13	[p1l938t362r1059b388],
3	;	:	O	;	_	0	SENT_13	[p1l938t362r1059b388],
4	269	CD	NUMBER	269	dep	1	SENT_13	[p1l938t362r1059b388],
5	:	:	O	:	_	0	SENT_13	[p1l938t362r1059b388],
6	syndrom	NN	O	syndrom	dep	4	SENT_13	[p1l1099t360r1207b390],
7	.	.	O	.	_	0	SENT_13	[p1l1223t362r1257b384],

1	N	NN	O	n	_	0	SENT_14	[p1l1223t362r1257b384],
2	En	IN	O	en	_	0	SENT_14	[p1l1264t362r1296b383],
3	Med	JJ	O	med	amod	4	SENT_14	[p1l1341t360r1395b384],
4	1998	CD	DATE	1998	prep_en	1	SENT_14	[p1l1403t362r1620b388],
5	;	:	O	;	_	0	SENT_14	[p1l1403t362r1620b388],
6	338:347	CD	NUMBER	338:347	number	7	SENT_14	[p1l1403t362r1620b388],
7	—	CD	NUMBER	—	dep	1	SENT_14	[p1l1403t362r1620b388],
8	54	CD	NUMBER	54	dep	7	SENT_14	[p1l1403t362r1620b388],
9	.	.	O	.	_	0	SENT_14	[p1l1403t362r1620b388],

1	2122-7	CD	NUMBER	2122-7	_	0	SENT_15	[p1l236t399r329b420],
2	.	.	O	.	_	0	SENT_15	[p1l236t399r329b420],

1	rratum	NN	O	rratum	_	0	SENT_16	[p1l365t402r456b425],
2	,	,	O	,	_	0	SENT_16	[p1l365t402r456b425],
3	A	DT	O	a	det	4	SENT_16	[p1l517t399r536b420],
4	199	CD	NUMBER	199	appos	1	SENT_16	[p1l543t399r587b420],
5	;	:	O	;	_	0	SENT_16	[p1l606t407r610b425],
6	0:1814	CD	NUMBER	0:1814	dep	1	SENT_16	[p1l643t399r744b424],
7	.	.	O	.	_	0	SENT_16	[p1l643t399r744b424],
8	]	SYM	O	]	dep	1	SENT_16	[p1l643t399r744b424],

1	Copyright	NN	O	copyright	_	0	SENT_17	[p1l1099t401r1192b426],
2	©	CD	NUMBER	©	num	4	SENT_17	[p1l1200t403r1221b424],
3	Z004	NN	O	z004	nn	4	SENT_17	[p1l1230t402r1279b420],
4	assachusetts	NNS	O	assachusett	dep	1	SENT_17	[p1l1307t401r1427b420],
5	Medical	JJ	ORGANIZATION	medical	amod	6	SENT_17	[p1l1435t401r1512b420],
6	Society	NNP	ORGANIZATION	Society	dep	4	SENT_17	[p1l1519t402r1590b426],
7	.	.	O	.	_	0	SENT_17	[p1l1519t402r1590b426],

1	12	CD	NUMBER	12	_	0	SENT_18	[p1l237t437r270b457],
2	.	.	O	.	_	0	SENT_18	[p1l237t437r270b457],

1	Gattinoni	NNP	PERSON	Gattinoni	nn	2	SENT_19	[p1l286t434r404b457],
2	L	NNP	PERSON	L	_	0	SENT_19	[p1l411t436r432b462],
3	,	,	O	,	_	0	SENT_19	[p1l411t436r432b462],
4	Pe	NNP	O	Pe	appos	2	SENT_19	[p1l441t436r469b457],
5	si	FW	O	si	dep	4	SENT_19	[p1l494t434r513b457],
6	P	NN	O	p	dep	2	SENT_19	[p1l520t436r539b462],
7	,	,	O	,	_	0	SENT_19	[p1l520t436r539b462],
8	Crotti	NNP	PERSON	Crotti	nn	9	SENT_19	[p1l547t434r618b457],
9	S	NNP	O	S	appos	6	SENT_19	[p1l626t436r646b462],
10	,	,	O	,	_	0	SENT_19	[p1l626t436r646b462],
11	Valenze	NNP	O	Valenze	nn	13	SENT_19	[p1l653t434r748b457],
12	F.	NNP	O	F.	nn	13	SENT_19	[p1l755t436r773b457],
13	Effects	NNS	O	effect	appos	6	SENT_19	[p1l782t434r864b457],
14	of	IN	O	of	_	0	SENT_19	[p1l872t434r902b457],
15	positive	JJ	O	positive	amod	16	SENT_19	[p1l903t434r998b463],
16	endNew	NN	O	endnew	prep_of	13	SENT_19	[p1l1005t434r1060b457, p1l481t534r599b579],

1	Treatment	NN	O	treatment	nn	2	SENT_20	[p1l615t534r884b579],
2	Options	NNS	O	option	_	0	SENT_20	[p1l901t531r1114b593],
3	for	IN	O	for	_	0	SENT_20	[p1l1132t529r1206b579],
4	Colorectal	JJ	O	colorectal	amod	5	SENT_20	[p1l1222t530r1482b579],
5	Cancer	NN	O	cancer	prep_for	2	SENT_20	[p1l1502t534r1684b579],

1	Charles	NNP	PERSON	Charles	nn	2	SENT_21	[p1l621t607r746b638],
2	Erlichman	NNP	PERSON	Erlichman	_	0	SENT_21	[p1l763t607r941b644],
3	,	,	O	,	_	0	SENT_21	[p1l763t607r941b644],
4	M.D.	NNP	O	M.D.	appos	2	SENT_21	[p1l958t610r1048b644],
5	,	,	O	,	_	0	SENT_21	[p1l958t610r1048b644],
6	and	CC	O	and	_	0	SENT_21	[p1l1063t607r1123b638],
7	Daniel	NNP	PERSON	Daniel	nn	8	SENT_21	[p1l1140t607r1278b647],
8	]	NNP	O	]	appos	2	SENT_21	[p1l1140t607r1278b647],
9	.	.	O	.	_	0	SENT_21	[p1l1140t607r1278b647],

1	Sargent	NNP	PERSON	Sargent	_	0	SENT_22	[p1l1292t609r1430b648],
2	,	,	O	,	_	0	SENT_22	[p1l1292t609r1430b648],
3	Ph.D.	NNP	O	Ph.D.	appos	1	SENT_22	[p1l1447t607r1536b638],
4	.	.	O	.	_	0	SENT_22	[p1l1447t607r1536b638],

1	Epidermal	JJ	O	epidermal	amod	3	SENT_23	[p1l9t710r440b810],
2	growth	NN	O	growth	nn	3	SENT_23	[p1l462t710r759b811],
3	factor	NN	O	factor	nsubj	10	SENT_23	[p1l782t709r1022b788],
4	receptor	NN	O	receptor	nn	7	SENT_23	[p1l1041t727r1384b810],
5	(	CD	NUMBER	(	num	7	SENT_23	[p1l1409t715r1709b801],
6	EGFR	NN	ORGANIZATION	egfr	nn	7	SENT_23	[p1l1409t715r1709b801],
7	)	NN	O	)	dep	3	SENT_23	[p1l1409t715r1709b801],
8	is	VBZ	O	be	cop	10	SENT_23	[p1l1736t711r1800b788],
9	a	DT	O	a	det	10	SENT_23	[p1l1824t736r1868b788],
10	member	NN	O	member	_	0	SENT_23	[p1l1890t736r2134b788, p1l11t838r147b916],
11	of	IN	O	of	_	0	SENT_23	[p1l176t837r278b916],
12	the	DT	O	the	det	14	SENT_23	[p1l291t838r422b916],
13	HER	NN	O	her	nn	14	SENT_23	[p1l453t845r663b921],
14	family	NN	O	family	prep_of	10	SENT_23	[p1l684t837r954b938],
15	of	IN	O	of	_	0	SENT_23	[p1l982t837r1084b916],
16	tyrosine	NN	O	tyrosine	nn	23	SENT_23	[p1l1097t839r1440b938],
17	kinase	NN	O	kinase	nn	23	SENT_23	[p1l1471t838r1747b917],
18	cell	NN	O	cell	nn	23	SENT_23	[p1l1779t838r2132b917],
19	—	NN	O	—	nn	23	SENT_23	[p1l1779t838r2132b917],
20	sur	NN	O	sur	nn	23	SENT_23	[p1l1779t838r2132b917],
21	—	CD	NUMBER	—	num	23	SENT_23	[p1l1779t838r2132b917],
22	face	NN	O	face	nn	23	SENT_23	[p1l10t965r180b1044],
23	receptors	NNS	O	receptor	prep_of	14	SENT_23	[p1l205t983r603b1066],
24	that	WDT	O	that	nsubjpass	26	SENT_23	[p1l632t966r802b1044],
25	are	VBP	O	be	auxpass	26	SENT_23	[p1l822t992r950b1044],
26	dysregulated	VBN	O	dysregulate	rcmod	10	SENT_23	[p1l976t966r1524b1067],
27	in	IN	O	in	_	0	SENT_23	[p1l1548t967r1631b1043],
28	many	JJ	O	many	amod	29	SENT_23	[p1l1656t992r1893b1066],
29	types	NNS	O	type	prep_in	26	SENT_23	[p1l1915t983r2131b1066],
30	of	IN	O	of	_	0	SENT_23	[p1l11t1093r113b1172],
31	tumor	NN	O	tumor	prep_of	29	SENT_23	[p1l123t1110r413b1189],
32	;	:	O	;	_	0	SENT_23	[p1l123t1110r413b1189],
33	its	PRP$	O	its	poss	34	SENT_23	[p1l445t1095r544b1172],
34	expression	NN	O	expression	nsubjpass	37	SENT_23	[p1l574t1095r1038b1194],
35	has	VBZ	O	have	aux	37	SENT_23	[p1l1066t1094r1209b1172],
36	been	VBN	O	be	auxpass	37	SENT_23	[p1l1240t1094r1443b1172],
37	associated	VBN	O	associate	parataxis	10	SENT_23	[p1l1471t1094r1917b1172],
38	with	IN	O	with	_	0	SENT_23	[p1l1941t1094r2133b1173],
39	a	DT	O	a	det	41	SENT_23	[p1l10t1248r54b1300],
40	poor	JJ	O	poor	amod	41	SENT_23	[p1l93t1248r298b1322],
41	prognosis	NN	O	prognosis	prep_with	37	SENT_23	[p1l335t1223r767b1323],
42	in	IN	O	in	_	0	SENT_23	[p1l810t1223r892b1299],
43	colon	NN	O	colon	nn	44	SENT_23	[p1l935t1222r1173b1300],
44	cancer	NN	O	cancer	prep_in	41	SENT_23	[p1l1215t1217r1560b1300],
45	.1	CD	NUMBER	.1	num	44	SENT_23	[p1l1215t1217r1560b1300],
46	There	EX	O	there	expl	47	SENT_23	[p1l1598t1222r1847b1300],
47	are	VBP	O	be	rcmod	41	SENT_23	[p1l1889t1248r2017b1300],
48	at	IN	O	at	quantmod	50	SENT_23	[p1l2058t1238r2138b1300],
49	least	JJS	O	least	mwe	48	SENT_23	[p1l9t1350r204b1428],
50	two	CD	NUMBER	two	num	51	SENT_23	[p1l228t1366r379b1429],
51	opportunities	NNS	O	opportunity	nsubj	47	SENT_23	[p1l410t1351r974b1450],
52	to	TO	O	to	aux	53	SENT_23	[p1l1005t1366r1084b1428],
53	interfere	VB	O	interfere	infmod	51	SENT_23	[p1l1113t1349r1467b1428],
54	with	IN	O	with	_	0	SENT_23	[p1l1491t1350r1679b1429],
55	EGFR	NN	ORGANIZATION	egfr	nn	56	SENT_23	[p1l1706t1355r1964b1433],
56	signaling	NN	O	signaling	prep_with	53	SENT_23	[p1l1983t1351r2134b1451, p1l10t1478r286b1579],
57	that	WDT	O	that	nsubjpass	60	SENT_23	[p1l317t1478r487b1556],
58	are	VBP	O	be	aux	60	SENT_23	[p1l515t1504r642b1556],
59	being	VBG	O	be	auxpass	60	SENT_23	[p1l677t1478r920b1579],
60	exploited	VBN	O	exploit	rcmod	56	SENT_23	[p1l951t1478r1346b1578],
61	clinically	RB	O	clinically	advmod	60	SENT_23	[p1l1380t1473r1823b1578],
62	?	.	O	?	_	0	SENT_23	[p1l1380t1473r1823b1578],

1	In	IN	O	in	_	0	SENT_24	[p1l1856t1485r1944b1555],
2	one	CD	NUMBER	one	num	3	SENT_24	[p1l1978t1503r2133b1556],
3	approach	NN	O	approach	prep_in	10	SENT_24	[p1l9t1606r438b1705],
4	,	,	O	,	_	0	SENT_24	[p1l9t1606r438b1705],
5	the	DT	O	the	det	8	SENT_24	[p1l499t1606r630b1683],
6	extracellular	JJ	O	extracellular	amod	8	SENT_24	[p1l686t1606r1218b1685],
7	receptor	NN	O	receptor	nn	8	SENT_24	[p1l1271t1622r1629b1705],
8	domain	NN	O	domain	nsubjpass	10	SENT_24	[p1l1682t1606r2011b1683],
9	is	VBZ	O	be	auxpass	10	SENT_24	[p1l2065t1607r2131b1683],
10	bound	VBN	O	bind	_	0	SENT_24	[p1l11t1734r283b1813],
11	by	IN	O	by	_	0	SENT_24	[p1l305t1734r402b1833],
12	antibodies	NNS	O	antibody	agent	10	SENT_24	[p1l418t1734r883b1828],
13	,	,	O	,	_	0	SENT_24	[p1l418t1734r883b1828],
14	such	JJ	O	such	_	0	SENT_24	[p1l911t1734r1105b1812],
15	as	IN	O	as	_	0	SENT_24	[p1l1126t1760r1210b1811],
16	cetuximab	NN	O	cetuximab	prep_such_as	12	SENT_24	[p1l1234t1734r1693b1829],
17	,	,	O	,	_	0	SENT_24	[p1l1234t1734r1693b1829],
18	that	WDT	O	that	nsubj	19	SENT_24	[p1l1721t1734r1887b1811],
19	block	VBP	O	block	rcmod	16	SENT_24	[p1l1904t1734r2139b1813],
20	ligand	NN	O	ligand	nn	21	SENT_24	[p1l9t1862r705b1963],
21	—	NN	O	—	nsubj	22	SENT_24	[p1l9t1862r705b1963],
22	mediated	VBD	O	mediate	ccomp	19	SENT_24	[p1l9t1862r705b1963],
23	dimerization	NN	O	dimerization	nn	26	SENT_24	[p1l738t1862r1280b1940],
24	and	CC	O	and	_	0	SENT_24	[p1l1311t1862r1466b1940],
25	subsequent	JJ	O	subsequent	nn	26	SENT_24	[p1l1499t1862r1986b1962],
26	activation	NN	O	activation	dobj	22	SENT_24	[p1l2012t1888r2133b1940, p1l11t1991r326b2069],
27	of	IN	O	of	_	0	SENT_24	[p1l353t1989r453b2068],
28	the	DT	O	the	det	29	SENT_24	[p1l463t1990r592b2068],
29	receptor	NN	O	receptor	prep_of	26	SENT_24	[p1l619t2006r986b2090],
30	.	.	O	.	_	0	SENT_24	[p1l619t2006r986b2090],

1	In	IN	O	in	_	0	SENT_25	[p1l1018t1997r1105b2067],
2	the	DT	O	the	det	3	SENT_25	[p1l1133t1990r1262b2068],
3	second	JJ	ORDINAL	second	prep_in	10	SENT_25	[p1l1290t1990r1609b2085],
4	,	,	O	,	_	0	SENT_25	[p1l1290t1990r1609b2085],
5	the	DT	O	the	det	8	SENT_25	[p1l1642t1990r1772b2068],
6	tyrosine	NN	O	tyrosine	nn	8	SENT_25	[p1l1800t1991r2134b2090],
7	kinase	NN	O	kinase	nn	8	SENT_25	[p1l10t2118r281b2197],
8	domain	NN	O	domain	nsubjpass	10	SENT_25	[p1l303t2118r627b2196],
9	is	VBZ	O	be	auxpass	10	SENT_25	[p1l648t2119r713b2196],
10	bound	VBN	O	bind	_	0	SENT_25	[p1l737t2118r1009b2197],
11	by	IN	O	by	_	0	SENT_25	[p1l1032t2118r1128b2218],
12	drugs	NNS	O	drug	agent	10	SENT_25	[p1l1147t2118r1384b2219],
13	that	WDT	O	that	nsubj	14	SENT_25	[p1l1409t2118r1575b2196],
14	inhibit	VBP	O	inhibit	rcmod	12	SENT_25	[p1l1591t2118r1877b2196],
15	phosphorylation	NN	O	phosphorylation	dobj	14	SENT_25	[p1l1892t2118r2133b2218, p1l9t2246r523b2346],
16	,	,	O	,	_	0	SENT_25	[p1l1892t2118r2133b2218, p1l9t2246r523b2346],
17	such	JJ	O	such	_	0	SENT_25	[p1l555t2246r750b2325],
18	as	IN	O	as	_	0	SENT_25	[p1l774t2272r857b2324],
19	geﬁtinib	NN	O	geﬁtinib	prep_such_as	12	SENT_25	[p1l885t2245r1239b2347],
20	and	CC	O	and	_	0	SENT_25	[p1l1265t2246r1421b2324],
21	erlotinib	NN	O	erlotinib	prep_such_as	12	SENT_25	[p1l1446t2246r1830b2324],
22	.	.	O	.	_	0	SENT_25	[p1l1446t2246r1830b2324],

1	Irinotecan	NNP	MISC	Irinotecan	nsubj	6	SENT_26	[p1l138t2375r571b2451],
2	is	VBZ	O	be	cop	6	SENT_26	[p1l616t2375r680b2451],
3	a	DT	O	a	det	6	SENT_26	[p1l727t2400r771b2451],
4	topoisomerase	NN	O	topoisomerase	nn	6	SENT_26	[p1l814t2375r1438b2473],
5	1	CD	NUMBER	1	num	6	SENT_26	[p1l1481t2381r1512b2450],
6	inhibitor	NN	O	inhibitor	_	0	SENT_26	[p1l1555t2374r1930b2451],
7	that	WDT	O	that	nsubjpass	10	SENT_26	[p1l1973t2374r2139b2451],
8	has	VBZ	O	have	aux	10	SENT_26	[p1l11t2502r152b2580],
9	been	VBN	O	be	auxpass	10	SENT_26	[p1l185t2502r384b2580],
10	approved	VBN	O	approve	rcmod	6	SENT_26	[p1l413t2502r804b2602],
11	for	IN	O	for	_	0	SENT_26	[p1l834t2501r957b2580],
12	the	DT	O	the	det	13	SENT_26	[p1l985t2502r1114b2580],
13	treatment	NN	O	treatment	prep_for	10	SENT_26	[p1l1145t2519r1559b2580],
14	of	IN	O	of	_	0	SENT_26	[p1l1584t2501r1685b2580],
15	metastatic	JJ	O	metastatic	amod	17	SENT_26	[p1l1697t2503r2135b2580],
16	Colorectal	JJ	O	colorectal	amod	17	SENT_26	[p1l11t2630r417b2708],
17	cancer	NN	O	cancer	prep_of	13	SENT_26	[p1l438t2655r709b2708],
18	when	WRB	O	when	advmod	19	SENT_26	[p1l721t2630r953b2709],
19	given	VBN	O	give	advcl	10	SENT_26	[p1l973t2631r1193b2731],
20	either	CC	O	either	prep	19	SENT_26	[p1l1214t2630r1453b2708],
21	alone	RB	O	alone	dep	20	SENT_26	[p1l1470t2630r1694b2708],
22	or	CC	O	or	_	0	SENT_26	[p1l1716t2655r1804b2708],
23	in	IN	O	in	advcl	10	SENT_26	[p1l1821t2631r1901b2707],
24	combination	NN	O	combination	pobj	23	SENT_26	[p1l1922t2655r2134b2708, p1l11t2758r364b2836],
25	with	IN	O	with	_	0	SENT_26	[p1l391t2758r580b2837],
26	ﬂuorouracil	NN	O	ﬂuorouracil	prep_with	23	SENT_26	[p1l611t2757r1109b2837],
27	and	CC	O	and	_	0	SENT_26	[p1l1138t2758r1294b2836],
28	leucovorin	NN	O	leucovorin	conj_and	26	SENT_26	[p1l1324t2758r1791b2837],
29	.	.	O	.	_	0	SENT_26	[p1l1324t2758r1791b2837],

1	Studies	NNS	O	study	nsubj	3	SENT_27	[p1l1831t2758r2132b2837],
2	have	VBP	O	have	aux	3	SENT_27	[p1l10t2886r198b2965],
3	shown	VBN	O	show	_	0	SENT_27	[p1l228t2886r508b2965],
4	that	IN	O	that	_	0	SENT_27	[p1l536t2886r702b2964],
5	the	DT	O	the	det	6	SENT_27	[p1l725t2886r854b2964],
6	addition	NN	O	addition	prep_that	3	SENT_27	[p1l881t2886r1234b2964],
7	of	IN	O	of	_	0	SENT_27	[p1l1262t2885r1363b2964],
8	irinotecan	NN	O	irinotecan	prep_of	6	SENT_27	[p1l1371t2887r1799b2964],
9	to	TO	O	to	_	0	SENT_27	[p1l1827t2903r1906b2964],
10	ﬂuorouracil	NN	O	ﬂuorouracil	prep_to	3	SENT_27	[p1l1934t2885r2133b2965, p1l11t3014r337b3093],

1	and	CC	O	and	dep	2	SENT_28	[p1l370t3014r526b3091],
2	leucovorin	NN	O	leucovorin	_	0	SENT_28	[p1l558t3014r1002b3093],
3	increases	VBZ	O	increase	rcmod	2	SENT_28	[p1l1035t3015r1422b3091],
4	the	DT	O	the	det	7	SENT_28	[p1l1458t3014r1587b3091],
5	objective	JJ	O	objective	amod	7	SENT_28	[p1l1622t3014r1988b3113],
6	response	NN	O	response	nn	7	SENT_28	[p1l2022t3039r2133b3091, p1l12t3168r312b3243],
7	rate	NN	O	rate	dobj	3	SENT_28	[p1l349t3159r533b3238],
8	,	,	O	,	_	0	SENT_28	[p1l349t3159r533b3238],
9	the	DT	O	the	det	10	SENT_28	[p1l576t3143r707b3221],
10	time	NN	O	time	dobj	3	SENT_28	[p1l745t3144r934b3221],
11	to	TO	O	to	_	0	SENT_28	[p1l972t3159r1052b3221],
12	tumor	NN	O	tumor	nn	13	SENT_28	[p1l1090t3159r1358b3222],
13	progression	NN	O	progression	prep_to	10	SENT_28	[p1l1390t3144r1934b3244],
14	,	,	O	,	_	0	SENT_28	[p1l1390t3144r1934b3244],
15	and	CC	O	and	_	0	SENT_28	[p1l1975t3143r2134b3221],
16	overall	JJ	O	overall	amod	18	SENT_28	[p1l11t3271r289b3350],
17	survival	NN	O	survival	nn	18	SENT_28	[p1l315t3266r766b3350],
18	.3	NN	NUMBER	.3	conj_and	7	SENT_28	[p1l315t3266r766b3350],
19	’	CD	NUMBER	’	number	20	SENT_28	[p1l315t3266r766b3350],
20	4	CD	NUMBER	4	dep	18	SENT_28	[p1l315t3266r766b3350],

1	Cetuximab	NNP	O	Cetuximab	nsubjpass	4	SENT_29	[p1l140t3400r588b3479],
2	has	VBZ	O	have	aux	4	SENT_29	[p1l616t3400r755b3478],
3	been	VBN	O	be	auxpass	4	SENT_29	[p1l784t3400r981b3478],
4	shown	VBN	O	show	_	0	SENT_29	[p1l1009t3400r1285b3479],
5	to	TO	O	to	aux	6	SENT_29	[p1l1312t3416r1390b3478],
6	enhance	VB	O	enhance	xcomp	4	SENT_29	[p1l1418t3400r1764b3478],
7	the	DT	O	the	det	8	SENT_29	[p1l1791t3400r1919b3478],
8	antitumor	NN	O	antitumor	dobj	6	SENT_29	[p1l1944t3401r2134b3478, p1l11t3543r270b3606],

1	activity	NN	O	activity	nsubj	14	SENT_30	[p1l302t3528r591b3626],
2	of	IN	O	of	_	0	SENT_30	[p1l622t3526r722b3605],
3	irinotecan	NN	O	irinotecan	prep_of	1	SENT_30	[p1l738t3528r1158b3604],
4	in	IN	O	in	_	0	SENT_30	[p1l1192t3528r1273b3603],
5	preclinical	JJ	O	preclinical	amod	6	SENT_30	[p1l1307t3527r1740b3626],
6	studies	NNS	O	study	prep_in	3	SENT_30	[p1l1777t3522r2131b3606],
7	.5	CD	NUMBER	.5	amod	6	SENT_30	[p1l1777t3522r2131b3606],
8	The	DT	O	the	det	9	SENT_30	[p1l7t3655r171b3733],
9	mechanism	NN	O	mechanism	dep	7	SENT_30	[p1l208t3655r710b3733],
10	underlying	VBG	O	underlie	dep	9	SENT_30	[p1l747t3655r1216b3756],
11	this	DT	O	this	det	12	SENT_30	[p1l1250t3655r1405b3733],
12	enhancement	NN	O	enhancement	dobj	10	SENT_30	[p1l1445t3655r2034b3733],
13	is	VBZ	O	be	cop	14	SENT_30	[p1l2065t3656r2131b3733],
14	unclear	JJ	O	unclear	_	0	SENT_30	[p2l11t21r334b117],
15	,	,	O	,	_	0	SENT_30	[p2l11t21r334b117],
16	but	CC	O	but	_	0	SENT_30	[p2l364t21r503b100],
17	it	PRP	O	it	nsubj	19	SENT_30	[p2l520t22r580b99],
18	may	MD	O	may	aux	19	SENT_30	[p2l598t47r772b121],
19	involve	VB	O	involve	conj_but	14	SENT_30	[p2l791t21r1080b100],
20	an	DT	O	a	det	22	SENT_30	[p2l1103t47r1203b99],
21	antiapoptotic	JJ	O	antiapoptotic	amod	22	SENT_30	[p2l1225t22r1778b121],
22	effect	NN	O	effect	dobj	19	SENT_30	[p2l1801t20r2031b99],
23	or	CC	O	or	_	0	SENT_30	[p2l2050t46r2138b99],
24	the	DT	O	the	det	27	SENT_30	[p2l11t149r138b227],
25	independent	JJ	O	independent	amod	27	SENT_30	[p2l161t149r690b249],
26	antiangiogenic	JJ	O	antiangiogenic	amod	27	SENT_30	[p2l707t150r1328b250],
27	effect	NN	O	effect	dobj	19	SENT_30	[p2l1352t148r1581b227],
28	of	IN	O	of	_	0	SENT_30	[p2l1601t148r1700b227],
29	the	DT	O	the	det	30	SENT_30	[p2l1706t149r1833b227],
30	inhibition	NN	O	inhibition	prep_of	27	SENT_30	[p2l1856t149r2134b227, p2l11t278r174b355],
31	of	IN	O	of	_	0	SENT_30	[p2l194t276r294b355],
32	EGFR	NN	ORGANIZATION	egfr	nn	33	SENT_30	[p2l293t282r550b360],
33	signaling	NN	O	signaling	prep_of	30	SENT_30	[p2l561t277r968b378],
34	.	.	O	.	_	0	SENT_30	[p2l561t277r968b378],

1	The	DT	O	the	det	3	SENT_31	[p2l990t277r1149b355],
2	experimental	JJ	O	experimental	amod	3	SENT_31	[p2l1170t277r1715b377],
3	paradigm	NN	O	paradigm	nsubj	53	SENT_31	[p2l1733t277r2135b378],
4	of	IN	O	of	_	0	SENT_31	[p2l11t404r110b483],
5	combining	VBG	O	combine	prepc_of	3	SENT_31	[p2l133t405r590b506],
6	agents	NNS	O	agent	dobj	5	SENT_31	[p2l626t421r895b506],
7	that	WDT	O	that	nsubj	8	SENT_31	[p2l938t405r1102b483],
8	interfere	VBP	O	interfere	rcmod	6	SENT_31	[p2l1136t404r1487b483],
9	with	IN	O	with	_	0	SENT_31	[p2l1523t405r1710b484],
10	signaling	NN	O	signaling	nn	11	SENT_31	[p2l1751t405r2138b506],
11	pathways	NNS	O	pathway	prep_with	8	SENT_31	[p2l9t533r395b632],
12	that	WDT	O	that	nsubj	13	SENT_31	[p2l421t533r585b610],
13	make	VBP	O	make	rcmod	11	SENT_31	[p2l604t533r830b612],
14	cells	NNS	O	cell	nsubj	15	SENT_31	[p2l854t533r1033b610],
15	resistant	JJ	O	resistant	xcomp	13	SENT_31	[p2l1059t534r1420b610],
16	to	TO	O	to	_	0	SENT_31	[p2l1439t549r1516b610],
17	chemotherapy	NN	O	chemotherapy	prep_to	15	SENT_31	[p2l1542t533r2140b632],
18	or	CC	O	or	_	0	SENT_31	[p2l11t686r101b739],
19	agents	NNS	O	agent	conj_or	17	SENT_31	[p2l133t677r411b762],
20	that	WDT	O	that	nsubj	21	SENT_31	[p2l449t661r619b739],
21	target	VBP	O	target	rcmod	17	SENT_31	[p2l650t677r904b762],
22	a	DT	O	a	det	23	SENT_31	[p2l934t687r978b739],
23	mechanism	NN	O	mechanism	dobj	21	SENT_31	[p2l1012t661r1514b739],
24	that	WDT	O	that	nsubj	26	SENT_31	[p2l1550t661r1720b739],
25	independently	RB	O	independently	advmod	26	SENT_31	[p2l1749t661r2132b761, p2l11t789r266b889],
26	inﬂuences	VBZ	O	inﬂuences	rcmod	23	SENT_31	[p2l280t788r706b868],
27	tumor	NN	O	tumor	nn	28	SENT_31	[p2l728t805r987b868],
28	growth	NN	O	growth	nsubj	36	SENT_31	[p2l1004t789r1325b890],
29	,	,	O	,	_	0	SENT_31	[p2l1004t789r1325b890],
30	such	JJ	O	such	_	0	SENT_31	[p2l1352t789r1544b868],
31	as	IN	O	as	_	0	SENT_31	[p2l1564t815r1647b867],
32	angiogenesis	NN	O	angiogenesis	prep_such_as	28	SENT_31	[p2l1668t790r2134b890, p2l12t919r141b1012],
33	,	,	O	,	_	0	SENT_31	[p2l1668t790r2134b890, p2l12t919r141b1012],
34	has	VBZ	O	have	aux	36	SENT_31	[p2l167t917r306b995],
35	been	VBN	O	be	aux	36	SENT_31	[p2l329t917r526b995],
36	gaining	VBG	O	gain	ccomp	26	SENT_31	[p2l546t919r865b1018],
37	traction	NN	O	traction	dobj	36	SENT_31	[p2l883t919r1203b995],
38	in	IN	O	in	_	0	SENT_31	[p2l1222t919r1302b994],
39	the	DT	O	the	det	41	SENT_31	[p2l1323t917r1450b995],
40	clinical	JJ	O	clinical	amod	41	SENT_31	[p2l1471t917r1766b995],
41	setting	NN	O	setting	prep_in	37	SENT_31	[p2l1787t911r2134b1018],
42	.6	CD	NUMBER	.6	npadvmod	43	SENT_31	[p2l1787t911r2134b1018],
43	In	IN	O	in	dep	15	SENT_31	[p2l9t1052r96b1122],
44	this	DT	O	this	det	45	SENT_31	[p2l132t1045r285b1123],
45	issue	NN	O	issue	pobj	43	SENT_31	[p2l322t1046r533b1124],
46	of	IN	O	of	_	0	SENT_31	[p2l570t1044r670b1123],
47	the	DT	O	the	det	48	SENT_31	[p2l689t1045r818b1123],
48	journal	NN	O	journal	prep_of	45	SENT_31	[p2l837t1044r1149b1145],
49	,	,	O	,	_	0	SENT_31	[p2l837t1044r1149b1145],
50	Cunningham	NNP	PERSON	Cunningham	prep_of	45	SENT_31	[p2l1189t1045r1750b1146],
51	and	CC	O	and	_	0	SENT_31	[p2l1786t1045r1942b1123],
52	colleagues7	NN	O	colleagues7	prep_of	45	SENT_31	[p2l1978t1045r2133b1123, p2l9t1169r365b1273],
53	report	VBP	O	report	_	0	SENT_31	[p2l393t1189r655b1272],
54	the	DT	O	the	det	55	SENT_31	[p2l678t1173r807b1250],
55	results	NNS	O	result	dobj	53	SENT_31	[p2l835t1173r1111b1251],
56	of	IN	O	of	_	0	SENT_31	[p2l1142t1171r1242b1250],
57	a	DT	O	a	det	59	SENT_31	[p2l1250t1198r1294b1250],
58	randomized	JJ	O	randomized	amod	59	SENT_31	[p2l1320t1173r1831b1250],
59	trial	NN	O	trial	prep_of	55	SENT_31	[p2l1859t1173r2025b1250],
60	of	IN	O	of	_	0	SENT_31	[p2l2052t1171r2152b1250],
61	cetuximab	JJ	O	cetuximab	amod	62	SENT_31	[p2l11t1300r446b1378],
62	monotherapy	NN	O	monotherapy	prep_of	59	SENT_31	[p2l481t1300r1053b1399],
63	as	IN	O	as	amod	62	SENT_31	[p2l1082t1326r1166b1377],
64	compared	VBN	O	compare	_	0	SENT_31	[p2l1204t1300r1627b1399],
65	with	IN	O	with	prepc_compared_with	62	SENT_31	[p2l1657t1300r1846b1379],
66	cetuXimab	NN	O	cetuximab	pobj	62	SENT_31	[p2l1881t1316r2133b1379, p2l9t1428r219b1505],
67	and	CC	O	and	_	0	SENT_31	[p2l242t1428r395b1505],
68	irinotecan	NN	O	irinotecan	conj_and	66	SENT_31	[p2l417t1429r837b1505],
69	in	IN	O	in	_	0	SENT_31	[p2l858t1429r938b1504],
70	combination	NN	O	combination	prep_in	66	SENT_31	[p2l961t1428r1492b1505],
71	in	IN	O	in	_	0	SENT_31	[p2l1514t1429r1594b1504],
72	a	DT	O	a	det	73	SENT_31	[p2l1615t1454r1660b1505],
73	population	NN	O	population	prep_in	70	SENT_31	[p2l1679t1428r2135b1527],
74	of	IN	O	of	_	0	SENT_31	[p2l11t1555r110b1634],
75	patients	NNS	O	patient	prep_of	73	SENT_31	[p2l118t1557r447b1656],
76	with	IN	O	with	_	0	SENT_31	[p2l471t1556r658b1635],
77	advanced	JJ	O	advanced	amod	81	SENT_31	[p2l684t1556r1093b1652],
78	,	,	O	,	_	0	SENT_31	[p2l684t1556r1093b1652],
79	irinotecan-refractory	JJ	O	irinotecan-refractory	amod	81	SENT_31	[p2l1125t1555r1986b1656],
80	colorectal	JJ	O	colorectal	amod	81	SENT_31	[p2l2009t1581r2134b1634, p2l9t1684r326b1762],
81	cancer	NN	O	cancer	prep_with	75	SENT_31	[p2l353t1710r644b1762],
82	.	.	O	.	_	0	SENT_31	[p2l353t1710r644b1762],

1	It	PRP	O	it	nsubjpass	3	SENT_32	[p2l675t1691r741b1762],
2	is	VBZ	O	be	auxpass	3	SENT_32	[p2l763t1685r828b1762],
3	difﬁcult	VBN	O	difﬁcult	_	0	SENT_32	[p2l858t1683r1194b1763],
4	to	TO	O	to	aux	5	SENT_32	[p2l1216t1700r1295b1762],
5	achieve	VB	O	achieve	xcomp	3	SENT_32	[p2l1323t1684r1631b1763],
6	a	DT	O	a	det	9	SENT_32	[p2l1658t1710r1702b1762],
7	meaningful	JJ	O	meaningful	amod	9	SENT_32	[p2l1727t1685r2133b1785, p2l11t1811r121b1891],
8	treatment	NN	O	treatment	nn	9	SENT_32	[p2l151t1828r560b1890],
9	beneﬁt	NN	O	beneﬁt	dobj	5	SENT_32	[p2l585t1811r876b1890],
10	in	IN	O	in	_	0	SENT_32	[p2l899t1813r980b1889],
11	such	JJ	O	such	amod	12	SENT_32	[p2l1010t1812r1202b1891],
12	patients	NNS	O	patient	prep_in	5	SENT_32	[p2l1229t1813r1582b1912],
13	.	.	O	.	_	0	SENT_32	[p2l1229t1813r1582b1912],

1	Those	DT	O	those	nsubjpass	11	SENT_33	[p2l1613t1812r1870b1890],
2	in	IN	O	in	_	0	SENT_33	[p2l1898t1813r1978b1889],
3	the	DT	O	the	det	4	SENT_33	[p2l2008t1812r2135b1890],
4	study	NN	O	study	prep_in	1	SENT_33	[p2l12t1940r234b2040],
5	by	IN	O	by	_	0	SENT_33	[p2l257t1940r353b2040],
6	Cunningham	NNP	PERSON	Cunningham	prep_by	4	SENT_33	[p2l376t1940r929b2041],
7	et	FW	O	et	nn	8	SENT_33	[p2l957t1956r1033b2018],
8	al.	FW	O	al.	dep	6	SENT_33	[p2l1054t1940r1146b2018],
9	were	VBD	O	be	auxpass	11	SENT_33	[p2l1174t1966r1373b2019],
10	carefully	RB	O	carefully	advmod	11	SENT_33	[p2l1401t1939r1755b2040],
11	selected	VBN	O	select	_	0	SENT_33	[p2l1779t1940r2129b2036],
12	,	,	O	,	_	0	SENT_33	[p2l1779t1940r2129b2036],
13	and	CC	O	and	_	0	SENT_33	[p2l10t2068r163b2146],
14	their	PRP$	O	they	poss	15	SENT_33	[p2l200t2068r394b2146],
15	disease	NN	O	disease	nsubjpass	18	SENT_33	[p2l428t2068r726b2146],
16	was	VBD	O	be	auxpass	18	SENT_33	[p2l758t2094r917b2147],
17	independently	RB	O	independently	advmod	18	SENT_33	[p2l955t2068r1551b2168],
18	conﬁrmed	VBN	O	conﬁrmed	conj_and	11	SENT_33	[p2l1583t2067r2014b2146],
19	as	IN	O	as	_	0	SENT_33	[p2l2050t2094r2133b2146],
20	refractory	JJ	O	refractory	prep_as	18	SENT_33	[p2l10t2195r413b2296],
21	to	TO	O	to	_	0	SENT_33	[p2l445t2213r523b2274],
22	irinotecan	NN	O	irinotecan	prep_to	20	SENT_33	[p2l560t2197r1003b2274],
23	.	.	O	.	_	0	SENT_33	[p2l560t2197r1003b2274],

1	Thus	RB	O	thus	advmod	11	SENT_34	[p2l1040t2196r1274b2292],
2	,	,	O	,	_	0	SENT_34	[p2l1040t2196r1274b2292],
3	a	DT	O	a	det	5	SENT_34	[p2l1315t2222r1360b2274],
4	meaningful	JJ	O	meaningful	amod	5	SENT_34	[p2l1393t2195r1875b2297],
5	interpretation	NN	O	interpretation	nsubjpass	11	SENT_34	[p2l1909t2197r2134b2274, p2l9t2325r390b2424],
6	of	IN	O	of	_	0	SENT_34	[p2l414t2323r514b2402],
7	the	DT	O	the	det	8	SENT_34	[p2l519t2324r646b2402],
8	results	NNS	O	result	prep_of	5	SENT_34	[p2l670t2324r941b2403],
9	could	MD	O	could	aux	11	SENT_34	[p2l968t2324r1196b2403],
10	be	VB	O	be	auxpass	11	SENT_34	[p2l1221t2324r1315b2402],
11	expected	VBN	O	expect	_	0	SENT_34	[p2l1339t2324r1723b2424],
12	.	.	O	.	_	0	SENT_34	[p2l1339t2324r1723b2424],

1	Although	IN	O	although	mark	5	SENT_35	[p2l136t2452r537b2553],
2	the	DT	O	the	det	3	SENT_35	[p2l560t2452r689b2530],
3	trial	NN	O	trial	nsubjpass	5	SENT_35	[p2l713t2452r879b2530],
4	was	VBD	O	be	auxpass	5	SENT_35	[p2l896t2478r1058b2531],
5	designed	VBN	O	design	advcl	23	SENT_35	[p2l1083t2452r1463b2553],
6	to	TO	O	to	aux	7	SENT_35	[p2l1486t2469r1565b2530],
7	assess	VB	O	assess	xcomp	5	SENT_35	[p2l1589t2478r1849b2530],
8	the	DT	O	the	det	9	SENT_35	[p2l1874t2452r2003b2530],
9	efficacy	NN	O	efficacy	dobj	7	SENT_35	[p2l2027t2451r2134b2530, p2l11t2579r251b2680],
10	of	IN	O	of	_	0	SENT_35	[p2l269t2579r369b2658],
11	cetuximab	JJ	O	cetuximab	amod	12	SENT_35	[p2l372t2580r807b2659],
12	monotherapy	NN	O	monotherapy	prep_of	9	SENT_35	[p2l830t2580r1401b2680],
13	and	CC	O	and	_	0	SENT_35	[p2l1417t2580r1573b2658],
14	of	IN	O	of	_	0	SENT_35	[p2l1595t2579r1695b2658],
15	cetuximab	NN	O	cetuximab	prep_of	18	SENT_35	[p2l1699t2580r2134b2659],
16	and	CC	O	and	_	0	SENT_35	[p2l10t2708r168b2785],
17	irinotecan	NN	O	irinotecan	prep_of	18	SENT_35	[p2l212t2709r650b2785],
18	in	IN	O	in	conj_and	9	SENT_35	[p2l694t2709r776b2784],
19	combination	NN	O	combination	pobj	18	SENT_35	[p2l822t2708r1397b2803],
20	,	,	O	,	_	0	SENT_35	[p2l822t2708r1397b2803],
21	it	PRP	O	it	nsubj	23	SENT_35	[p2l1447t2709r1509b2785],
22	implicitly	RB	O	implicitly	advmod	23	SENT_35	[p2l1548t2708r1959b2807],
23	addressed	VBD	O	address	_	0	SENT_35	[p2l1999t2708r2132b2785, p2l11t2836r333b2914],
24	the	DT	O	the	det	25	SENT_35	[p2l358t2836r487b2914],
25	question	NN	O	question	nsubj	32	SENT_35	[p2l513t2837r878b2936],
26	of	IN	O	of	_	0	SENT_35	[p2l905t2835r1005b2914],
27	Whether	NNP	O	Whether	prep_of	25	SENT_35	[p2l1007t2836r1358b2915],
28	adding	VBG	O	add	partmod	27	SENT_35	[p2l1380t2836r1677b2937],
29	cetuximab	NN	O	cetuximab	dobj	28	SENT_35	[p2l1699t2836r2134b2915],
30	to	TO	O	to	_	0	SENT_35	[p2l11t2980r90b3042],
31	irinotecan	NN	O	irinotecan	prep_to	28	SENT_35	[p2l112t2965r539b3042],
32	resensitizes	VBZ	O	resensitize	ccomp	23	SENT_35	[p2l561t2965r1051b3042],
33	tumors	NNS	O	tumor	dobj	32	SENT_35	[p2l1075t2980r1376b3043],
34	that	WDT	O	that	nsubj	36	SENT_35	[p2l1399t2964r1566b3042],
35	are	VBP	O	be	cop	36	SENT_35	[p2l1581t2990r1707b3042],
36	refractory	JJ	O	refractory	rcmod	33	SENT_35	[p2l1728t2963r2140b3064],
37	to	TO	O	to	_	0	SENT_35	[p2l11t3108r90b3169],
38	irinotecan	NN	O	irinotecan	prep_to	36	SENT_35	[p2l117t3093r568b3169],
39	.	.	O	.	_	0	SENT_35	[p2l117t3093r568b3169],

1	In	IN	O	in	_	0	SENT_36	[p2l599t3099r686b3168],
2	that	DT	O	that	det	3	SENT_36	[p2l713t3092r879b3169],
3	sense	NN	O	sense	prep_in	9	SENT_36	[p2l902t3117r1156b3186],
4	,	,	O	,	_	0	SENT_36	[p2l902t3117r1156b3186],
5	the	DT	O	the	det	6	SENT_36	[p2l1188t3092r1317b3169],
6	trial	NN	O	trial	nsubj	9	SENT_36	[p2l1344t3092r1510b3169],
7	was	VBD	O	be	cop	9	SENT_36	[p2l1532t3118r1693b3170],
8	a	DT	O	a	det	9	SENT_36	[p2l1720t3118r1765b3169],
9	success	NN	O	success	_	0	SENT_36	[p2l1791t3118r2130b3187],
10	,	,	O	,	_	0	SENT_36	[p2l1791t3118r2130b3187],
11	and	CC	O	and	_	0	SENT_36	[p2l10t3219r166b3297],
12	the	DT	O	the	det	13	SENT_36	[p2l192t3219r321b3297],
13	ﬁndings	NNS	O	ﬁndings	nsubj	15	SENT_36	[p2l346t3218r696b3320],
14	clearly	RB	O	clearly	advmod	15	SENT_36	[p2l726t3219r998b3319],
15	support	VBP	O	support	conj_and	9	SENT_36	[p2l1020t3236r1353b3319],
16	the	DT	O	the	det	17	SENT_36	[p2l1373t3219r1503b3297],
17	notion	NN	O	notion	dobj	15	SENT_36	[p2l1528t3220r1807b3297],
18	that	IN	O	that	complm	24	SENT_36	[p2l1833t3219r2000b3297],
19	interfering	VBG	O	interfere	csubj	24	SENT_36	[p2l2020t3220r2134b3296, p2l11t3346r379b3448],
20	with	IN	O	with	_	0	SENT_36	[p2l414t3347r603b3426],
21	EGFR	NN	ORGANIZATION	egfr	nn	22	SENT_36	[p2l643t3352r903b3430],
22	signaling	NN	O	signaling	prep_with	19	SENT_36	[p2l936t3347r1330b3448],
23	can	MD	O	can	aux	24	SENT_36	[p2l1369t3373r1513b3425],
24	overcome	VB	O	overcome	ccomp	15	SENT_36	[p2l1556t3372r1963b3426],
25	the	DT	O	the	det	26	SENT_36	[p2l2006t3347r2135b3425],
26	resistance	NN	O	resistance	dobj	24	SENT_36	[p2l11t3476r442b3552],
27	to	TO	O	to	_	0	SENT_36	[p2l472t3491r552b3552],
28	irinotecan	NN	O	irinotecan	prep_to	24	SENT_36	[p2l581t3476r1043b3552],
29	.	.	O	.	_	0	SENT_36	[p2l581t3476r1043b3552],

1	Nevertheless	RB	O	nevertheless	advmod	8	SENT_37	[p2l1075t3475r1652b3570],
2	,	,	O	,	_	0	SENT_37	[p2l1075t3475r1652b3570],
3	the	DT	O	the	det	4	SENT_37	[p2l1688t3475r1819b3552],
4	appropriateness	NN	O	appropriateness	nsubj	8	SENT_37	[p2l1848t3500r2132b3574, p2l9t3604r448b3703],
5	of	IN	O	of	_	0	SENT_37	[p2l479t3602r579b3681],
6	the	DT	O	the	det	7	SENT_37	[p2l590t3603r719b3681],
7	authors	NNS	O	author	prep_of	4	SENT_37	[p2l746t3603r1092b3682],
8	’	VBP	O	’	_	0	SENT_37	[p2l746t3603r1092b3682],
9	reporting	VBG	O	report	xcomp	8	SENT_37	[p2l1124t3604r1525b3704],
10	methods	NNS	O	method	nn	11	SENT_37	[p2l1550t3603r1918b3681],
11	warrants	NNS	O	warrant	dobj	9	SENT_37	[p2l1944t3629r2134b3682, p3l11t37r220b99],

1	discussion	NN	O	discussion	_	0	SENT_38	[p3l247t21r718b100],
2	.	.	O	.	_	0	SENT_38	[p3l247t21r718b100],

1	The	DT	O	the	det	4	SENT_39	[p3l744t21r905b99],
2	primary	JJ	O	primary	amod	4	SENT_39	[p3l928t22r1265b121],
3	end	NN	O	end	nn	4	SENT_39	[p3l1285t21r1438b99],
4	point	NN	O	point	nsubj	11	SENT_39	[p3l1461t22r1690b121],
5	of	IN	O	of	_	0	SENT_39	[p3l1709t20r1810b99],
6	the	DT	O	the	det	7	SENT_39	[p3l1816t21r1944b99],
7	trial	NN	O	trial	prep_of	4	SENT_39	[p3l1969t21r2136b99],
8	was	VBD	O	be	cop	11	SENT_39	[p3l6t175r166b228],
9	a	DT	O	a	det	11	SENT_39	[p3l190t175r235b226],
10	tumor	NN	O	tumor	nn	11	SENT_39	[p3l256t165r517b227],
11	response	NN	O	response	_	0	SENT_39	[p3l537t174r935b248],
12	,	,	O	,	_	0	SENT_39	[p3l537t174r935b248],
13	and	CC	O	and	_	0	SENT_39	[p3l963t149r1118b226],
14	the	DT	O	the	det	17	SENT_39	[p3l1141t149r1269b226],
15	planned	VBN	O	plan	amod	17	SENT_39	[p3l1291t149r1632b248],
16	sample	NN	O	sample	nn	17	SENT_39	[p3l1656t149r1954b248],
17	size	NN	O	size	nsubjpass	19	SENT_39	[p3l1978t150r2135b226],
18	was	VBD	O	be	auxpass	19	SENT_39	[p3l6t303r167b356],
19	based	VBN	O	base	conj_and	11	SENT_39	[p3l191t277r432b355],
20	not	RB	O	not	neg	19	SENT_39	[p3l453t294r597b355],
21	on	IN	O	on	_	0	SENT_39	[p3l613t303r720b355],
22	a	DT	O	a	det	23	SENT_39	[p3l740t303r784b355],
23	comparison	NN	O	comparison	prep_on	19	SENT_39	[p3l804t278r1309b377],
24	of	IN	O	of	_	0	SENT_39	[p3l1331t276r1431b355],
25	groups	NNS	O	group	prep_of	23	SENT_39	[p3l1433t303r1727b378],
26	but	CC	O	but	_	0	SENT_39	[p3l1750t277r1891b356],
27	on	IN	O	on	_	0	SENT_39	[p3l1908t303r2015b355],
28	an	DT	O	a	det	29	SENT_39	[p3l2035t303r2135b355],
29	estimation	NN	O	estimation	conj_but	23	SENT_39	[p3l11t406r459b483],
30	of	IN	O	of	_	0	SENT_39	[p3l491t404r591b483],
31	the	DT	O	the	det	33	SENT_39	[p3l603t405r733b483],
32	response	NN	O	response	nn	33	SENT_39	[p3l763t430r1143b505],
33	rate	NN	O	rate	prep_of	29	SENT_39	[p3l1173t421r1330b483],
34	to	TO	O	to	_	0	SENT_39	[p3l1360t422r1439b483],
35	a	DT	O	a	det	37	SENT_39	[p3l1470t431r1514b483],
36	speciﬁed	JJ	O	speciﬁed	amod	37	SENT_39	[p3l1545t404r1919b505],
37	level	NN	O	level	prep_to	19	SENT_39	[p3l1949t405r2136b484],
38	of	IN	O	of	_	0	SENT_39	[p3l11t532r112b611],
39	precision	NN	O	precision	prep_of	37	SENT_39	[p3l114t534r530b633],
40	.	.	O	.	_	0	SENT_39	[p3l114t534r530b633],

1	Thus	RB	O	thus	advmod	8	SENT_40	[p3l554t533r792b628],
2	,	,	O	,	_	0	SENT_40	[p3l554t533r792b628],
3	the	DT	O	the	det	4	SENT_40	[p3l820t533r949b611],
4	trial	NN	O	trial	nsubjpass	8	SENT_40	[p3l972t533r1139b611],
5	could	MD	O	could	aux	8	SENT_40	[p3l1161t533r1393b612],
6	be	VB	O	be	auxpass	8	SENT_40	[p3l1416t533r1511b611],
7	best	JJS	O	best	advmod	8	SENT_40	[p3l1535t533r1709b611],
8	labeled	VBN	O	label	_	0	SENT_40	[p3l1726t533r2028b611],
9	as	IN	O	as	_	0	SENT_40	[p3l2049t559r2133b611],
10	a	DT	O	a	prep_as	8	SENT_40	[p3l10t687r54b738],
11	randomized	VBN	O	randomize	partmod	10	SENT_40	[p3l85t661r614b756],
12	,	,	O	,	_	0	SENT_40	[p3l85t661r614b756],
13	phase	NN	O	phase	nn	15	SENT_40	[p3l651t661r895b760],
14	2	CD	NUMBER	2	num	15	SENT_40	[p3l927t666r974b737],
15	trial	NN	O	trial	dobj	11	SENT_40	[p3l1007t661r1194b738],
16	.	.	O	.	_	0	SENT_40	[p3l1007t661r1194b738],

1	However	RB	O	however	advmod	19	SENT_41	[p3l1231t668r1620b756],
2	,	,	O	,	_	0	SENT_41	[p3l1231t668r1620b756],
3	the	DT	O	the	det	4	SENT_41	[p3l1657t661r1785b738],
4	authors	NNS	O	author	nsubj	19	SENT_41	[p3l1817t661r2134b739],
5	present	JJ	DATE	present	amod	8	SENT_41	[p3l9t805r335b889],
6	multiple	JJ	O	multiple	amod	8	SENT_41	[p3l358t789r720b889],
7	comparative	JJ	O	comparative	amod	8	SENT_41	[p3l750t790r1277b889],
8	analyses	NNS	O	analysis	dep	4	SENT_41	[p3l1305t789r1688b889],
9	,	,	O	,	_	0	SENT_41	[p3l1305t789r1688b889],
10	including	VBG	O	include	_	0	SENT_41	[p3l1722t789r2137b890],
11	an	DT	O	a	det	12	SENT_41	[p3l10t943r110b995],
12	analysis	NN	O	analysis	prep_including	19	SENT_41	[p3l153t917r480b1017],
13	of	IN	O	of	_	0	SENT_41	[p3l527t916r627b995],
14	overall	JJ	O	overall	amod	15	SENT_41	[p3l653t917r927b996],
15	survival	NN	O	survival	prep_of	12	SENT_41	[p3l972t917r1309b1012],
16	,	,	O	,	_	0	SENT_41	[p3l972t917r1309b1012],
17	which	WDT	O	which	nsubj	19	SENT_41	[p3l1354t917r1612b996],
18	was	VBD	O	be	cop	19	SENT_41	[p3l1652t943r1812b996],
19	underpowered	JJ	O	underpowered	_	0	SENT_41	[p3l1857t917r2134b996, p3l9t1045r371b1145],
20	to	TO	O	to	aux	21	SENT_41	[p3l393t1062r471b1123],
21	detect	VB	O	detect	xcomp	19	SENT_41	[p3l495t1045r746b1123],
22	a	DT	O	a	det	26	SENT_41	[p3l762t1071r806b1123],
23	clinically	RB	O	clinically	advmod	24	SENT_41	[p3l826t1045r1197b1145],
24	meaningful	JJ	O	meaningful	amod	26	SENT_41	[p3l1213t1044r1698b1146],
25	difference	NN	O	difference	nn	26	SENT_41	[p3l1719t1044r2135b1123],
26	(	NN	O	(	dobj	21	SENT_41	[p3l15t1173r330b1274],
27	having	VBG	O	have	xcomp	21	SENT_41	[p3l15t1173r330b1274],
28	less	JJR	O	less	mwe	29	SENT_41	[p3l351t1173r506b1251],
29	than	IN	O	than	quantmod	30	SENT_41	[p3l534t1173r722b1251],
30	60	CD	PERCENT	60	num	32	SENT_41	[p3l747t1178r847b1251],
31	percent	NN	PERCENT	percent	nn	32	SENT_41	[p3l871t1189r1192b1273],
32	power	NN	O	power	nsubj	34	SENT_41	[p3l1211t1198r1477b1273],
33	to	TO	O	to	aux	34	SENT_41	[p3l1500t1189r1579b1251],
34	detect	VB	O	detect	ccomp	27	SENT_41	[p3l1606t1173r1860b1251],
35	a	DT	O	a	det	37	SENT_41	[p3l1879t1199r1923b1251],
36	twomonth	JJ	O	twomonth	amod	37	SENT_41	[p3l1947t1189r2134b1252, p3l11t1301r294b1378],
37	improvement	NN	O	improvement	dobj	34	SENT_41	[p3l318t1302r892b1400],
38	in	IN	O	in	_	0	SENT_41	[p3l912t1302r993b1377],
39	median	JJ	O	median	amod	41	SENT_41	[p3l1017t1301r1334b1378],
40	survival	NN	O	survival	nn	41	SENT_41	[p3l1360t1301r1736b1391],
41	)	NN	O	)	prep_in	34	SENT_41	[p3l1360t1301r1736b1391],
42	.	.	O	.	_	0	SENT_41	[p3l1360t1301r1736b1391],

1	In	IN	O	in	_	0	SENT_42	[p3l138t1436r225b1506],
2	addition	NN	O	addition	prep_in	13	SENT_42	[p3l245t1429r616b1525],
3	,	,	O	,	_	0	SENT_42	[p3l245t1429r616b1525],
4	two	CD	NUMBER	two	nsubjpass	13	SENT_42	[p3l643t1445r794b1508],
5	of	IN	O	of	_	0	SENT_42	[p3l817t1428r917b1507],
6	Cunningham	NNP	LOCATION	Cunningham	prep_of	4	SENT_42	[p3l919t1429r1476b1530],
7	and	CC	O	and	_	0	SENT_42	[p3l1496t1429r1651b1507],
8	colleagues	NNS	O	colleague	nsubjpass	13	SENT_42	[p3l1672t1429r2131b1530],
9	’	CD	NUMBER	’	num	10	SENT_42	[p3l1672t1429r2131b1530],
10	conclusions	NNS	O	conclusion	dep	8	SENT_42	[p3l11t1557r526b1636],
11	are	VBP	O	be	auxpass	13	SENT_42	[p3l580t1583r708b1634],
12	perhaps	RB	O	perhaps	advmod	13	SENT_42	[p3l759t1557r1104b1656],
13	overstated	VBN	O	overstate	_	0	SENT_42	[p3l1159t1557r1625b1636],
14	.	.	O	.	_	0	SENT_42	[p3l1159t1557r1625b1636],

1	First	RB	ORDINAL	first	advmod	4	SENT_43	[p3l1682t1558r1900b1652],
2	,	,	O	,	_	0	SENT_43	[p3l1682t1558r1900b1652],
3	they	PRP	O	they	nsubj	4	SENT_43	[p3l1959t1557r2139b1656],
4	suggest	VBP	O	suggest	_	0	SENT_43	[p3l12t1702r338b1786],
5	single	JJ	O	single	amod	8	SENT_43	[p3l367t1685r892b1786],
6	—	JJ	O	—	amod	8	SENT_43	[p3l367t1685r892b1786],
7	agent	NN	O	agent	nn	8	SENT_43	[p3l367t1685r892b1786],
8	cetuximab	NN	O	cetuximab	dobj	4	SENT_43	[p3l920t1685r1354b1764],
9	for	IN	O	for	_	0	SENT_43	[p3l1388t1684r1511b1763],
10	those	DT	O	those	det	11	SENT_43	[p3l1540t1685r1767b1763],
11	patients	NNS	O	patient	prep_for	8	SENT_43	[p3l1798t1686r2132b1785],
12	who	WP	O	who	nsubj	16	SENT_43	[p3l6t1813r189b1892],
13	may	MD	O	may	aux	16	SENT_43	[p3l225t1838r401b1912],
14	not	RB	O	not	neg	16	SENT_43	[p3l430t1829r574b1890],
15	be	VB	O	be	cop	16	SENT_43	[p3l603t1813r699b1890],
16	able	JJ	O	able	rcmod	11	SENT_43	[p3l732t1813r904b1890],
17	to	TO	O	to	aux	18	SENT_43	[p3l938t1829r1017b1890],
18	tolerate	VB	O	tolerate	xcomp	16	SENT_43	[p3l1052t1813r1368b1890],
19	the	DT	O	the	det	20	SENT_43	[p3l1403t1813r1531b1890],
20	combination	NN	O	combination	dobj	18	SENT_43	[p3l1567t1813r2130b1890],
21	.	.	O	.	_	0	SENT_43	[p3l1567t1813r2130b1890],

1	The	DT	O	the	det	3	SENT_44	[p3l7t1941r169b2019],
2	toxicity	NN	O	toxicity	nn	3	SENT_44	[p3l194t1942r500b2041],
3	profile	NN	O	profile	nsubj	10	SENT_44	[p3l518t1940r797b2041],
4	of	IN	O	of	_	0	SENT_44	[p3l823t1940r923b2019],
5	the	DT	O	the	det	7	SENT_44	[p3l930t1941r1059b2019],
6	single	JJ	O	single	amod	7	SENT_44	[p3l1085t1941r1335b2042],
7	agent	NN	O	agent	prep_of	3	SENT_44	[p3l1359t1957r1596b2042],
8	is	VBZ	O	be	cop	10	SENT_44	[p3l1614t1942r1679b2019],
9	sufficiently	RB	O	sufficiently	advmod	10	SENT_44	[p3l1707t1940r2134b2020, p3l10t2069r81b2169],
10	favorable	JJ	O	favorable	_	0	SENT_44	[p3l107t2068r493b2148],
11	to	TO	O	to	aux	12	SENT_44	[p3l524t2085r602b2147],
12	justify	VB	O	justify	xcomp	10	SENT_44	[p3l621t2068r891b2169],
13	such	PDT	O	such	predet	15	SENT_44	[p3l919t2069r1113b2148],
14	a	DT	O	a	det	15	SENT_44	[p3l1144t2095r1188b2147],
15	statement	NN	O	statement	dobj	12	SENT_44	[p3l1218t2085r1659b2165],
16	,	,	O	,	_	0	SENT_44	[p3l1218t2085r1659b2165],
17	but	CC	O	but	_	0	SENT_44	[p3l1696t2069r1837b2148],
18	the	DT	O	the	det	23	SENT_44	[p3l1862t2069r1992b2147],
19	response	NN	O	response	nn	23	SENT_44	[p3l2022t2095r2134b2147, p3l12t2222r307b2296],
20	rate	NN	O	rate	nn	23	SENT_44	[p3l333t2213r489b2274],
21	—	CD	PERCENT	—	number	22	SENT_44	[p3l512t2242r619b2249],
22	10.8	CD	PERCENT	10.8	num	23	SENT_44	[p3l645t2202r823b2274],
23	percent	NN	PERCENT	percent	nsubj	35	SENT_44	[p3l849t2213r1188b2296],
24	,	,	O	,	_	0	SENT_44	[p3l849t2213r1188b2296],
25	with	IN	O	with	_	0	SENT_44	[p3l1215t2197r1405b2276],
26	a	DT	O	a	det	28	SENT_44	[p3l1430t2223r1474b2274],
27	median	JJ	O	median	amod	28	SENT_44	[p3l1499t2197r1815b2274],
28	time	NN	O	time	prep_with	23	SENT_44	[p3l1842t2198r2028b2274],
29	to	TO	O	to	_	0	SENT_44	[p3l2055t2213r2134b2274],
30	progression	NN	O	progression	prep_to	28	SENT_44	[p3l9t2326r518b2426],
31	of	IN	O	of	_	0	SENT_44	[p3l553t2324r654b2403],
32	1.5	CD	DURATION	1.5	num	33	SENT_44	[p3l673t2330r797b2403],
33	months	NNS	NUMBER	month	prep_of	23	SENT_44	[p3l834t2325r1158b2403],
34	—	RB	O	—	advmod	35	SENT_44	[p3l1192t2370r1300b2377],
35	raises	VBZ	O	raise	conj_but	10	SENT_44	[p3l1330t2326r1568b2403],
36	the	DT	O	the	det	37	SENT_44	[p3l1606t2325r1735b2403],
37	question	NN	O	question	dobj	35	SENT_44	[p3l1770t2326r2135b2425],
38	of	IN	O	of	_	0	SENT_44	[p3l11t2452r112b2531],
39	the	DT	O	the	det	40	SENT_44	[p3l125t2453r254b2531],
40	magnitude	NN	O	magnitude	prep_of	37	SENT_44	[p3l286t2453r741b2554],
41	of	IN	O	of	_	0	SENT_44	[p3l773t2452r874b2531],
42	the	DT	O	the	det	43	SENT_44	[p3l887t2453r1016b2531],
43	beneﬁt	NN	O	beneﬁt	prep_of	40	SENT_44	[p3l1056t2452r1371b2531],
44	.	.	O	.	_	0	SENT_44	[p3l1056t2452r1371b2531],

1	Furthermore	RB	O	furthermore	advmod	18	SENT_45	[p3l1407t2453r1968b2549],
2	,	,	O	,	_	0	SENT_45	[p3l1407t2453r1968b2549],
3	the	DT	O	the	det	4	SENT_45	[p3l2006t2453r2135b2531],
4	population	NN	O	population	nsubjpass	18	SENT_45	[p3l9t2581r473b2681],
5	for	IN	O	for	_	0	SENT_45	[p3l509t2580r632b2659],
6	whom	WP	O	whom	dep	9	SENT_45	[p3l660t2581r932b2660],
7	the	DT	O	the	det	8	SENT_45	[p3l968t2581r1098b2659],
8	authors	NNS	O	author	nsubj	9	SENT_45	[p3l1133t2581r1452b2660],
9	suggest	VBP	O	suggest	prepc_for	4	SENT_45	[p3l1492t2597r1818b2682],
10	singleagent	JJ	O	singleagent	amod	11	SENT_45	[p3l1851t2581r2134b2682, p3l10t2726r247b2810],
11	therapy	NN	O	therapy	nsubjpass	14	SENT_45	[p3l264t2709r581b2809],
12	should	MD	O	should	aux	14	SENT_45	[p3l601t2709r887b2788],
13	be	VB	O	be	auxpass	14	SENT_45	[p3l910t2709r1006b2787],
14	considered	VBN	O	consider	ccomp	9	SENT_45	[p3l1029t2709r1491b2787],
15	was	VBD	O	be	auxpass	18	SENT_45	[p3l1509t2735r1669b2788],
16	not	RB	O	not	neg	18	SENT_45	[p3l1694t2726r1837b2787],
17	specifically	RB	O	specifically	advmod	18	SENT_45	[p3l1856t2708r2134b2809, p3l10t2837r234b2936],
18	studied	VBN	O	study	_	0	SENT_45	[p3l281t2837r595b2916],
19	in	IN	O	in	_	0	SENT_45	[p3l643t2838r726b2913],
20	this	DT	O	this	det	21	SENT_45	[p3l776t2837r931b2914],
21	trial	NN	O	trial	prep_in	18	SENT_45	[p3l984t2837r1179b2914],
22	.	.	O	.	_	0	SENT_45	[p3l984t2837r1179b2914],

1	Second	RB	ORDINAL	second	advmod	9	SENT_46	[p3l1237t2837r1570b2931],
2	,	,	O	,	_	0	SENT_46	[p3l1237t2837r1570b2931],
3	the	DT	O	the	det	5	SENT_46	[p3l1625t2837r1757b2914],
4	authors	NNS	O	author	nn	5	SENT_46	[p3l1806t2837r2132b2916],
5	state	NN	O	state	nsubj	9	SENT_46	[p3l12t2981r231b3061],
6	,	,	O	,	_	0	SENT_46	[p3l12t2981r231b3061],
7	“	CD	NUMBER	“	appos	5	SENT_46	[p3l277t2965r775b3044],
8	Cetuximab	NNP	O	Cetuximab	dep	7	SENT_46	[p3l277t2965r775b3044],
9	compares	VBZ	O	compare	_	0	SENT_46	[p3l814t2990r1222b3065],
10	favorably	RB	O	favorably	advmod	9	SENT_46	[p3l1261t2964r1648b3065],
11	with	IN	O	with	_	0	SENT_46	[p3l1675t2965r1865b3044],
12	oxaliplatin	NN	O	oxaliplatin	nn	13	SENT_46	[p3l1902t2965r2134b3043, p3l9t3093r547b3192],
13	—	NN	O	—	prep_with	9	SENT_46	[p3l1902t2965r2134b3043, p3l9t3093r547b3192],
14	based	VBN	O	base	partmod	13	SENT_46	[p3l1902t2965r2134b3043, p3l9t3093r547b3192],
15	therapy	NN	O	therapy	dobj	14	SENT_46	[p3l584t3093r907b3192],
16	in	IN	O	in	_	0	SENT_46	[p3l939t3094r1021b3169],
17	patients	NNS	O	patient	prep_in	15	SENT_46	[p3l1056t3094r1398b3192],
18	with	IN	O	with	_	0	SENT_46	[p3l1433t3093r1625b3172],
19	irinotecan	NN	O	irinotecan	prep_with	14	SENT_46	[p3l1661t3094r2132b3170],
20	—	CD	NUMBER	—	num	22	SENT_46	[p3l1661t3094r2132b3170],
21	refractory	JJ	O	refractory	amod	22	SENT_46	[p3l11t3220r413b3321],
22	disease	NN	O	disease	dep	19	SENT_46	[p3l428t3221r796b3299],
23	.	.	O	.	_	0	SENT_46	[p3l428t3221r796b3299],

1	”	NN	O	”	nsubj	15	SENT_47	[p3l428t3221r796b3299],
2	The	DT	O	the	det	3	SENT_47	[p3l816t3221r975b3299],
3	efficacy	NN	O	efficacy	nsubj	8	SENT_47	[p3l995t3220r1308b3321],
4	of	IN	O	of	_	0	SENT_47	[p3l1323t3220r1423b3299],
5	oXaliplatin	NN	O	oxaliplatin	nn	7	SENT_47	[p3l1424t3221r2034b3321],
6	—	CD	NUMBER	—	num	7	SENT_47	[p3l1424t3221r2034b3321],
7	bas	NN	O	ba	prep_of	3	SENT_47	[p3l1424t3221r2034b3321],
8	ed	VBD	O	ed	rcmod	1	SENT_47	[p3l2042t3221r2136b3299],
9	therapy	NN	O	therapy	dobj	8	SENT_47	[p3l11t3349r328b3449],
10	in	IN	O	in	_	0	SENT_47	[p3l366t3350r447b3426],
11	this	DT	O	this	det	12	SENT_47	[p3l491t3349r643b3427],
12	setting	NN	O	setting	prep_in	8	SENT_47	[p3l690t3350r979b3450],
13	has	VBZ	O	have	aux	15	SENT_47	[p3l1018t3349r1159b3427],
14	been	VBN	O	be	aux	15	SENT_47	[p3l1205t3349r1405b3427],
15	established	VBN	O	establish	_	0	SENT_47	[p3l1448t3349r1926b3427],
16	in	IN	O	in	_	0	SENT_47	[p3l1968t3350r2050b3426],
17	a	DT	O	a	det	18	SENT_47	[p3l2092t3375r2136b3427],
18	large	JJ	O	large	prep_in	15	SENT_47	[p3l10t3477r242b3578],
19	,	,	O	,	_	0	SENT_47	[p3l10t3477r242b3578],
20	randomized	VBN	O	randomize	dep	15	SENT_47	[p3l287t3477r821b3572],
21	,	,	O	,	_	0	SENT_47	[p3l287t3477r821b3572],
22	phase	NN	O	phase	nn	24	SENT_47	[p3l865t3477r1112b3577],
23	3	CD	NUMBER	3	num	24	SENT_47	[p3l1153t3482r1196b3556],
24	trialg	NN	O	trialg	dobj	15	SENT_47	[p3l1240t3472r1471b3572],
25	;	:	O	;	_	0	SENT_47	[p3l1240t3472r1471b3572],
26	cetuximab	NN	O	cetuximab	nsubjpass	31	SENT_47	[p3l1516t3477r1950b3556],
27	has	VBZ	O	have	aux	31	SENT_47	[p3l1991t3477r2132b3555],
28	not	RB	O	not	neg	31	SENT_47	[p3l11t3621r154b3683],
29	yet	RB	O	yet	advmod	31	SENT_47	[p3l170t3621r294b3705],
30	been	VBN	O	be	auxpass	31	SENT_47	[p3l314t3605r514b3683],
31	subjected	VBN	O	subject	parataxis	15	SENT_47	[p3l540t3605r935b3705],
32	to	TO	O	to	_	0	SENT_47	[p3l961t3621r1040b3683],
33	such	JJ	O	such	amod	35	SENT_47	[p3l1068t3605r1262b3684],
34	rigorous	JJ	O	rigorous	amod	35	SENT_47	[p3l1287t3606r1644b3706],
35	validation	NN	O	validation	prep_to	31	SENT_47	[p3l1667t3605r2109b3684],
36	.	.	O	.	_	0	SENT_47	[p3l1667t3605r2109b3684],

1	This	DT	O	this	det	2	SENT_48	[p4l136t20r320b97],
2	trial	NN	O	trial	nsubj	3	SENT_48	[p4l377t20r541b97],
3	raises	VBZ	O	raise	_	0	SENT_48	[p4l595t20r831b97],
4	several	JJ	O	several	amod	6	SENT_48	[p4l890t20r1171b99],
5	additional	JJ	O	additional	amod	6	SENT_48	[p4l1225t20r1647b97],
6	questions	NNS	O	question	dobj	3	SENT_48	[p4l1703t21r2130b119],
7	.	.	O	.	_	0	SENT_48	[p4l1703t21r2130b119],

1	The	DT	O	the	det	2	SENT_49	[p4l7t148r167b226],
2	authors	NNS	O	author	nsubj	3	SENT_49	[p4l196t148r512b227],
3	attempt	VBP	O	attempt	_	0	SENT_49	[p4l542t164r869b248],
4	to	TO	O	to	aux	5	SENT_49	[p4l893t165r972b226],
5	address	VB	O	address	xcomp	3	SENT_49	[p4l1002t148r1319b226],
6	the	DT	O	the	det	8	SENT_49	[p4l1351t148r1478b226],
7	critical	JJ	O	critical	amod	8	SENT_49	[p4l1508t148r1788b226],
8	issue	NN	O	issue	nsubj	16	SENT_49	[p4l1816t149r2025b227],
9	of	IN	O	of	_	0	SENT_49	[p4l2054t147r2154b226],
10	Whether	NNP	O	Whether	nn	12	SENT_49	[p4l6t276r354b355],
11	EGFR	NN	ORGANIZATION	egfr	nn	12	SENT_49	[p4l377t281r635b359],
12	expression	NN	O	expression	prep_of	8	SENT_49	[p4l653t277r1101b376],
13	is	VBZ	O	be	cop	16	SENT_49	[p4l1128t277r1193b354],
14	a	DT	O	a	det	16	SENT_49	[p4l1222t302r1266b354],
15	predictive	JJ	O	predictive	amod	16	SENT_49	[p4l1291t276r1697b376],
16	marker	NN	O	marker	ccomp	5	SENT_49	[p4l1725t276r2029b355],
17	of	IN	O	of	_	0	SENT_49	[p4l2054t275r2154b354],
18	a	DT	O	a	det	19	SENT_49	[p4l10t430r54b482],
19	response	NN	O	response	prep_of	16	SENT_49	[p4l89t430r487b504],
20	.	.	O	.	_	0	SENT_49	[p4l89t430r487b504],

1	Although	IN	O	although	mark	4	SENT_50	[p4l526t404r922b505],
2	the	DT	O	the	det	3	SENT_50	[p4l959t404r1087b482],
3	investigators	NNS	O	investigator	nsubj	4	SENT_50	[p4l1122t405r1654b505],
4	performed	VBN	O	perform	_	0	SENT_50	[p4l1691t403r2136b504],

1	ENGLJ	NNP	O	ENGLJ	nn	2	SENT_51	[p4l553t571r637b593],
2	MED	NNP	O	MED	_	0	SENT_51	[p4l652t572r705b587],
3	351	CD	NUMBER	351	num	2	SENT_51	[p4l717t571r782b593],
4	;	:	O	;	_	0	SENT_51	[p4l717t571r782b593],
5	4	CD	NUMBER	4	num	7	SENT_51	[p4l717t571r782b593],
6	WWW.NEJM.ORG	NN	O	www.nejm.org	nn	7	SENT_51	[p4l815t571r1027b593],
7	ULY	NN	O	uly	dep	2	SENT_51	[p4l1075t572r1120b587],
8	22	CD	NUMBER	22	dep	7	SENT_51	[p4l1132t571r1169b591],
9	,	,	O	,	_	0	SENT_51	[p4l1132t571r1169b591],
10	2oo4	CD	NUMBER	2oo4	number	11	SENT_51	[p4l1182t571r1250b593],
11	391	CD	NUMBER	391	appos	8	SENT_51	[p4l1959t570r2016b592],

1	The	DT	O	the	det	5	SENT_52	[p4l702t604r753b627],
2	New	NNP	O	New	nn	5	SENT_52	[p4l762t605r824b627],
3	England	NNP	O	England	nn	5	SENT_52	[p4l833t604r944b634],
4	Jouma	NNP	PERSON	Jouma	nn	5	SENT_52	[p4l952t605r1041b627],
5	o	NN	O	o	_	0	SENT_52	[p4l1060t611r1075b627],
6	Medicine	NN	O	medicine	dep	5	SENT_52	[p4l1095t604r1220b627],

1	Downloaded	VBN	O	download	_	0	SENT_53	[p4l144t644r314b667],
2	from	IN	O	from	_	0	SENT_53	[p4l323t644r387b667],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_53	[p4l396t644r514b674],
4	at	IN	O	at	_	0	SENT_53	[p4l524t648r547b667],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_53	[p4l556t644r739b667],
6	on	IN	O	on	_	0	SENT_53	[p4l748t651r780b667],
7	Janu	NNP	DATE	Janu	prep_on	1	SENT_53	[p4l789t644r849b667],
8	5	CD	DATE	5	num	7	SENT_53	[p4l902t644r924b672],
9	,	,	DATE	,	_	0	SENT_53	[p4l902t644r924b672],
10	2014	CD	DATE	2014	num	7	SENT_53	[p4l935t644r1007b667],
11	.	.	O	.	_	0	SENT_53	[p4l935t644r1007b667],

1	For	IN	O	for	_	0	SENT_54	[p4l1018t644r1064b667],
2	personal	JJ	O	personal	amod	3	SENT_54	[p4l1072t644r1184b674],
3	use	NN	O	use	pobj	1	SENT_54	[p4l1194t651r1237b667],
4	only	RB	O	only	advmod	3	SENT_54	[p4l1247t644r1311b674],
5	.	.	O	.	_	0	SENT_54	[p4l1247t644r1311b674],

1	No	DT	O	no	det	3	SENT_55	[p4l1322t644r1362b667],
2	other	JJ	O	other	amod	3	SENT_55	[p4l1372t644r1440b667],
3	uses	NNS	O	use	_	0	SENT_55	[p4l1448t651r1504b667],
4	without	IN	O	without	_	0	SENT_55	[p4l1514t644r1615b667],
5	permission	NN	O	permission	prep_without	3	SENT_55	[p4l1624t644r1776b674],
6	.	.	O	.	_	0	SENT_55	[p4l1624t644r1776b674],

1	Copyright	NN	O	copyright	nn	5	SENT_56	[p4l494t685r629b715],
2	©	CD	NUMBER	©	num	5	SENT_56	[p4l638t685r661b708],
3	2004	CD	DATE	2004	num	5	SENT_56	[p4l672t685r737b708],
4	Massac	NNP	LOCATION	Massac	nn	5	SENT_56	[p4l746t686r844b708],
5	usetts	NNP	O	usetts	_	0	SENT_56	[p4l863t689r937b708],
6	Medical	NNP	ORGANIZATION	Medical	nn	7	SENT_56	[p4l947t685r1055b708],
7	Society	NNP	ORGANIZATION	Society	dep	5	SENT_56	[p4l1065t685r1170b715],
8	.	.	O	.	_	0	SENT_56	[p4l1065t685r1170b715],

1	All	DT	O	all	det	2	SENT_57	[p4l1181t685r1223b708],
2	rights	NNS	O	rights	nsubj	3	SENT_57	[p4l1232t685r1306b715],
3	reserved	VBN	O	reserve	_	0	SENT_57	[p4l1316t685r1435b708],
4	.	.	O	.	_	0	SENT_57	[p4l1316t685r1435b708],

1	EDITORIALS	NNS	O	editorial	_	0	SENT_58	[p4l979t790r1181b809],

1	this	DT	O	this	det	2	SENT_59	[p4l12t1005r163b1083],
2	analysis	NN	O	analysis	nsubjpass	17	SENT_59	[p4l201t1005r530b1105],
3	in	IN	O	in	_	0	SENT_59	[p4l568t1005r649b1082],
4	a	DT	O	a	det	6	SENT_59	[p4l685t1031r729b1083],
5	central	JJ	O	central	amod	6	SENT_59	[p4l765t1005r1050b1083],
6	laboratory	NN	O	laboratory	prep_in	2	SENT_59	[p4l1085t1005r1518b1105],
7	and	CC	O	and	_	0	SENT_59	[p4l1549t1005r1705b1083],
8	in	IN	O	in	_	0	SENT_59	[p4l1740t1005r1821b1082],
9	a	DT	O	a	det	11	SENT_59	[p4l1857t1031r1902b1083],
10	standardized	JJ	O	standardized	amod	11	SENT_59	[p4l1938t1021r2145b1083, p4l12t1132r377b1211],
11	manner	NN	O	manner	conj_and	6	SENT_59	[p4l408t1158r753b1228],
12	,	,	O	,	_	0	SENT_59	[p4l408t1158r753b1228],
13	several	JJ	O	several	amod	14	SENT_59	[p4l792t1133r1074b1212],
14	caveats	NNS	O	caveat	appos	11	SENT_59	[p4l1106t1149r1400b1212],
15	should	MD	O	should	aux	17	SENT_59	[p4l1434t1132r1720b1212],
16	be	VB	O	be	auxpass	17	SENT_59	[p4l1752t1133r1847b1211],
17	noted	VBN	O	note	_	0	SENT_59	[p4l1879t1132r2141b1211],
18	.	.	O	.	_	0	SENT_59	[p4l1879t1132r2141b1211],

1	The	DT	O	the	det	2	SENT_60	[p4l8t1262r169b1340],
2	specimens	NNS	O	specimen	nsubj	8	SENT_60	[p4l196t1262r638b1362],
3	examined	VBN	O	examine	partmod	2	SENT_60	[p4l666t1262r1073b1340],
4	may	MD	O	may	aux	8	SENT_60	[p4l1098t1288r1274b1362],
5	not	RB	O	not	neg	8	SENT_60	[p4l1296t1278r1439b1340],
6	have	VB	O	have	aux	8	SENT_60	[p4l1458t1262r1646b1341],
7	been	VBN	O	be	cop	8	SENT_60	[p4l1672t1261r1871b1340],
8	representative	JJ	O	representative	_	0	SENT_60	[p4l1896t1288r2145b1362, p4l13t1390r379b1469],
9	of	IN	O	of	_	0	SENT_60	[p4l429t1389r529b1468],
10	the	DT	O	the	det	11	SENT_60	[p4l559t1389r688b1468],
11	tumor	NN	O	tumor	prep_of	8	SENT_60	[p4l737t1406r999b1469],
12	at	IN	O	at	_	0	SENT_60	[p4l1044t1406r1123b1468],
13	the	DT	O	the	det	14	SENT_60	[p4l1167t1390r1296b1468],
14	time	NN	O	time	prep_at	11	SENT_60	[p4l1345t1390r1531b1468],
15	of	IN	O	of	_	0	SENT_60	[p4l1581t1389r1681b1468],
16	treatment	NN	O	treatment	prep_of	14	SENT_60	[p4l1711t1406r2141b1485],
17	,	,	O	,	_	0	SENT_60	[p4l1711t1406r2141b1485],
18	since	IN	O	since	mark	21	SENT_60	[p4l13t1519r225b1597],
19	they	PRP	O	they	nsubjpass	21	SENT_60	[p4l248t1519r425b1619],
20	were	VBD	O	be	auxpass	21	SENT_60	[p4l439t1545r640b1598],
21	obtained	VBN	O	obtain	advcl	8	SENT_60	[p4l664t1518r1034b1597],
22	from	IN	O	from	_	0	SENT_60	[p4l1056t1518r1263b1597],
23	primary	JJ	O	primary	amod	24	SENT_60	[p4l1285t1519r1620b1619],
24	tumors	NNS	O	tumor	prep_from	21	SENT_60	[p4l1639t1535r1939b1598],
25	or	CC	O	or	_	0	SENT_60	[p4l1965t1544r2053b1597],
26	at	IN	O	at	quantmod	28	SENT_60	[p4l2073t1535r2152b1597],
27	least	JJS	O	least	mwe	26	SENT_60	[p4l10t1648r206b1726],
28	one	CD	NUMBER	one	num	29	SENT_60	[p4l222t1673r374b1726],
29	metastasis	NN	O	metastasis	prep_from	21	SENT_60	[p4l394t1648r837b1726],
30	at	IN	O	at	_	0	SENT_60	[p4l859t1664r938b1726],
31	some	DT	O	some	det	32	SENT_60	[p4l955t1673r1178b1726],
32	point	NN	O	point	prep_at	21	SENT_60	[p4l1197t1648r1425b1748],
33	but	CC	O	but	_	0	SENT_60	[p4l1441t1648r1581b1727],
34	not	RB	O	not	_	0	SENT_60	[p4l1596t1664r1739b1726],
35	necessarily	RB	O	necessarily	advmod	21	SENT_60	[p4l1755t1673r2145b1726, p4l11t1776r108b1876],
36	at	IN	O	at	_	0	SENT_60	[p4l123t1792r202b1854],
37	the	DT	O	the	det	38	SENT_60	[p4l217t1776r345b1854],
38	time	NN	O	time	prep_at	21	SENT_60	[p4l366t1776r550b1854],
39	of	IN	O	of	_	0	SENT_60	[p4l571t1775r671b1854],
40	the	DT	O	the	det	42	SENT_60	[p4l673t1776r801b1854],
41	study	NN	O	study	nn	42	SENT_60	[p4l824t1776r1047b1876],
42	treatment	NN	O	treatment	prep_of	38	SENT_60	[p4l1062t1792r1489b1854],
43	.	.	O	.	_	0	SENT_60	[p4l1062t1792r1489b1854],

1	The	DT	O	the	det	2	SENT_61	[p4l1512t1776r1672b1854],
2	processing	NN	O	processing	nsubj	11	SENT_61	[p4l1691t1776r2151b1876],
3	and	CC	O	and	_	0	SENT_61	[p4l11t1904r166b1982],
4	handling	NN	O	handling	nsubj	11	SENT_61	[p4l206t1903r588b2004],
5	of	IN	O	of	_	0	SENT_61	[p4l625t1903r726b1982],
6	the	DT	O	the	det	8	SENT_61	[p4l749t1903r877b1982],
7	original	JJ	O	original	amod	8	SENT_61	[p4l919t1904r1246b2004],
8	specimens	NNS	O	specimen	prep_of	2	SENT_61	[p4l1287t1904r1729b2004],
9	were	VBD	O	be	cop	11	SENT_61	[p4l1768t1930r1968b1983],
10	not	RB	O	not	neg	11	SENT_61	[p4l2009t1920r2152b1982],
11	standardized	JJ	O	standardized	_	0	SENT_61	[p4l13t2031r580b2110],
12	.	.	O	.	_	0	SENT_61	[p4l13t2031r580b2110],

1	If	IN	O	if	mark	6	SENT_62	[p4l608t2031r689b2109],
2	the	DT	O	the	det	3	SENT_62	[p4l695t2031r824b2110],
3	specimens	NNS	O	specimen	nsubjpass	6	SENT_62	[p4l850t2032r1292b2132],
4	Were	VBD	O	be	auxpass	6	SENT_62	[p4l1314t2058r1515b2111],
5	not	RB	O	not	neg	6	SENT_62	[p4l1539t2048r1682b2110],
6	ﬁxed	VBN	O	ﬁxed	advcl	24	SENT_62	[p4l1702t2031r1905b2110],
7	Within	IN	O	within	dep	6	SENT_62	[p4l1925t2032r2145b2111, p4l11t2160r91b2237],
8	a	DT	O	a	det	10	SENT_62	[p4l111t2186r155b2238],
9	short	JJ	O	short	amod	10	SENT_62	[p4l175t2160r396b2238],
10	interval	NN	O	interval	pobj	7	SENT_62	[p4l410t2159r719b2239],
11	after	IN	O	after	_	0	SENT_62	[p4l738t2159r929b2238],
12	collection	NN	O	collection	prep_after	6	SENT_62	[p4l947t2159r1375b2255],
13	,	,	O	,	_	0	SENT_62	[p4l947t2159r1375b2255],
14	then	RB	O	then	advmod	16	SENT_62	[p4l1401t2160r1587b2238],
15	catalytic	JJ	O	catalytic	amod	16	SENT_62	[p4l1607t2160r1944b2260],
16	degradation	NN	O	degradation	nsubj	24	SENT_62	[p4l1965t2160r2146b2260, p4l11t2288r362b2366],
17	of	IN	O	of	_	0	SENT_62	[p4l395t2287r495b2366],
18	cell	NN	O	cell	nn	21	SENT_62	[p4l509t2287r987b2367],
19	—	NN	O	—	nn	21	SENT_62	[p4l509t2287r987b2367],
20	surface	NN	O	surface	nn	21	SENT_62	[p4l509t2287r987b2367],
21	receptors	NNS	O	receptor	prep_of	16	SENT_62	[p4l1019t2304r1406b2388],
22	may	MD	O	may	aux	24	SENT_62	[p4l1440t2314r1616b2388],
23	have	VB	O	have	aux	24	SENT_62	[p4l1643t2288r1831b2367],
24	altered	VBN	O	alter	_	0	SENT_62	[p4l1862t2287r2147b2366],
25	protein	NN	O	protein	nn	26	SENT_62	[p4l10t2416r315b2516],
26	expression	NN	O	expression	dobj	24	SENT_62	[p4l337t2416r811b2516],
27	.	.	O	.	_	0	SENT_62	[p4l337t2416r811b2516],

1	The	DT	O	the	det	2	SENT_63	[p4l834t2415r995b2494],
2	antibody	NN	O	antibody	nsubj	11	SENT_63	[p4l1017t2415r1386b2516],
3	used	VBN	O	use	partmod	2	SENT_63	[p4l1402t2416r1597b2495],
4	to	TO	O	to	aux	5	SENT_63	[p4l1619t2432r1697b2494],
5	determine	VB	O	determine	xcomp	3	SENT_63	[p4l1720t2416r2147b2494],
6	the	DT	O	the	det	7	SENT_63	[p4l12t2544r141b2622],
7	expression	NN	O	expression	dobj	5	SENT_63	[p4l175t2544r626b2644],
8	of	IN	O	of	_	0	SENT_63	[p4l660t2543r760b2622],
9	EGFR	NN	ORGANIZATION	egfr	prep_of	7	SENT_63	[p4l773t2549r1033b2627],
10	may	MD	O	may	aux	11	SENT_63	[p4l1056t2570r1232b2644],
11	recognize	VB	O	recognize	_	0	SENT_63	[p4l1261t2544r1669b2644],
12	an	DT	O	a	det	13	SENT_63	[p4l1703t2569r1803b2622],
13	epitope	NN	O	epitope	dobj	11	SENT_63	[p4l1837t2544r2147b2644],
14	that	WDT	O	that	nsubj	15	SENT_63	[p4l12t2672r178b2750],
15	differs	VBZ	O	differ	rcmod	13	SENT_63	[p4l196t2671r462b2750],
16	from	IN	O	from	_	0	SENT_63	[p4l488t2671r694b2750],
17	the	DT	O	the	det	18	SENT_63	[p4l718t2672r846b2750],
18	one	CD	NUMBER	one	prep_from	15	SENT_63	[p4l870t2697r1022b2750],
19	to	TO	O	to	_	0	SENT_63	[p4l1046t2688r1125b2750],
20	which	WDT	O	which	rel	22	SENT_63	[p4l1145t2672r1405b2751],
21	cetuximab	NN	O	cetuximab	nsubj	22	SENT_63	[p4l1428t2671r1860b2751],
22	binds	VBZ	O	bind	rcmod	18	SENT_63	[p4l1886t2671r2142b2750],
23	.	.	O	.	_	0	SENT_63	[p4l1886t2671r2142b2750],

1	In	IN	O	in	_	0	SENT_64	[p4l10t2807r97b2877],
2	such	JJ	O	such	amod	3	SENT_64	[p4l130t2799r324b2879],
3	cases	NNS	O	case	prep_in	10	SENT_64	[p4l357t2826r598b2895],
4	,	,	O	,	_	0	SENT_64	[p4l357t2826r598b2895],
5	a	DT	O	a	det	7	SENT_64	[p4l636t2826r680b2878],
6	positive	JJ	O	positive	amod	7	SENT_64	[p4l709t2800r1033b2900],
7	tumor	NN	O	tumor	nsubj	10	SENT_64	[p4l1065t2816r1327b2879],
8	may	MD	O	may	aux	10	SENT_64	[p4l1357t2826r1533b2900],
9	be	VB	O	be	cop	10	SENT_64	[p4l1561t2800r1657b2878],
10	negative	JJ	O	negative	_	0	SENT_64	[p4l1689t2800r2034b2900],
11	in	IN	O	in	_	0	SENT_64	[p4l2066t2800r2147b2877],
12	terms	NNS	O	term	prep_in	10	SENT_64	[p4l12t2944r248b3006],
13	of	IN	O	of	_	0	SENT_64	[p4l278t2927r378b3006],
14	cetuximab	NN	O	cetuximab	nn	15	SENT_64	[p4l386t2928r819b3007],
15	binding	NN	O	binding	prep_of	12	SENT_64	[p4l847t2928r1200b3028],
16	;	:	O	;	_	0	SENT_64	[p4l847t2928r1200b3028],
17	conversely	RB	O	conversely	advmod	22	SENT_64	[p4l1231t2928r1681b3028],
18	,	,	O	,	_	0	SENT_64	[p4l1231t2928r1681b3028],
19	cetuximab	NN	O	cetuximab	nsubj	22	SENT_64	[p4l1713t2928r2145b3007],
20	may	MD	O	may	aux	22	SENT_64	[p4l11t3082r188b3156],
21	not	RB	O	not	neg	22	SENT_64	[p4l214t3072r357b3134],
22	bind	VB	O	bind	parataxis	10	SENT_64	[p4l384t3056r574b3134],
23	to	TO	O	to	_	0	SENT_64	[p4l605t3072r684b3134],
24	a	DT	O	a	det	27	SENT_64	[p4l716t3082r760b3134],
25	positively	RB	O	positively	amod	27	SENT_64	[p4l789t3056r1187b3156],
26	staining	VBG	O	stain	amod	27	SENT_64	[p4l1215t3056r1559b3156],
27	tumor	NN	O	tumor	prep_to	22	SENT_64	[p4l1587t3072r1864b3135],
28	.	.	O	.	_	0	SENT_64	[p4l1587t3072r1864b3135],

1	In	IN	O	in	_	0	SENT_65	[p4l1900t3063r1987b3133],
2	the	DT	O	the	det	4	SENT_65	[p4l2018t3056r2147b3134],
3	current	JJ	DATE	current	amod	4	SENT_65	[p4l12t3200r319b3263],
4	trial	NN	O	trial	prep_in	16	SENT_65	[p4l340t3183r527b3279],
5	,	,	O	,	_	0	SENT_65	[p4l340t3183r527b3279],
6	the	DT	O	the	det	7	SENT_65	[p4l559t3183r688b3262],
7	sample	NN	O	sample	nsubj	16	SENT_65	[p4l715t3184r1015b3284],
8	for	IN	O	for	_	0	SENT_65	[p4l1041t3183r1164b3262],
9	the	DT	O	the	det	11	SENT_65	[p4l1187t3184r1315b3262],
10	analysis	NN	O	analysis	nn	11	SENT_65	[p4l1340t3184r1668b3284],
11	ofwhether	NN	O	ofwhether	prep_for	7	SENT_65	[p4l1698t3183r2150b3263],
12	a	DT	O	a	det	13	SENT_65	[p4l11t3338r55b3390],
13	correlation	NN	O	correlation	nsubj	14	SENT_65	[p4l95t3311r568b3390],
14	existed	VBD	O	exist	rcmod	11	SENT_65	[p4l609t3312r908b3390],
15	was	VBD	O	be	cop	16	SENT_65	[p4l943t3338r1108b3391],
16	small	JJ	O	small	_	0	SENT_65	[p4l1152t3311r1409b3407],
17	,	,	O	,	_	0	SENT_65	[p4l1152t3311r1409b3407],
18	and	CC	O	and	_	0	SENT_65	[p4l1454t3312r1612b3390],
19	no	DT	O	no	det	20	SENT_65	[p4l1652t3337r1759b3390],
20	patients	NNS	O	patient	nsubjpass	25	SENT_65	[p4l1799t3312r2143b3412],
21	Without	IN	O	without	_	0	SENT_65	[p4l7t3440r340b3519],
22	EGFR	NN	ORGANIZATION	egfr	nn	23	SENT_65	[p4l373t3445r632b3523],
23	expression	NN	O	expression	prep_without	25	SENT_65	[p4l661t3440r1112b3540],
24	were	VBD	O	be	auxpass	25	SENT_65	[p4l1147t3466r1348b3519],
25	tested	VBN	O	test	conj_and	16	SENT_65	[p4l1388t3440r1657b3518],
26	.	.	O	.	_	0	SENT_65	[p4l1388t3440r1657b3518],

1	Whether	IN	O	whether	complm	14	SENT_66	[p4l1698t3440r2069b3518],
2	a	DT	O	a	det	5	SENT_66	[p4l2104t3466r2148b3518],
3	post	NN	O	post	amod	5	SENT_66	[p4l10t3584r196b3668],
4	hoc	FW	O	hoc	dep	3	SENT_66	[p4l225t3567r377b3646],
5	analysis	NN	O	analysis	nsubj	14	SENT_66	[p4l409t3567r737b3668],
6	of	IN	O	of	_	0	SENT_66	[p4l774t3567r874b3646],
7	EGFR	NN	ORGANIZATION	egfr	nn	8	SENT_66	[p4l887t3573r1147b3651],
8	mutations	NNS	O	mutation	prep_of	5	SENT_66	[p4l1170t3568r1598b3647],
9	in	IN	O	in	_	0	SENT_66	[p4l1633t3568r1714b3645],
10	the	DT	O	the	det	12	SENT_66	[p4l1748t3568r1877b3646],
11	extracellular	JJ	O	extracellular	amod	12	SENT_66	[p4l1911t3584r2145b3646, p4l12t3695r321b3775],
12	domain	NN	O	domain	prep_in	8	SENT_66	[p4l344t3695r667b3774],
13	Will	MD	O	will	aux	14	SENT_66	[p4l688t3696r844b3775],
14	identify	VB	O	identify	_	0	SENT_66	[p4l868t3695r1187b3796],
15	a	DT	O	a	det	16	SENT_66	[p4l1208t3722r1252b3774],
16	subgroup	NN	O	subgroup	dobj	14	SENT_66	[p4l1278t3695r1679b3796],
17	of	IN	O	of	_	0	SENT_66	[p4l1707t3695r1807b3774],
18	patients	NNS	O	patient	prep_of	16	SENT_66	[p4l1812t3696r2145b3796],

1	Who	WP	O	who	nsubj	4	SENT_67	[p5l7t20r190b100],
2	are	VBP	O	be	cop	4	SENT_67	[p5l218t47r344b99],
3	more	RBR	O	more	advmod	4	SENT_67	[p5l372t46r592b99],
4	likely	JJ	O	likely	csubj	28	SENT_67	[p5l619t20r844b121],
5	than	IN	O	than	_	0	SENT_67	[p5l868t21r1055b99],
6	others	NNS	O	other	prep_than	4	SENT_67	[p5l1083t20r1344b99],
7	to	TO	O	to	aux	8	SENT_67	[p5l1375t37r1454b99],
8	have	VB	O	have	infmod	6	SENT_67	[p5l1484t21r1671b100],
9	a	DT	O	a	det	10	SENT_67	[p5l1699t47r1743b99],
10	response	NN	O	response	dobj	8	SENT_67	[p5l1769t46r2147b121],
11	to	TO	O	to	_	0	SENT_67	[p5l12t165r90b227],
12	cetuximab	NN	O	cetuximab	prep_to	8	SENT_67	[p5l131t149r588b244],
13	,	,	O	,	_	0	SENT_67	[p5l131t149r588b244],
14	as	IN	O	as	mark	16	SENT_67	[p5l632t175r715b227],
15	recently	RB	DATE	recently	advmod	16	SENT_67	[p5l756t149r1087b249],
16	reported	VBN	O	report	advcl	8	SENT_67	[p5l1121t148r1479b249],
17	for	IN	O	for	_	0	SENT_67	[p5l1516t148r1640b227],
18	geﬁtinib	NN	O	geﬁtinib	prep_for	16	SENT_67	[p5l1674t148r2027b249],
19	in	IN	O	in	_	0	SENT_67	[p5l2066t149r2147b226],
20	patients	NNS	O	patient	prep_in	18	SENT_67	[p5l10t278r343b378],
21	With	IN	O	with	_	0	SENT_67	[p5l365t278r553b357],
22	lung	NN	O	lung	nn	23	SENT_67	[p5l576t278r769b378],
23	cancer	NN	O	cancer	prep_with	8	SENT_67	[p5l790t273r1125b373],
24	,9	CD	NUMBER	,9	num	23	SENT_67	[p5l790t273r1125b373],
25	is	VBZ	O	be	cop	28	SENT_67	[p5l1149t278r1214b356],
26	an	DT	O	a	det	28	SENT_67	[p5l1240t303r1340b356],
27	open	JJ	O	open	amod	28	SENT_67	[p5l1365t303r1573b378],
28	question	NN	O	question	_	0	SENT_67	[p5l1598t278r1984b378],
29	.	.	O	.	_	0	SENT_67	[p5l1598t278r1984b378],

1	Finally	RB	O	finally	advmod	15	SENT_68	[p5l139t405r430b506],
2	,	,	O	,	_	0	SENT_68	[p5l139t405r430b506],
3	the	DT	O	the	det	4	SENT_68	[p5l467t406r595b484],
4	authors	NNS	O	author	nn	7	SENT_68	[p5l625t406r940b485],
5	present	JJ	DATE	present	amod	7	SENT_68	[p5l972t422r1286b506],
6	intriguing	JJ	O	intriguing	amod	7	SENT_68	[p5l1311t406r1733b506],
7	data	NNS	O	datum	nsubjpass	15	SENT_68	[p5l1761t405r1938b484],
8	suggesting	VBG	O	suggest	partmod	7	SENT_68	[p5l1969t432r2146b506, p5l11t534r319b634],
9	that	IN	O	that	advmod	8	SENT_68	[p5l340t534r504b612],
10	the	DT	O	the	det	11	SENT_68	[p5l523t534r651b612],
11	response	NN	O	response	pobj	9	SENT_68	[p5l675t559r1048b634],
12	to	TO	O	to	_	0	SENT_68	[p5l1073t550r1151b612],
13	cetuximab	NN	O	cetuximab	prep_to	8	SENT_68	[p5l1177t534r1605b613],
14	is	VBZ	O	be	auxpass	15	SENT_68	[p5l1629t534r1693b612],
15	associated	VBN	O	associate	_	0	SENT_68	[p5l1719t534r2148b612],
16	With	IN	O	with	_	0	SENT_68	[p5l7t662r197b741],
17	a	DT	O	a	det	18	SENT_68	[p5l234t688r279b740],
18	rash	NN	O	rash	prep_with	15	SENT_68	[p5l315t662r521b740],
19	.	.	O	.	_	0	SENT_68	[p5l315t662r521b740],

1	Among	IN	O	among	_	0	SENT_69	[p5l560t669r881b762],
2	patients	NNS	O	patient	prep_among	10	SENT_69	[p5l915t662r1251b762],
3	in	IN	O	in	_	0	SENT_69	[p5l1291t662r1372b739],
4	Whom	WP	O	whom	rel	7	SENT_69	[p5l1406t662r1679b741],
5	a	DT	O	a	det	6	SENT_69	[p5l1716t688r1761b740],
6	rash	NN	O	rash	nsubj	7	SENT_69	[p5l1797t662r1979b740],
7	occurred	VBD	O	occur	rcmod	2	SENT_69	[p5l2018t687r2145b740, p5l12t790r300b885],
8	,	,	O	,	_	0	SENT_69	[p5l2018t687r2145b740, p5l12t790r300b885],
9	it	PRP	O	it	nsubj	10	SENT_69	[p5l326t790r385b868],
10	developed	VBD	O	develop	_	0	SENT_69	[p5l400t789r818b890],
11	Within	IN	O	within	_	0	SENT_69	[p5l833t790r1104b869],
12	the	DT	O	the	det	13	SENT_69	[p5l1125t790r1252b868],
13	ﬁrst	NN	O	ﬁrst	prep_within	35	SENT_69	[p5l1272t789r1442b868],
14	three	CD	DURATION	three	num	15	SENT_69	[p5l1458t789r1667b868],
15	Weeks	NNS	DURATION	week	dep	13	SENT_69	[p5l1682t789r1939b869],
16	after	IN	O	after	_	0	SENT_69	[p5l1961t789r2151b868],
17	the	DT	O	the	det	18	SENT_69	[p5l12t918r139b996],
18	start	NN	O	start	prep_after	15	SENT_69	[p5l165t934r353b996],
19	of	IN	O	of	_	0	SENT_69	[p5l373t917r473b996],
20	therapy	NN	O	therapy	prep_of	18	SENT_69	[p5l479t918r791b1018],
21	in	IN	O	in	_	0	SENT_69	[p5l810t918r890b995],
22	89	CD	PERCENT	89	num	23	SENT_69	[p5l916t923r1014b996],
23	percent	NN	PERCENT	percent	prep_in	20	SENT_69	[p5l1038t934r1353b1018],
24	of	IN	O	of	_	0	SENT_69	[p5l1373t917r1473b996],
25	the	DT	O	the	det	26	SENT_69	[p5l1479t918r1607b996],
26	patients	NNS	O	patient	prep_of	23	SENT_69	[p5l1629t918r1983b1018],
27	,	,	O	,	_	0	SENT_69	[p5l1629t918r1983b1018],
28	but	CC	O	but	_	0	SENT_69	[p5l2013t917r2153b997],
29	in	IN	O	in	dep	13	SENT_69	[p5l11t1046r91b1123],
30	23	CD	PERCENT	23	num	31	SENT_69	[p5l124t1051r221b1124],
31	percent	NN	PERCENT	percent	pobj	29	SENT_69	[p5l256t1062r572b1146],
32	a	DT	O	a	det	33	SENT_69	[p5l599t1072r644b1124],
33	rash	NN	O	rash	nsubj	35	SENT_69	[p5l675t1046r853b1124],
34	never	RB	O	never	neg	35	SENT_69	[p5l886t1071r1111b1125],
35	developed	VBD	O	develop	ccomp	10	SENT_69	[p5l1141t1045r1581b1146],
36	,	,	O	,	_	0	SENT_69	[p5l1141t1045r1581b1146],
37	and	CC	O	and	_	0	SENT_69	[p5l1619t1046r1773b1124],
38	thus	RB	O	thus	advmod	42	SENT_69	[p5l1807t1046r1984b1125],
39	the	DT	O	the	det	40	SENT_69	[p5l2019t1046r2147b1124],
40	analysis	NN	O	analysis	nsubj	42	SENT_69	[p5l11t1174r335b1274],
41	becomes	VBZ	O	become	cop	42	SENT_69	[p5l361t1174r725b1252],
42	subject	JJ	O	subject	conj_and	10	SENT_69	[p5l751t1174r1045b1274],
43	to	TO	O	to	_	0	SENT_69	[p5l1062t1190r1140b1252],
44	bias	NN	O	bias	prep_to	42	SENT_69	[p5l1165t1174r1353b1252],
45	.	.	O	.	_	0	SENT_69	[p5l1165t1174r1353b1252],

1	Patients	NNS	O	patient	nsubjpass	5	SENT_70	[p5l1379t1174r1706b1252],
2	must	MD	O	must	aux	5	SENT_70	[p5l1730t1190r1944b1253],
3	have	VB	O	have	aux	5	SENT_70	[p5l1961t1173r2147b1253],
4	been	VBN	O	be	auxpass	5	SENT_70	[p5l12t1302r209b1380],
5	treated	VBN	O	treat	_	0	SENT_70	[p5l242t1301r526b1380],
6	sufficiently	RB	O	sufficiently	advmod	7	SENT_70	[p5l560t1301r1019b1402],
7	long	RB	O	long	advmod	5	SENT_70	[p5l1047t1302r1238b1402],
8	for	IN	O	for	_	0	SENT_70	[p5l1267t1301r1388b1380],
9	the	DT	O	the	det	11	SENT_70	[p5l1419t1302r1546b1380],
10	toxic	JJ	O	toxic	amod	11	SENT_70	[p5l1580t1302r1777b1380],
11	effect	NN	O	effect	prep_for	5	SENT_70	[p5l1810t1301r2040b1380],
12	to	TO	O	to	aux	13	SENT_70	[p5l2068t1318r2146b1380],
13	develop	VB	O	develop	xcomp	5	SENT_70	[p5l12t1429r361b1530],
14	;	:	O	;	_	0	SENT_70	[p5l12t1429r361b1530],
15	rapid	JJ	O	rapid	amod	16	SENT_70	[p5l403t1430r623b1530],
16	failures	NNS	O	failure	nsubj	18	SENT_70	[p5l660t1429r973b1509],
17	Were	VBD	O	be	cop	18	SENT_70	[p5l1008t1456r1211b1509],
18	likely	JJ	O	likely	parataxis	5	SENT_70	[p5l1248t1429r1475b1530],
19	to	TO	O	to	aux	20	SENT_70	[p5l1508t1446r1588b1508],
20	occur	VB	O	occur	xcomp	18	SENT_70	[p5l1628t1455r1863b1509],
21	in	IN	O	in	_	0	SENT_70	[p5l1897t1430r1978b1507],
22	the	DT	O	the	det	23	SENT_70	[p5l2017t1430r2146b1508],
23	group	NN	O	group	prep_in	20	SENT_70	[p5l11t1583r259b1658],
24	of	IN	O	of	_	0	SENT_70	[p5l286t1557r386b1636],
25	patients	NNS	O	patient	prep_of	23	SENT_70	[p5l391t1558r720b1658],
26	without	IN	O	without	_	0	SENT_70	[p5l742t1558r1073b1637],
27	a	DT	O	a	det	28	SENT_70	[p5l1092t1584r1137b1636],
28	rash	NN	O	rash	prep_without	20	SENT_70	[p5l1160t1558r1361b1653],
29	,	,	O	,	_	0	SENT_70	[p5l1160t1558r1361b1653],
30	biasing	VBG	O	bias	xcomp	20	SENT_70	[p5l1392t1557r1698b1658],
31	the	DT	O	the	det	32	SENT_70	[p5l1721t1558r1848b1636],
32	results	NNS	O	result	dobj	30	SENT_70	[p5l1873t1558r2145b1637],
33	toward	IN	O	toward	_	0	SENT_70	[p5l12t1686r301b1765],
34	poor	JJ	O	poor	amod	36	SENT_70	[p5l323t1711r522b1786],
35	response	NN	O	response	nn	36	SENT_70	[p5l542t1711r916b1786],
36	rates	NNS	O	rate	prep_toward	30	SENT_70	[p5l939t1702r1134b1764],
37	in	IN	O	in	_	0	SENT_70	[p5l1158t1686r1239b1763],
38	this	DT	O	this	det	39	SENT_70	[p5l1262t1686r1413b1764],
39	group	NN	O	group	prep_in	36	SENT_70	[p5l1437t1711r1709b1786],
40	.	.	O	.	_	0	SENT_70	[p5l1437t1711r1709b1786],

1	Prolonga	NNP	O	Prolonga	nn	3	SENT_71	[p5l1737t1686r2146b1786],
2	—	CD	NUMBER	—	num	3	SENT_71	[p5l1737t1686r2146b1786],
3	tion	NN	O	tion	_	0	SENT_71	[p5l12t1814r175b1892],
4	of	IN	O	of	_	0	SENT_71	[p5l214t1813r314b1892],
5	the	DT	O	the	det	6	SENT_71	[p5l335t1813r462b1892],
6	time	NN	O	time	prep_of	3	SENT_71	[p5l501t1814r685b1892],
7	to	TO	O	to	_	0	SENT_71	[p5l724t1830r803b1892],
8	progression	NN	O	progression	nn	11	SENT_71	[p5l841t1814r1341b1914],
9	and	CC	O	and	_	0	SENT_71	[p5l1379t1814r1533b1892],
10	moderate	JJ	O	moderate	nn	11	SENT_71	[p5l1572t1813r1965b1892],
11	improvements	NNS	O	improvement	prep_to	3	SENT_71	[p5l2004t1814r2146b1891, p5l10t1958r499b2042],
12	in	IN	O	in	_	0	SENT_71	[p5l546t1942r626b2019],
13	the	DT	O	the	det	14	SENT_71	[p5l672t1942r800b2020],
14	rate	NN	O	rate	prep_in	3	SENT_71	[p5l846t1958r999b2020],
15	of	IN	O	of	_	0	SENT_71	[p5l1046t1941r1146b2020],
16	response	NN	O	response	prep_of	3	SENT_71	[p5l1173t1967r1546b2042],
17	to	TO	O	to	_	0	SENT_71	[p5l1592t1958r1671b2020],
18	cetuximab	NN	O	cetuximab	nn	19	SENT_71	[p5l1718t1942r2146b2021],
19	therapy	NN	O	therapy	prep_to	3	SENT_71	[p5l12t2070r324b2170],
20	come	VBN	O	come	partmod	3	SENT_71	[p5l345t2095r570b2148],
21	at	IN	O	at	_	0	SENT_71	[p5l596t2086r674b2148],
22	a	DT	O	a	det	23	SENT_71	[p5l694t2096r738b2148],
23	price	NN	O	price	prep_at	20	SENT_71	[p5l761t2071r989b2170],
24	,	,	O	,	_	0	SENT_71	[p5l761t2071r989b2170],
25	as	IN	O	as	mark	26	SENT_71	[p5l1019t2096r1103b2148],
26	discussed	VBN	O	discuss	dep	23	SENT_71	[p5l1131t2070r1534b2149],
27	by	IN	O	by	_	0	SENT_71	[p5l1560t2070r1656b2170],
28	Schrag1	NN	O	schrag1	nn	29	SENT_71	[p5l1680t2064r2041b2170],
29	°	NN	O	°	prep_by	26	SENT_71	[p5l1680t2064r2041b2170],
30	in	IN	O	in	_	0	SENT_71	[p5l2066t2071r2147b2147],
31	a	DT	O	a	det	33	SENT_71	[p5l11t2224r55b2276],
32	Perspective	NNP	O	Perspective	nn	33	SENT_71	[p5l75t2198r539b2298],
33	article	NN	O	article	prep_in	29	SENT_71	[p5l561t2198r836b2293],
34	,	,	O	,	_	0	SENT_71	[p5l561t2198r836b2293],
35	also	RB	O	also	advmod	26	SENT_71	[p5l864t2198r1029b2276],
36	in	IN	O	in	_	0	SENT_71	[p5l1053t2198r1134b2275],
37	this	DT	O	this	det	38	SENT_71	[p5l1157t2198r1307b2276],
38	issue	NN	O	issue	prep_in	26	SENT_71	[p5l1331t2198r1540b2277],
39	of	IN	O	of	_	0	SENT_71	[p5l1563t2197r1663b2276],
40	thejoumal	NN	O	thejoumal	prep_of	38	SENT_71	[p5l1668t2197r2084b2298],
41	.	.	O	.	_	0	SENT_71	[p5l2093t2262r2106b2276],

1	In	IN	O	in	_	0	SENT_72	[p5l139t2333r227b2403],
2	essence	NN	O	essence	prep_in	7	SENT_72	[p5l249t2351r596b2421],
3	,	,	O	,	_	0	SENT_72	[p5l249t2351r596b2421],
4	the	DT	O	the	det	6	SENT_72	[p5l623t2326r753b2404],
5	current	JJ	DATE	current	amod	6	SENT_72	[p5l775t2342r1085b2405],
6	trial	NN	O	trial	nsubj	7	SENT_72	[p5l1102t2326r1269b2404],
7	seems	VBZ	O	seem	_	0	SENT_72	[p5l1291t2352r1550b2404],
8	to	TO	O	to	aux	9	SENT_72	[p5l1574t2342r1653b2404],
9	validate	VB	O	validate	xcomp	7	SENT_72	[p5l1672t2325r1997b2405],
10	the	DT	O	the	det	14	SENT_72	[p5l2019t2326r2147b2404],
11	previously	RB	DATE	previously	advmod	12	SENT_72	[p5l10t2455r439b2555],
12	reported	VBN	O	report	amod	14	SENT_72	[p5l473t2455r828b2555],
13	single	JJ	O	single	amod	14	SENT_72	[p5l868t2455r1402b2555],
14	—	NN	O	—	dobj	9	SENT_72	[p5l868t2455r1402b2555],
15	group	NN	O	group	nn	16	SENT_72	[p5l868t2455r1402b2555],
16	studies	NNS	O	study	nsubj	35	SENT_72	[p5l1444t2455r1734b2534],
17	of	IN	O	of	_	0	SENT_72	[p5l1776t2454r1876b2533],
18	cetuximab	NN	O	cetuximab	prep_of	16	SENT_72	[p5l1897t2471r2146b2534, p5l11t2583r227b2661],
19	alone	RB	O	alone	advmod	18	SENT_72	[p5l275t2583r509b2661],
20	and	CC	O	and	_	0	SENT_72	[p5l556t2583r715b2661],
21	cetuximab	NN	O	cetuximab	conj_and	18	SENT_72	[p5l763t2583r1208b2662],
22	plus	CC	O	plus	prep	21	SENT_72	[p5l1256t2583r1436b2683],
23	irinotecan	NN	O	irinotecan	nn	25	SENT_72	[p5l1485t2577r2145b2661],
24	.11	CD	NUMBER	.11	num	25	SENT_72	[p5l1485t2577r2145b2661],
25	’12	NN	O	’12	dep	22	SENT_72	[p5l1485t2577r2145b2661],
26	For	IN	O	for	_	0	SENT_72	[p5l10t2718r157b2789],
27	these	DT	O	these	det	28	SENT_72	[p5l188t2711r412b2789],
28	reasons	NNS	O	reason	prep_for	25	SENT_72	[p5l445t2736r776b2789],
29	and	CC	O	and	_	0	SENT_72	[p5l811t2710r969b2789],
30	others	NNS	O	other	conj_and	28	SENT_72	[p5l1004t2711r1273b2789],
31	that	WDT	O	that	nsubj	34	SENT_72	[p5l1309t2711r1479b2789],
32	have	VBP	O	have	aux	34	SENT_72	[p5l1507t2710r1700b2790],
33	been	VBN	O	be	cop	34	SENT_72	[p5l1734t2711r1938b2789],
34	Well	UH	O	well	rcmod	28	SENT_72	[p5l1967t2711r2146b2790],
35	chronicled	VBD	O	chronicle	rcmod	14	SENT_72	[p5l12t2833r571b2934],
36	,13	CD	NUMBER	,13	nsubj	42	SENT_72	[p5l12t2833r571b2934],
37	the	DT	DURATION	the	det	40	SENT_72	[p5l598t2839r728b2917],
38	past	JJ	DURATION	past	amod	40	SENT_72	[p5l752t2855r932b2939],
39	three	CD	DURATION	three	num	40	SENT_72	[p5l952t2839r1165b2917],
40	years	NNS	NUMBER	year	tmod	36	SENT_72	[p5l1186t2865r1401b2939],
41	have	VBP	O	have	aux	42	SENT_72	[p5l1428t2839r1617b2918],
42	provided	VBN	O	provide	ccomp	35	SENT_72	[p5l1641t2839r2014b2939],
43	no	DT	O	no	det	45	SENT_72	[p5l2039t2864r2145b2917],
44	mature	JJ	O	mature	amod	45	SENT_72	[p5l11t2983r311b3046],
45	data	NNS	O	datum	dobj	42	SENT_72	[p5l346t2966r526b3045],
46	on	IN	O	on	_	0	SENT_72	[p5l559t2992r666b3045],
47	cetuximab	NN	O	cetuximab	prep_on	45	SENT_72	[p5l700t2967r1137b3046],
48	and	CC	O	and	_	0	SENT_72	[p5l1171t2966r1327b3045],
49	irinotecan	NN	O	irinotecan	prep_on	45	SENT_72	[p5l1360t2967r1790b3045],
50	as	IN	O	as	_	0	SENT_72	[p5l1822t2993r1907b3045],
51	firstline	NN	O	firstline	prep_as	42	SENT_72	[p5l1943t2966r2145b3045, p5l10t3095r166b3173],

1	treatment	NN	O	treatment	nsubj	3	SENT_73	[p5l195t3111r612b3173],
2	or	CC	O	or	dep	3	SENT_73	[p5l636t3120r726b3173],
3	in	IN	O	in	_	0	SENT_73	[p5l750t3095r832b3172],
4	combination	NN	O	combination	pobj	3	SENT_73	[p5l861t3095r1404b3173],
5	with	IN	O	with	_	0	SENT_73	[p5l1428t3095r1618b3174],
6	ﬂuorouracil	NN	O	ﬂuorouracil	nn	9	SENT_73	[p5l1647t3094r2147b3174],
7	or	CC	O	or	_	0	SENT_73	[p5l12t3248r101b3301],
8	ﬂuorouracil	NN	O	ﬂuorouracil	conj_or	6	SENT_73	[p5l118t3222r1288b3323],
9	—	NN	O	—	prep_with	3	SENT_73	[p5l118t3222r1288b3323],
10	and	CC	O	and	_	0	SENT_73	[p5l118t3222r1288b3323],
11	—	NN	O	—	nn	13	SENT_73	[p5l118t3222r1288b3323],
12	oxaliplatin	NN	O	oxaliplatin	nn	13	SENT_73	[p5l118t3222r1288b3323],
13	regimens	NNS	O	regimen	conj_and	9	SENT_73	[p5l1309t3223r1724b3323],
14	.	.	O	.	_	0	SENT_73	[p5l1309t3223r1724b3323],

1	N	NN	O	n	nn	2	SENT_74	[p5l1748t3230r1824b3302],
2	onethe	NN	O	onethe	tmod	7	SENT_74	[p5l1827t3223r2145b3301],
3	—	CD	NUMBER	—	npadvmod	4	SENT_74	[p5l1827t3223r2145b3301],
4	less	JJR	O	less	advmod	2	SENT_74	[p5l10t3351r189b3446],
5	,	,	O	,	_	0	SENT_74	[p5l10t3351r189b3446],
6	trials	NNS	O	trial	nsubj	7	SENT_74	[p5l217t3351r423b3429],
7	ofcetuximab	VBP	O	ofcetuximab	_	0	SENT_74	[p5l448t3350r985b3430],
8	as	IN	O	as	mark	17	SENT_74	[p5l1007t3377r1091b3429],
9	a	DT	O	a	det	10	SENT_74	[p5l1114t3377r1160b3429],
10	component	NN	O	component	nsubj	17	SENT_74	[p5l1180t3367r1667b3451],
11	of	IN	O	of	_	0	SENT_74	[p5l1685t3350r1785b3429],
12	ﬁrst	NN	O	ﬁrst	nn	15	SENT_74	[p5l1788t3350r2147b3429],
13	—	CD	NUMBER	—	num	15	SENT_74	[p5l1788t3350r2147b3429],
14	line	NN	O	line	nn	15	SENT_74	[p5l1788t3350r2147b3429],
15	treatment	NN	O	treatment	prep_of	10	SENT_74	[p5l12t3495r428b3557],
16	are	VBP	O	be	cop	17	SENT_74	[p5l445t3505r572b3557],
17	ongoing	JJ	O	ongoing	advcl	7	SENT_74	[p5l597t3479r976b3579],
18	,	,	O	,	_	0	SENT_74	[p5l597t3479r976b3579],
19	and	CC	O	and	_	0	SENT_74	[p5l1004t3479r1161b3557],
20	the	DT	O	the	det	21	SENT_74	[p5l1184t3479r1314b3557],
21	agent	NN	O	agent	nsubj	23	SENT_74	[p5l1337t3495r1575b3579],
22	is	VBZ	O	be	aux	23	SENT_74	[p5l1593t3479r1658b3557],
23	about	IN	O	about	conj_and	7	SENT_74	[p5l1682t3479r1927b3558],
24	to	TO	O	to	aux	26	SENT_74	[p5l1945t3495r2025b3557],
25	be	VB	O	be	auxpass	26	SENT_74	[p5l2050t3479r2146b3557],
26	added	VBN	O	add	xcomp	23	SENT_74	[p5l11t3606r267b3685],
27	to	TO	O	to	_	0	SENT_74	[p5l304t3623r383b3685],
28	an	DT	O	a	det	30	SENT_74	[p5l422t3632r523b3685],
29	ongoing	JJ	O	ongoing	amod	30	SENT_74	[p5l561t3607r920b3707],
30	trial	NN	O	trial	prep_to	26	SENT_74	[p5l955t3606r1122b3685],
31	of	IN	O	of	_	0	SENT_74	[p5l1160t3606r1261b3685],
32	adjuvant	JJ	O	adjuvant	amod	33	SENT_74	[p5l1279t3606r1642b3707],
33	therapy	NN	O	therapy	prep_of	30	SENT_74	[p5l1674t3607r1993b3707],
34	for	IN	O	for	_	0	SENT_74	[p5l2026t3606r2149b3685],
35	colon	NN	O	colon	nn	36	SENT_74	[p5l12t3709r247b3787],
36	cancer	NN	O	cancer	prep_for	33	SENT_74	[p5l273t3734r566b3787],
37	.	.	O	.	_	0	SENT_74	[p5l273t3734r566b3787],

1	For	IN	O	for	_	0	SENT_75	[p6l139t40r283b112],
2	patients	NNS	O	patient	prep_for	12	SENT_75	[p6l321t34r653b134],
3	With	IN	O	with	_	0	SENT_75	[p6l692t34r881b113],
4	metastatic	JJ	O	metastatic	amod	6	SENT_75	[p6l922t34r1358b112],
5	colorectal	JJ	O	colorectal	amod	6	SENT_75	[p6l1399t34r1810b112],
6	cancer	NN	O	cancer	prep_with	12	SENT_75	[p6l1852t59r2141b129],
7	,	,	O	,	_	0	SENT_75	[p6l1852t59r2141b129],
8	the	DT	DATE	the	det	10	SENT_75	[p6l15t162r143b240],
9	past	JJ	DATE	past	amod	10	SENT_75	[p6l169t178r347b262],
10	year	NN	DATE	year	nsubj	12	SENT_75	[p6l364t188r538b262],
11	has	VBZ	O	have	aux	12	SENT_75	[p6l562t162r703b240],
12	seen	VBN	O	see	_	0	SENT_75	[p6l733t187r918b240],
13	multiple	JJ	O	multiple	amod	14	SENT_75	[p6l945t161r1295b262],
14	new	JJ	O	new	dobj	12	SENT_75	[p6l1323t187r1498b241],
15	and	CC	O	and	_	0	SENT_75	[p6l1520t162r1675b240],
16	promising	JJ	O	promising	amod	18	SENT_75	[p6l1701t162r2142b262],
17	treatment	NN	O	treatment	nn	18	SENT_75	[p6l15t306r424b368],
18	options	NNS	O	option	dobj	12	SENT_75	[p6l441t290r780b390],
19	.	.	O	.	_	0	SENT_75	[p6l441t290r780b390],

1	The	DT	O	the	det	2	SENT_76	[p6l803t289r963b368],
2	addition	NN	O	addition	nsubjpass	18	SENT_76	[p6l984t290r1332b368],
3	of	IN	O	of	_	0	SENT_76	[p6l1354t289r1454b368],
4	cetuximab	NN	O	cetuximab	prep_of	2	SENT_76	[p6l1457t290r1887b369],
5	in	IN	O	in	_	0	SENT_76	[p6l1909t290r1989b367],
6	the	DT	O	the	det	7	SENT_76	[p6l2011t289r2139b368],
7	armamentarium	NN	O	armamentarium	prep_in	4	SENT_76	[p6l14t418r696b497],
8	of	IN	O	of	_	0	SENT_76	[p6l718t417r818b496],
9	treatment	NN	O	treatment	nn	10	SENT_76	[p6l820t434r1228b496],
10	options	NNS	O	option	prep_of	7	SENT_76	[p6l1244t418r1556b518],
11	for	IN	O	for	_	0	SENT_76	[p6l1578t417r1700b496],
12	this	DT	O	this	det	13	SENT_76	[p6l1718t418r1868b496],
13	group	NN	O	group	prep_for	10	SENT_76	[p6l1891t443r2138b518],
14	of	IN	O	of	_	0	SENT_76	[p6l15t545r115b624],
15	patients	NNS	O	patient	prep_of	13	SENT_76	[p6l118t546r449b646],
16	must	MD	O	must	aux	18	SENT_76	[p6l474t562r690b625],
17	be	VB	O	be	auxpass	18	SENT_76	[p6l709t546r803b624],
18	tempered	VBN	O	temper	_	0	SENT_76	[p6l828t545r1224b646],
19	by	IN	O	by	_	0	SENT_76	[p6l1247t545r1344b646],
20	the	DT	O	the	det	22	SENT_76	[p6l1363t546r1491b624],
21	small	JJ	O	small	amod	22	SENT_76	[p6l1515t545r1741b624],
22	advances	NNS	O	advance	agent	18	SENT_76	[p6l1763t545r2137b625],
23	that	IN	O	that	complm	25	SENT_76	[p6l15t674r180b752],
24	it	PRP	O	it	nsubj	25	SENT_76	[p6l196t674r255b752],
25	offers	VBZ	O	offer	ccomp	18	SENT_76	[p6l273t673r510b752],
26	in	IN	O	in	_	0	SENT_76	[p6l534t674r614b751],
27	terms	NNS	O	term	prep_in	25	SENT_76	[p6l637t690r872b752],
28	of	IN	O	of	_	0	SENT_76	[p6l897t673r997b752],
29	the	DT	O	the	det	30	SENT_76	[p6l1001t673r1129b752],
30	time	NN	O	time	prep_of	27	SENT_76	[p6l1152t674r1337b752],
31	to	TO	O	to	_	0	SENT_76	[p6l1360t690r1438b752],
32	progression	NN	O	progression	prep_to	25	SENT_76	[p6l1460t674r1963b774],
33	and	CC	O	and	_	0	SENT_76	[p6l1985t673r2140b752],
34	the	DT	O	the	det	36	SENT_76	[p6l15t802r143b880],
35	response	NN	O	response	nn	36	SENT_76	[p6l164t827r539b902],
36	rate	NN	O	rate	prep_to	25	SENT_76	[p6l561t818r716b880],
37	and	CC	O	and	_	0	SENT_76	[p6l736t802r891b880],
38	its	PRP$	O	its	poss	40	SENT_76	[p6l911t802r1006b880],
39	uncertain	JJ	O	uncertain	amod	40	SENT_76	[p6l1029t802r1428b881],
40	effect	NN	O	effect	dep	49	SENT_76	[p6l1449t801r1680b880],
41	on	IN	O	on	_	0	SENT_76	[p6l1697t827r1803b880],
42	survival	NN	O	survival	prep_on	40	SENT_76	[p6l1825t801r2140b881],
43	in	IN	O	in	_	0	SENT_76	[p6l14t930r94b1007],
44	patients	NNS	O	patient	prep_in	42	SENT_76	[p6l111t930r437b1030],
45	with	IN	O	with	_	0	SENT_76	[p6l454t929r640b1009],
46	irinotecan	NN	O	irinotecan	prep_with	44	SENT_76	[p6l658t929r1512b1030],
47	—	CD	NUMBER	—	num	49	SENT_76	[p6l658t929r1512b1030],
48	refractory	JJ	O	refractory	amod	49	SENT_76	[p6l658t929r1512b1030],
49	cancer	NN	O	cancer	ccomp	18	SENT_76	[p6l1527t955r1812b1008],
50	.	.	O	.	_	0	SENT_76	[p6l1527t955r1812b1008],

1	The	DT	O	the	det	2	SENT_77	[p6l1833t930r1992b1008],
2	development	NN	O	development	nsubj	5	SENT_77	[p6l2012t930r2139b1008, p6l10t1058r459b1158],
3	of	IN	O	of	prep	2	SENT_77	[p6l482t1057r581b1136],
4	fully	RB	O	fully	pcomp	3	SENT_77	[p6l590t1057r774b1158],
5	humanized	VBN	O	humanize	_	0	SENT_77	[p6l796t1057r1268b1137],
6	antibodies	NNS	O	antibody	dobj	5	SENT_77	[p6l1294t1057r1729b1136],
7	to	TO	O	to	_	0	SENT_77	[p6l1758t1074r1837b1136],
8	EGFR	NN	ORGANIZATION	egfr	prep_to	5	SENT_77	[p6l1864t1063r2134b1153],
9	,	,	O	,	_	0	SENT_77	[p6l1864t1063r2134b1153],
10	such	JJ	O	such	_	0	SENT_77	[p6l16t1186r209b1265],
11	as	IN	O	as	_	0	SENT_77	[p6l233t1212r316b1264],
12	EMD72000	NN	O	emd72000	prep_such_as	5	SENT_77	[p6l341t1191r815b1264],
13	and	CC	O	and	_	0	SENT_77	[p6l840t1186r995b1264],
14	ABX	NN	O	abx	prep_such_as	5	SENT_77	[p6l1016t1191r1428b1281],
15	.	.	O	.	_	0	SENT_77	[p6l1016t1191r1428b1281],

1	—	NN	O	—	_	0	SENT_78	[p6l1016t1191r1428b1281],
2	.	.	O	.	_	0	SENT_78	[p6l1016t1191r1428b1281],

1	EGF	NN	ORGANIZATION	egf	nsubj	3	SENT_79	[p6l1016t1191r1428b1281],
2	,	,	O	,	_	0	SENT_79	[p6l1016t1191r1428b1281],
3	holds	VBZ	O	hold	_	0	SENT_79	[p6l1457t1185r1687b1264],
4	the	DT	O	the	det	5	SENT_79	[p6l1714t1186r1842b1264],
5	potential	NN	O	potential	dobj	3	SENT_79	[p6l1866t1202r2137b1286, p6l15t1314r147b1392],
6	for	IN	O	for	_	0	SENT_79	[p6l174t1313r299b1392],
7	further	JJ	O	further	amod	8	SENT_79	[p6l324t1313r626b1393],
8	refinement	NN	O	refinement	prep_for	5	SENT_79	[p6l651t1313r1130b1392],
9	of	IN	O	of	_	0	SENT_79	[p6l1153t1313r1255b1392],
10	EGFR	NN	ORGANIZATION	egfr	prep_of	8	SENT_79	[p6l1262t1313r1904b1414],
11	—	CD	NUMBER	—	num	10	SENT_79	[p6l1262t1313r1904b1414],
12	targeted	VBN	O	target	partmod	10	SENT_79	[p6l1262t1313r1904b1414],
13	therapy	NN	O	therapy	dobj	12	SENT_79	[p6l1932t1314r2136b1392, p6l14t1468r171b1542],
14	.	.	O	.	_	0	SENT_79	[p6l1932t1314r2136b1392, p6l14t1468r171b1542],

1	Finally	RB	O	finally	advmod	21	SENT_80	[p6l203t1442r496b1542],
2	,	,	O	,	_	0	SENT_80	[p6l203t1442r496b1542],
3	the	DT	O	the	det	4	SENT_80	[p6l531t1442r658b1520],
4	addition	NN	O	addition	nsubj	21	SENT_80	[p6l686t1442r1035b1520],
5	of	IN	O	of	_	0	SENT_80	[p6l1064t1441r1164b1520],
6	cetuximab	NN	O	cetuximab	prep_of	4	SENT_80	[p6l1175t1442r1605b1521],
7	to	TO	O	to	_	0	SENT_80	[p6l1635t1458r1713b1520],
8	the	DT	O	the	det	10	SENT_80	[p6l1744t1442r1872b1520],
9	initial	JJ	O	initial	amod	10	SENT_80	[p6l1900t1441r2140b1520],
10	treatment	NN	O	treatment	prep_to	6	SENT_80	[p6l15t1587r424b1649],
11	of	IN	O	of	_	0	SENT_80	[p6l453t1570r553b1649],
12	metastatic	JJ	O	metastatic	amod	14	SENT_80	[p6l567t1571r1001b1649],
13	colorectal	JJ	O	colorectal	amod	14	SENT_80	[p6l1034t1571r1443b1649],
14	cancer	NN	O	cancer	prep_of	10	SENT_80	[p6l1476t1596r1748b1649],
15	or	CC	O	or	_	0	SENT_80	[p6l1779t1596r1868b1649],
16	in	IN	O	in	_	0	SENT_80	[p6l1897t1571r1977b1648],
17	the	DT	O	the	det	19	SENT_80	[p6l2011t1570r2139b1649],
18	adjuvant	JJ	O	adjuvant	amod	19	SENT_80	[p6l14t1698r370b1799],
19	setting	NN	O	setting	prep_in	6	SENT_80	[p6l388t1699r672b1799],
20	may	MD	O	may	aux	21	SENT_80	[p6l690t1725r865b1799],
21	increase	VB	O	increase	_	0	SENT_80	[p6l880t1699r1222b1777],
22	its	PRP$	O	its	poss	23	SENT_80	[p6l1242t1699r1337b1777],
23	usefulness	NN	O	usefulness	dobj	21	SENT_80	[p6l1359t1698r1824b1778],
24	.	.	O	.	_	0	SENT_80	[p6l1359t1698r1824b1778],

1	The	DT	O	the	det	2	SENT_81	[p6l1847t1699r2007b1777],
2	results	NNS	O	result	nsubj	14	SENT_81	[p6l2027t1725r2137b1777, p6l16t1826r206b1906],
3	of	IN	O	of	_	0	SENT_81	[p6l229t1826r329b1905],
4	the	DT	O	the	det	5	SENT_81	[p6l332t1827r460b1905],
5	trial	NN	O	trial	prep_of	2	SENT_81	[p6l482t1826r646b1905],
6	by	IN	O	by	_	0	SENT_81	[p6l667t1827r763b1927],
7	Cunningham	NNP	PERSON	Cunningham	prep_by	5	SENT_81	[p6l780t1827r1336b1927],
8	et	FW	O	et	nn	9	SENT_81	[p6l1358t1843r1434b1905],
9	al.	FW	O	al.	dep	7	SENT_81	[p6l1449t1827r1542b1905],
10	are	VBP	O	be	cop	14	SENT_81	[p6l1568t1853r1692b1905],
11	only	RB	O	only	advmod	14	SENT_81	[p6l1714t1827r1894b1927],
12	a	DT	O	a	det	14	SENT_81	[p6l1910t1853r1954b1905],
13	first	JJ	ORDINAL	first	amod	14	SENT_81	[p6l1973t1826r2144b1905],
14	step	NN	O	step	_	0	SENT_81	[p6l16t1971r188b2055],
15	toward	IN	O	toward	_	0	SENT_81	[p6l223t1954r522b2034],
16	deﬁning	VBG	O	deﬁning	prepc_toward	14	SENT_81	[p6l556t1954r921b2055],
17	the	DT	O	the	det	18	SENT_81	[p6l951t1955r1082b2033],
18	role	NN	O	role	dobj	16	SENT_81	[p6l1116t1955r1280b2033],
19	of	IN	O	of	_	0	SENT_81	[p6l1314t1954r1416b2033],
20	targeted	VBN	O	target	amod	21	SENT_81	[p6l1431t1954r1785b2055],
21	therapy	NN	O	therapy	prep_of	18	SENT_81	[p6l1818t1954r2142b2055],
22	with	IN	O	with	_	0	SENT_81	[p6l10t2083r197b2162],
23	the	DT	O	the	det	24	SENT_81	[p6l229t2083r357b2161],
24	use	NN	O	use	prep_with	16	SENT_81	[p6l388t2109r526b2162],
25	of	IN	O	of	_	0	SENT_81	[p6l559t2082r659b2161],
26	an	DT	O	a	det	27	SENT_81	[p6l670t2108r770b2161],
27	antibody	NN	O	antibody	prep_of	24	SENT_81	[p6l801t2082r1169b2183],
28	directed	VBN	O	direct	partmod	27	SENT_81	[p6l1197t2082r1531b2161],
29	against	IN	O	against	_	0	SENT_81	[p6l1562t2083r1867b2183],
30	EGFR	NN	ORGANIZATION	egfr	prep_against	28	SENT_81	[p6l1892t2088r2149b2166],
31	in	IN	O	in	_	0	SENT_81	[p6l14t2211r94b2288],
32	patients	NNS	O	patient	prep_in	28	SENT_81	[p6l117t2211r447b2311],
33	with	IN	O	with	_	0	SENT_81	[p6l469t2210r656b2290],
34	colorectal	JJ	O	colorectal	amod	35	SENT_81	[p6l682t2211r1090b2289],
35	cancer	NN	O	cancer	prep_with	32	SENT_81	[p6l1114t2236r1402b2289],
36	.	.	O	.	_	0	SENT_81	[p6l1114t2236r1402b2289],

1	From	IN	O	from	_	0	SENT_82	[p6l19t2387r180b2442],
2	the	DT	O	the	det	4	SENT_82	[p6l206t2381r309b2442],
3	Mayo	NNP	ORGANIZATION	Mayo	nn	4	SENT_82	[p6l339t2387r512b2461],
4	Clinic	NNP	ORGANIZATION	Clinic	pobj	1	SENT_82	[p6l537t2381r736b2452],
5	,	,	O	,	_	0	SENT_82	[p6l537t2381r736b2452],
6	Rochester	NNP	LOCATION	Rochester	nn	8	SENT_82	[p6l769t2381r1101b2452],
7	,	,	O	,	_	0	SENT_82	[p6l769t2381r1101b2452],
8	Minn.	NNP	LOCATION	Minn.	appos	4	SENT_82	[p6l1134t2387r1319b2442],
9	1	CD	NUMBER	1	num	8	SENT_82	[p6l16t2492r64b2543],
10	.	.	O	.	_	0	SENT_82	[p6l16t2492r64b2543],

1	Grunwald	NNP	PERSON	Grunwald	nn	2	SENT_83	[p6l143t2484r461b2544],
2	V	NNP	PERSON	V	_	0	SENT_83	[p6l475t2489r527b2555],
3	,	,	O	,	_	0	SENT_83	[p6l475t2489r527b2555],
4	Hidalgo	NNP	PERSON	Hidalgo	nn	5	SENT_83	[p6l548t2484r802b2559],
5	M.	NNP	O	M.	appos	2	SENT_83	[p6l818t2489r900b2543],
6	Developing	VBG	O	develop	partmod	5	SENT_83	[p6l919t2484r1284b2559],
7	inhibitors	NNS	O	inhibitor	dobj	6	SENT_83	[p6l1297t2484r1608b2543],
8	of	IN	O	of	_	0	SENT_83	[p6l1627t2483r1703b2543],
9	the	DT	O	the	det	13	SENT_83	[p6l1706t2484r1803b2542],
10	epidermal	JJ	O	epidermal	amod	13	SENT_83	[p6l1821t2484r2140b2559],
11	growth	NN	O	growth	nn	13	SENT_83	[p6l13t2580r241b2655],
12	factor	NN	O	factor	nn	13	SENT_83	[p6l256t2579r442b2639],
13	receptor	NN	O	receptor	prep_of	7	SENT_83	[p6l455t2592r720b2655],
14	for	IN	O	for	_	0	SENT_83	[p6l733t2579r825b2639],
15	cancer	NN	O	cancer	nn	16	SENT_83	[p6l840t2599r1046b2638],
16	treatment	NN	O	treatment	prep_for	13	SENT_83	[p6l1061t2592r1385b2639],
17	.	.	O	.	_	0	SENT_83	[p6l1061t2592r1385b2639],

1	J	NNP	O	J	nn	4	SENT_84	[p6l1398t2585r1427b2648],
2	Natl	NNP	O	Natl	nn	4	SENT_84	[p6l1439t2580r1575b2639],
3	Cancer	NNP	O	Cancer	nn	4	SENT_84	[p6l1590t2584r1812b2639],
4	Inst	NNP	O	Inst	_	0	SENT_84	[p6l1825t2585r1950b2638],
5	2003	CD	DATE	2003	num	4	SENT_84	[p6l1963t2584r2137b2651],
6	;	:	O	;	_	0	SENT_84	[p6l1963t2584r2137b2651],
7	95	CD	NUMBER	95	number	8	SENT_84	[p6l14t2679r86b2733],
8	:85	CD	NUMBER	:85	dep	4	SENT_84	[p6l97t2679r188b2733],
9	1-67	CD	NUMBER	1-67	dep	8	SENT_84	[p6l197t2679r353b2733],
10	.	.	O	.	_	0	SENT_84	[p6l197t2679r353b2733],

1	2	LS	NUMBER	2	_	0	SENT_85	[p6l12t2778r64b2829],
2	.	.	O	.	_	0	SENT_85	[p6l12t2778r64b2829],

1	Thomas	NNP	PERSON	Thomas	nn	2	SENT_86	[p6l140t2771r400b2830],
2	SM	NNP	PERSON	SM	_	0	SENT_86	[p6l436t2775r553b2842],
3	,	,	O	,	_	0	SENT_86	[p6l436t2775r553b2842],
4	Grandis	NNP	O	Grandis	nn	5	SENT_86	[p6l590t2771r844b2830],
5	JR.	NNP	O	JR.	appos	2	SENT_86	[p6l871t2776r965b2839],
6	.	.	O	.	_	0	SENT_86	[p6l871t2776r965b2839],

1	Pharmacokinetic	JJ	MISC	pharmacokinetic	amod	4	SENT_87	[p6l1001t2771r1538b2831],
2	and	CC	O	and	_	0	SENT_87	[p6l1570t2771r1687b2830],
3	pharmacody	JJ	O	pharmacody	conj_and	1	SENT_87	[p6l1719t2771r2139b2846],
4	—	NN	O	—	_	0	SENT_87	[p6l1719t2771r2139b2846],
5	namic	JJ	O	namic	amod	6	SENT_87	[p6l13t2868r209b2925],
6	properties	NNS	O	property	dep	4	SENT_87	[p6l237t2868r560b2942],
7	of	IN	O	of	_	0	SENT_87	[p6l592t2866r667b2926],
8	EGFR	NN	ORGANIZATION	egfr	nn	9	SENT_87	[p6l682t2871r877b2929],
9	inhibitors	NNS	O	inhibitor	prep_of	6	SENT_87	[p6l897t2867r1209b2926],
10	under	IN	O	under	_	0	SENT_87	[p6l1240t2867r1427b2927],
11	clinical	JJ	O	clinical	amod	12	SENT_87	[p6l1455t2867r1681b2925],
12	investigation	NN	O	investigation	prep_under	9	SENT_87	[p6l1709t2868r2136b2942],
13	.	.	O	.	_	0	SENT_87	[p6l1709t2868r2136b2942],

1	Cancer	NNP	O	Cancer	nn	3	SENT_88	[p6l13t2967r236b3022],
2	Treat	NNP	O	Treat	nn	3	SENT_88	[p6l249t2967r415b3021],
3	Rev	NN	O	rev	_	0	SENT_88	[p6l429t2968r545b3025],
4	2004	CD	DATE	2004	num	3	SENT_88	[p6l561t2967r1082b3034],
5	;	:	O	;	_	0	SENT_88	[p6l561t2967r1082b3034],
6	30:255	CD	NUMBER	30:255	number	7	SENT_88	[p6l561t2967r1082b3034],
7	—	CD	NUMBER	—	dep	3	SENT_88	[p6l561t2967r1082b3034],
8	68	CD	NUMBER	68	dep	7	SENT_88	[p6l561t2967r1082b3034],
9	.	.	O	.	_	0	SENT_88	[p6l561t2967r1082b3034],

1	3	LS	NUMBER	3	_	0	SENT_89	[p6l14t3066r64b3118],
2	.	.	O	.	_	0	SENT_89	[p6l14t3066r64b3118],

1	Saltz	NNP	PERSON	Saltz	nn	7	SENT_90	[p6l144t3059r294b3118],
2	LB	NNP	O	LB	nn	7	SENT_90	[p6l309t3064r410b3131],
3	,	,	O	,	_	0	SENT_90	[p6l309t3064r410b3131],
4	CoXJV	NNP	O	CoXJV	appos	7	SENT_90	[p6l431t3063r642b3130],
5	,	,	O	,	_	0	SENT_90	[p6l431t3063r642b3130],
6	Blanke	NNP	PERSON	Blanke	appos	7	SENT_90	[p6l661t3059r878b3119],
7	C	NNP	O	C	_	0	SENT_90	[p6l896t3063r958b3130],
8	,	,	O	,	_	0	SENT_90	[p6l896t3063r958b3130],
9	et	FW	O	et	nn	10	SENT_90	[p6l980t3072r1038b3117],
10	al.	FW	O	al.	appos	7	SENT_90	[p6l1051t3059r1121b3118],
11	.	.	O	.	_	0	SENT_90	[p6l1051t3059r1121b3118],

1	Irinotecan	NN	O	irinotecan	_	0	SENT_91	[p6l1141t3060r1467b3118],
2	plus	CC	O	plus	prep	1	SENT_91	[p6l1482t3059r1615b3134],
3	ﬂuorouracil	NN	O	ﬂuorouracil	dep	2	SENT_91	[p6l1633t3058r2007b3119],
4	and	CC	O	and	_	0	SENT_91	[p6l2023t3059r2140b3118],
5	leucovorin	NN	O	leucovorin	dep	2	SENT_91	[p6l12t3155r346b3215],
6	for	IN	O	for	_	0	SENT_91	[p6l364t3154r457b3214],
7	metastatic	JJ	O	metastatic	amod	9	SENT_91	[p6l473t3156r802b3213],
8	colorectal	JJ	O	colorectal	amod	9	SENT_91	[p6l821t3155r1131b3214],
9	cancer	NN	O	cancer	prep_for	1	SENT_91	[p6l1150t3174r1368b3214],
10	.	.	O	.	_	0	SENT_91	[p6l1150t3174r1368b3214],

1	N	NN	O	n	nn	2	SENT_92	[p6l1389t3160r1446b3215],
2	EnglJ	NN	O	englj	nsubj	3	SENT_92	[p6l1462t3155r1647b3230],
3	Med	VBD	O	med	_	0	SENT_92	[p6l1662t3155r1802b3214],
4	2000	CD	DATE	2000	dobj	3	SENT_92	[p6l1821t3159r2136b3226],
5	;	:	O	;	_	0	SENT_92	[p6l1821t3159r2136b3226],
6	343	CD	NUMBER	343	num	8	SENT_92	[p6l1821t3159r2136b3226],
7	:	:	O	:	_	0	SENT_92	[p6l1821t3159r2136b3226],
8	905-14	CD	NUMBER	905-14	dep	4	SENT_92	[p6l14t3254r252b3308],
9	.	.	O	.	_	0	SENT_92	[p6l14t3254r252b3308],

1	4	LS	NUMBER	4	_	0	SENT_93	[p6l11t3353r64b3404],
2	.	.	O	.	_	0	SENT_93	[p6l11t3353r64b3404],

1	Douillard	NNP	O	Douillard	nn	2	SENT_94	[p6l141t3346r436b3406],
2	JY	NN	O	jy	_	0	SENT_94	[p6l459t3351r536b3417],
3	,	,	O	,	_	0	SENT_94	[p6l459t3351r536b3417],
4	Cunningham	NNP	PERSON	Cunningham	nn	5	SENT_94	[p6l571t3346r985b3421],
5	D	NNP	O	D	appos	2	SENT_94	[p6l1015t3351r1081b3417],
6	,	,	O	,	_	0	SENT_94	[p6l1015t3351r1081b3417],
7	Roth	NNP	PERSON	Roth	nn	8	SENT_94	[p6l1114t3346r1267b3408],
8	AD	NN	O	ad	appos	2	SENT_94	[p6l1295t3351r1410b3417],
9	,	,	O	,	_	0	SENT_94	[p6l1295t3351r1410b3417],
10	et	FW	O	et	nn	11	SENT_94	[p6l1445t3358r1501b3404],
11	al.	FW	O	al.	appos	2	SENT_94	[p6l1528t3346r1597b3405],
12	.	.	O	.	_	0	SENT_94	[p6l1528t3346r1597b3405],

1	Irinotecan	JJ	O	irinotecan	amod	2	SENT_95	[p6l1631t3346r1949b3405],
2	combined	JJ	O	combined	dep	8	SENT_95	[p6l1981t3365r2139b3405, p6l14t3442r188b3501],
3	With	IN	O	with	_	0	SENT_95	[p6l202t3442r342b3502],
4	ﬂuorouracil	NN	O	ﬂuorouracil	prep_with	2	SENT_95	[p6l360t3441r725b3502],
5	compared	VBN	O	compare	_	0	SENT_95	[p6l743t3442r1055b3517],
6	with	IN	O	with	prepc_compared_with	4	SENT_95	[p6l1069t3442r1209b3502],
7	ﬂuorouracil	NN	O	ﬂuorouracil	pobj	4	SENT_95	[p6l1226t3441r1592b3502],
8	alone	RB	O	alone	_	0	SENT_95	[p6l1608t3442r1777b3501],
9	as	IN	O	as	dep	8	SENT_95	[p6l1795t3461r1857b3500],
10	ﬁrst	NN	O	ﬁrst	nn	13	SENT_95	[p6l1876t3441r2141b3500],
11	—	CD	NUMBER	—	num	13	SENT_95	[p6l1876t3441r2141b3500],
12	line	NN	O	line	nn	13	SENT_95	[p6l1876t3441r2141b3500],
13	treatment	NN	O	treatment	pobj	9	SENT_95	[p6l14t3550r318b3597],
14	for	IN	O	for	_	0	SENT_95	[p6l332t3537r424b3597],
15	metastatic	JJ	O	metastatic	amod	17	SENT_95	[p6l439t3539r761b3597],
16	colorectal	JJ	O	colorectal	amod	17	SENT_95	[p6l780t3538r1082b3597],
17	cancer	NN	O	cancer	prep_for	13	SENT_95	[p6l1101t3557r1319b3597],
18	:	:	O	:	_	0	SENT_95	[p6l1101t3557r1319b3597],
19	a	DT	O	a	det	22	SENT_95	[p6l1340t3558r1374b3597],
20	multicentre	JJ	O	multicentre	amod	21	SENT_95	[p6l1391t3538r1749b3598],
21	randomised	JJ	O	randomised	amod	22	SENT_95	[p6l1767t3538r2140b3597],
22	trial	NN	O	trial	dep	17	SENT_95	[p6l14t3634r152b3692],
23	.	.	O	.	_	0	SENT_95	[p6l14t3634r152b3692],

1	Lancet	NNP	O	Lancet	_	0	SENT_96	[p6l172t3639r379b3692],
2	2000	CD	DATE	2000	num	1	SENT_96	[p6l393t3638r941b3705],
3	;	:	O	;	_	0	SENT_96	[p6l393t3638r941b3705],
4	355:1041	CD	NUMBER	355:1041	number	5	SENT_96	[p6l393t3638r941b3705],
5	-7	CD	NUMBER	-7	dep	1	SENT_96	[p6l393t3638r941b3705],
6	.	.	O	.	_	0	SENT_96	[p6l393t3638r941b3705],

1	[	NN	O	[	_	0	SENT_97	[p6l969t3639r1263b3705],
2	Erratum	NN	O	erratum	dep	1	SENT_97	[p6l969t3639r1263b3705],
3	,	,	O	,	_	0	SENT_97	[p6l969t3639r1263b3705],
4	Lancet	NNP	O	Lancet	appos	2	SENT_97	[p6l1283t3639r1490b3692],
5	2000	CD	DATE	2000	rcmod	4	SENT_97	[p6l1504t3638r2012b3705],
6	;	:	O	;	_	0	SENT_97	[p6l1504t3638r2012b3705],
7	355:1372	CD	NUMBER	355:1372	dep	5	SENT_97	[p6l1504t3638r2012b3705],
8	.	.	O	.	_	0	SENT_97	[p6l1504t3638r2012b3705],
9	]	SYM	O	]	dep	5	SENT_97	[p6l1504t3638r2012b3705],

1	5	CD	NUMBER	5	_	0	SENT_98	[p7l14t26r64b77],
2	.	.	O	.	_	0	SENT_98	[p7l14t26r64b77],

1	Prewett	NNP	PERSON	Prewett	nn	2	SENT_99	[p7l141t24r382b78],
2	MC	NNP	O	MC	_	0	SENT_99	[p7l395t23r526b90],
3	,	,	O	,	_	0	SENT_99	[p7l395t23r526b90],
4	Hooper	NNP	PERSON	Hooper	nn	5	SENT_99	[p7l549t24r793b94],
5	AT	NNP	O	AT	appos	2	SENT_99	[p7l807t23r908b90],
6	,	,	O	,	_	0	SENT_99	[p7l807t23r908b90],
7	Bassi	NNP	PERSON	Bassi	nn	8	SENT_99	[p7l931t19r1096b77],
8	R	NNP	PERSON	R	appos	5	SENT_99	[p7l1114t24r1179b90],
9	,	,	O	,	_	0	SENT_99	[p7l1114t24r1179b90],
10	Ellis	NNP	ORGANIZATION	Ellis	nn	11	SENT_99	[p7l1201t19r1335b77],
11	LM	NNP	ORGANIZATION	LM	appos	5	SENT_99	[p7l1355t24r1476b90],
12	,	,	O	,	_	0	SENT_99	[p7l1355t24r1476b90],
13	Waksal	NNP	PERSON	Waksal	nn	14	SENT_99	[p7l1497t19r1727b79],
14	HW	NNP	O	HW	appos	5	SENT_99	[p7l1746t24r1881b90],
15	,	,	O	,	_	0	SENT_99	[p7l1746t24r1881b90],
16	Hicklin	NNP	PERSON	Hicklin	nn	17	SENT_99	[p7l1904t19r2139b79],
17	DJ	NNP	O	DJ	appos	5	SENT_99	[p7l12t120r104b183],
18	.	.	O	.	_	0	SENT_99	[p7l12t120r104b183],

1	Enhanced	VBN	O	enhance	_	0	SENT_100	[p7l141t115r457b174],
2	antitumor	NN	O	antitumor	nn	3	SENT_100	[p7l491t116r811b175],
3	activity	NN	O	activity	nsubj	10	SENT_100	[p7l843t116r1065b190],
4	of	IN	O	of	_	0	SENT_100	[p7l1097t114r1172b174],
5	anti	JJ	O	anti	amod	6	SENT_100	[p7l1193t115r1661b190],
6	—	NN	O	—	prep_of	3	SENT_100	[p7l1193t115r1661b190],
7	epidermal	JJ	O	epidermal	amod	10	SENT_100	[p7l1193t115r1661b190],
8	growth	NN	O	growth	nn	10	SENT_100	[p7l1696t115r1923b190],
9	factor	NN	O	factor	nn	10	SENT_100	[p7l1958t114r2142b174],
10	receptor	NN	O	receptor	xcomp	1	SENT_100	[p7l13t224r277b286],
11	monoclonal	JJ	O	monoclonal	amod	13	SENT_100	[p7l320t211r703b270],
12	antibody	NN	O	antibody	nn	13	SENT_100	[p7l748t211r1027b286],
13	IMC	NN	O	imc	dep	10	SENT_100	[p7l1068t215r1395b270],
14	.	.	O	.	_	0	SENT_100	[p7l1068t215r1395b270],

1	—	NN	O	—	_	0	SENT_101	[p7l1068t215r1395b270],
2	.	.	O	.	_	0	SENT_101	[p7l1068t215r1395b270],

1	C225	NN	O	c225	_	0	SENT_102	[p7l1068t215r1395b270],
2	in	IN	O	in	_	0	SENT_102	[p7l1443t211r1504b269],
3	combination	NN	O	combination	prep_in	1	SENT_102	[p7l1550t211r1956b270],
4	with	IN	O	with	_	0	SENT_102	[p7l1998t211r2140b271],
5	irinotecan	NN	O	irinotecan	nn	7	SENT_102	[p7l12t308r334b366],
6	(	CD	NUMBER	(	num	7	SENT_102	[p7l372t311r647b376],
7	CPT	NNP	O	CPT	prep_with	1	SENT_102	[p7l372t311r647b376],
8	—	CD	NUMBER	—	number	9	SENT_102	[p7l372t311r647b376],
9	11	CD	NUMBER	11	num	10	SENT_102	[p7l372t311r647b376],
10	)	NN	O	)	dep	7	SENT_102	[p7l372t311r647b376],
11	against	IN	O	against	_	0	SENT_102	[p7l686t308r917b382],
12	human	JJ	O	human	amod	15	SENT_102	[p7l948t307r1173b367],
13	colorectal	JJ	O	colorectal	amod	15	SENT_102	[p7l1208t307r1518b366],
14	tumor	NN	O	tumor	nn	15	SENT_102	[p7l1552t319r1749b367],
15	xenografts	NNS	O	xenograft	prep_against	10	SENT_102	[p7l1780t306r2135b382],
16	.	.	O	.	_	0	SENT_102	[p7l1780t306r2135b382],

1	Clin	NNP	O	Clin	nn	3	SENT_103	[p7l13t403r143b461],
2	Cancer	NNP	O	Cancer	nn	3	SENT_103	[p7l162t407r384b461],
3	Res	NNP	O	Res	_	0	SENT_103	[p7l399t408r512b465],
4	2002	CD	DATE	2002	num	3	SENT_103	[p7l532t407r1092b474],
5	;	:	O	;	_	0	SENT_103	[p7l532t407r1092b474],
6	8:994	CD	NUMBER	8:994	number	7	SENT_103	[p7l532t407r1092b474],
7	—	CD	NUMBER	—	dep	3	SENT_103	[p7l532t407r1092b474],
8	1003	CD	DATE	1003	dep	7	SENT_103	[p7l532t407r1092b474],
9	.	.	O	.	_	0	SENT_103	[p7l532t407r1092b474],

1	6	CD	NUMBER	6	_	0	SENT_104	[p7l14t505r64b558],
2	.	.	O	.	_	0	SENT_104	[p7l14t505r64b558],

1	Hurwitz	NNP	PERSON	Hurwitz	nn	2	SENT_105	[p7l141t499r401b559],
2	H	NNP	PERSON	H	_	0	SENT_105	[p7l416t504r489b570],
3	,	,	O	,	_	0	SENT_105	[p7l416t504r489b570],
4	Fehrenbacher	NNP	PERSON	Fehrenbacher	nn	5	SENT_105	[p7l508t499r947b558],
5	L	NNP	PERSON	L	appos	2	SENT_105	[p7l959t504r1015b570],
6	,	,	O	,	_	0	SENT_105	[p7l959t504r1015b570],
7	N	NNP	O	N	nn	9	SENT_105	[p7l1033t504r1089b558],
8	ovotny	NN	O	ovotny	nn	9	SENT_105	[p7l1092t512r1304b574],
9	W	NN	O	w	appos	2	SENT_105	[p7l1314t504r1392b570],
10	,	,	O	,	_	0	SENT_105	[p7l1314t504r1392b570],
11	et	FW	O	et	nn	12	SENT_105	[p7l1412t511r1469b557],
12	al.	FW	O	al.	appos	2	SENT_105	[p7l1481t499r1552b558],
13	.	.	O	.	_	0	SENT_105	[p7l1481t499r1552b558],

1	Bevacizumab	NNP	PERSON	Bevacizumab	_	0	SENT_106	[p7l1571t499r1989b559],
2	plus	CC	O	plus	_	0	SENT_106	[p7l2004t499r2137b574],
3	irinotecan	NNP	O	irinotecan	conj_plus	1	SENT_106	[p7l13t595r351b665],
4	,	,	O	,	_	0	SENT_106	[p7l13t595r351b665],
5	ﬂuorouracil	NN	O	ﬂuorouracil	conj_plus	1	SENT_106	[p7l390t593r782b665],
6	,	,	O	,	_	0	SENT_106	[p7l390t593r782b665],
7	and	CC	O	and	_	0	SENT_106	[p7l820t594r937b653],
8	leucovorin	NN	O	leucovorin	conj_and	1	SENT_106	[p7l971t594r1305b654],
9	for	IN	O	for	_	0	SENT_106	[p7l1340t593r1433b653],
10	metastatic	JJ	O	metastatic	amod	12	SENT_106	[p7l1465t595r1793b652],
11	colorectal	JJ	O	colorectal	amod	12	SENT_106	[p7l1829t594r2139b653],
12	cancer	NN	O	cancer	prep_for	8	SENT_106	[p7l14t709r232b749],
13	.	.	O	.	_	0	SENT_106	[p7l14t709r232b749],

1	N	NN	O	n	nn	2	SENT_107	[p7l254t695r310b749],
2	EnglJ	NN	O	englj	nsubj	3	SENT_107	[p7l326t690r511b765],
3	Med	VBD	O	med	_	0	SENT_107	[p7l526t690r666b749],
4	2004	CD	DATE	2004	dobj	3	SENT_107	[p7l684t694r1285b761],
5	;	:	O	;	_	0	SENT_107	[p7l684t694r1285b761],
6	350:2335	CD	NUMBER	350:2335	number	7	SENT_107	[p7l684t694r1285b761],
7	—	CD	NUMBER	—	dep	4	SENT_107	[p7l684t694r1285b761],
8	42	CD	NUMBER	42	dep	7	SENT_107	[p7l684t694r1285b761],
9	.	.	O	.	_	0	SENT_107	[p7l684t694r1285b761],

1	7	CD	NUMBER	7	_	0	SENT_108	[p7l15t793r64b844],
2	.	.	O	.	_	0	SENT_108	[p7l15t793r64b844],

1	Cunningham	NNP	ORGANIZATION	Cunningham	nn	2	SENT_109	[p7l142t786r564b861],
2	D	NNP	ORGANIZATION	D	_	0	SENT_109	[p7l585t791r652b857],
3	,	,	O	,	_	0	SENT_109	[p7l585t791r652b857],
4	Humblet	NNP	O	Humblet	nn	5	SENT_109	[p7l678t786r965b846],
5	Y	NN	O	y	appos	2	SENT_109	[p7l981t791r1032b857],
6	,	,	O	,	_	0	SENT_109	[p7l981t791r1032b857],
7	Siena	NNP	LOCATION	Siena	nn	8	SENT_109	[p7l1061t786r1230b845],
8	S	NNP	O	S	appos	2	SENT_109	[p7l1253t790r1305b857],
9	,	,	O	,	_	0	SENT_109	[p7l1253t790r1305b857],
10	et	FW	O	et	nn	11	SENT_109	[p7l1332t798r1390b844],
11	al.	FW	O	al.	appos	2	SENT_109	[p7l1409t786r1479b845],
12	.	.	O	.	_	0	SENT_109	[p7l1409t786r1479b845],

1	A	DT	O	a	det	3	SENT_110	[p7l1504t791r1553b844],
2	randomised	JJ	O	randomised	amod	3	SENT_110	[p7l1574t786r1954b845],
3	comparison	NN	O	comparison	_	0	SENT_110	[p7l1977t805r2139b845, p7l12t883r253b957],
4	of	IN	O	of	_	0	SENT_110	[p7l278t881r353b941],
5	cetuximab	JJ	O	cetuximab	amod	6	SENT_110	[p7l365t882r691b942],
6	monotherapy	NN	O	monotherapy	prep_of	3	SENT_110	[p7l717t882r1146b957],
7	and	CC	O	and	_	0	SENT_110	[p7l1167t882r1284b941],
8	cetuximab	NN	O	cetuximab	prep_of	3	SENT_110	[p7l1309t882r1636b942],
9	plus	CC	O	plus	prep	3	SENT_110	[p7l1661t882r1793b957],
10	irinotecan	NN	O	irinotecan	dep	9	SENT_110	[p7l1819t883r2140b941],
11	in	IN	O	in	_	0	SENT_110	[p7l12t979r74b1036],
12	irinotecan	NN	O	irinotecan	prep_in	3	SENT_110	[p7l97t977r757b1053],
13	—	CD	NUMBER	—	num	17	SENT_110	[p7l97t977r757b1053],
14	refractory	JJ	O	refractory	amod	17	SENT_110	[p7l97t977r757b1053],
15	metastatic	JJ	O	metastatic	amod	17	SENT_110	[p7l777t979r1105b1036],
16	colorectal	JJ	O	colorectal	amod	17	SENT_110	[p7l1130t978r1440b1037],
17	cancer	NN	O	cancer	dep	12	SENT_110	[p7l1465t997r1683b1037],
18	.	.	O	.	_	0	SENT_110	[p7l1465t997r1683b1037],

1	N	NN	O	n	nn	2	SENT_111	[p7l1710t983r1766b1037],
2	EnglJ	NN	O	englj	nsubj	3	SENT_111	[p7l1788t978r1979b1053],
3	Med	VBD	O	med	_	0	SENT_111	[p7l1999t978r2139b1037],
4	2004	CD	DATE	2004	dobj	3	SENT_111	[p7l13t1078r574b1145],
5	;	:	O	;	_	0	SENT_111	[p7l13t1078r574b1145],
6	351:337	CD	NUMBER	351:337	number	7	SENT_111	[p7l13t1078r574b1145],
7	—	CD	NUMBER	—	dep	4	SENT_111	[p7l13t1078r574b1145],
8	45	CD	NUMBER	45	dep	7	SENT_111	[p7l13t1078r574b1145],
9	.	.	O	.	_	0	SENT_111	[p7l13t1078r574b1145],

1	8	CD	NUMBER	8	_	0	SENT_112	[p7l12t1176r64b1229],
2	.	.	O	.	_	0	SENT_112	[p7l12t1176r64b1229],

1	Rothenberg	NNP	PERSON	Rothenberg	nn	2	SENT_113	[p7l141t1170r521b1245],
2	ML	NNP	O	ML	_	0	SENT_113	[p7l551t1175r673b1241],
3	,	,	O	,	_	0	SENT_113	[p7l551t1175r673b1241],
4	Oza	NNP	PERSON	Oza	nn	5	SENT_113	[p7l713t1174r838b1229],
5	AM	NNP	O	AM	appos	2	SENT_113	[p7l870t1175r1000b1241],
6	,	,	O	,	_	0	SENT_113	[p7l870t1175r1000b1241],
7	Bigelow	NNP	PERSON	Bigelow	nn	8	SENT_113	[p7l1039t1170r1299b1245],
8	RH	NNP	O	RH	appos	2	SENT_113	[p7l1331t1175r1453b1241],
9	,	,	O	,	_	0	SENT_113	[p7l1331t1175r1453b1241],
10	et	FW	O	et	nn	11	SENT_113	[p7l1493t1182r1552b1228],
11	al.	FW	O	al.	appos	2	SENT_113	[p7l1583t1170r1654b1229],
12	.	.	O	.	_	0	SENT_113	[p7l1583t1170r1654b1229],

1	Superiority	NN	O	superiority	_	0	SENT_114	[p7l1696t1171r2046b1245],
2	of	IN	O	of	_	0	SENT_114	[p7l2078t1169r2154b1229],
3	oxaliplatin	NN	O	oxaliplatin	prep_of	1	SENT_114	[p7l14t1266r349b1341],
4	and	CC	O	and	_	0	SENT_114	[p7l373t1266r490b1325],
5	ﬂuorouracil-leucovorin	NN	O	ﬂuorouracil-leucovorin	conj_and	3	SENT_114	[p7l515t1265r1251b1326],
6	compared	VBN	O	compare	_	0	SENT_114	[p7l1277t1266r1594b1341],
7	with	IN	O	with	prepc_compared_with	1	SENT_114	[p7l1615t1266r1758b1326],
8	either	CC	O	either	preconj	9	SENT_114	[p7l1783t1266r1966b1325],
9	therapy	NN	O	therapy	pobj	1	SENT_114	[p7l1989t1266r2139b1324, p7l13t1381r122b1437],
10	alone	RB	O	alone	advmod	9	SENT_114	[p7l135t1362r306b1421],
11	in	IN	O	in	_	0	SENT_114	[p7l322t1363r383b1420],
12	patients	NNS	O	patient	prep_in	9	SENT_114	[p7l397t1363r649b1437],
13	with	IN	O	with	_	0	SENT_114	[p7l663t1362r805b1422],
14	progressive	JJ	O	progressive	amod	16	SENT_114	[p7l820t1363r1184b1437],
15	colorectal	JJ	O	colorectal	amod	16	SENT_114	[p7l1201t1362r1510b1421],
16	cancer	NN	O	cancer	prep_with	12	SENT_114	[p7l1526t1381r1733b1420],
17	after	IN	O	after	_	0	SENT_114	[p7l1746t1361r1891b1420],
18	irinotecan	NN	O	irinotecan	prep_after	16	SENT_114	[p7l1905t1363r2138b1421, p7l14t1477r122b1516],
19	and	CC	O	and	_	0	SENT_114	[p7l144t1458r261b1517],
20	ﬂuorouracil	NN	O	ﬂuorouracil	nn	22	SENT_114	[p7l284t1457r1038b1518],
21	—	CD	NUMBER	—	num	22	SENT_114	[p7l284t1457r1038b1518],
22	leucoVorin	NN	O	leucovorin	pobj	1	SENT_114	[p7l284t1457r1038b1518],
23	:	:	O	:	_	0	SENT_114	[p7l284t1457r1038b1518],
24	interim	JJ	O	interim	amod	25	SENT_114	[p7l1064t1459r1298b1516],
25	results	NNS	O	result	dep	1	SENT_114	[p7l1320t1458r1528b1518],
26	of	IN	O	of	_	0	SENT_114	[p7l1553t1457r1629b1517],
27	a	DT	O	a	det	30	SENT_114	[p7l1638t1478r1671b1516],
28	phase	NN	O	phase	nn	30	SENT_114	[p7l1691t1458r1877b1533],
29	III	CD	NUMBER	iii	num	30	SENT_114	[p7l1898t1463r1971b1516],
30	trial	NN	O	trial	prep_of	25	SENT_114	[p7l1994t1458r2136b1517],
31	.	.	O	.	_	0	SENT_114	[p7l1994t1458r2136b1517],

1	JClin	NN	O	jclin	nn	2	SENT_115	[p7l6t1554r182b1622],
2	Oncol	NN	O	oncol	_	0	SENT_115	[p7l201t1554r391b1612],
3	2003	CD	DATE	2003	dep	2	SENT_115	[p7l410t1558r970b1625],
4	;	:	O	;	_	0	SENT_115	[p7l410t1558r970b1625],
5	21:2059	CD	NUMBER	21:2059	number	6	SENT_115	[p7l410t1558r970b1625],
6	—	CD	NUMBER	—	dep	2	SENT_115	[p7l410t1558r970b1625],
7	69	CD	NUMBER	69	dep	6	SENT_115	[p7l410t1558r970b1625],
8	.	.	O	.	_	0	SENT_115	[p7l410t1558r970b1625],

1	9	CD	NUMBER	9	_	0	SENT_116	[p7l13t1656r64b1708],
2	.	.	O	.	_	0	SENT_116	[p7l13t1656r64b1708],

1	Lynch	NNP	PERSON	Lynch	nn	3	SENT_117	[p7l141t1650r327b1725],
2	T	NN	O	t	nn	3	SENT_117	[p7l348t1654r430b1721],
3	]	NN	O	]	_	0	SENT_117	[p7l348t1654r430b1721],
4	,	,	O	,	_	0	SENT_117	[p7l348t1654r430b1721],
5	Bell	NNP	ORGANIZATION	Bell	nn	6	SENT_117	[p7l456t1650r574b1708],
6	DVV	NNP	ORGANIZATION	DVV	appos	3	SENT_117	[p7l595t1655r723b1721],
7	,	,	O	,	_	0	SENT_117	[p7l595t1655r723b1721],
8	Sordella	NNP	PERSON	Sordella	nn	9	SENT_117	[p7l752t1650r1003b1709],
9	R	NNP	PERSON	R	appos	3	SENT_117	[p7l1024t1655r1087b1721],
10	,	,	O	,	_	0	SENT_117	[p7l1024t1655r1087b1721],
11	et	FW	O	et	nn	12	SENT_117	[p7l1115t1662r1172b1708],
12	al.	FW	O	al.	appos	3	SENT_117	[p7l1190t1650r1260b1709],
13	.	.	O	.	_	0	SENT_117	[p7l1190t1650r1260b1709],

1	Activating	VBG	O	activate	amod	2	SENT_118	[p7l1284t1650r1601b1725],
2	mutations	NNS	O	mutation	_	0	SENT_118	[p7l1621t1650r1936b1710],
3	in	IN	O	in	_	0	SENT_118	[p7l1960t1650r2021b1708],
4	the	DT	O	the	det	7	SENT_118	[p7l2044t1650r2139b1708],
5	epidermal	JJ	O	epidermal	amod	7	SENT_118	[p7l14t1746r327b1821],
6	growth	NN	O	growth	nn	7	SENT_118	[p7l345t1746r569b1821],
7	factor	NN	O	factor	prep_in	2	SENT_118	[p7l586t1745r767b1805],
8	receptor	NN	O	receptor	nn	10	SENT_118	[p7l784t1759r1042b1821],
9	underlying	VBG	O	underlie	amod	10	SENT_118	[p7l1058t1746r1396b1821],
10	responsiveness	NN	O	responsiveness	dep	2	SENT_118	[p7l1412t1747r1881b1821],
11	of	IN	O	of	_	0	SENT_118	[p7l1901t1745r1976b1805],
12	nonsmall-cell	JJ	O	nonsmall-cell	amod	14	SENT_118	[p7l1980t1765r2143b1805, p7l15t1842r314b1900],
13	lung	NN	O	lung	nn	14	SENT_118	[p7l330t1842r473b1917],
14	cancer	NN	O	cancer	prep_of	10	SENT_118	[p7l488t1861r691b1901],
15	to	TO	O	to	_	0	SENT_118	[p7l706t1855r765b1901],
16	geﬁtinib	NN	O	geﬁtinib	prep_to	14	SENT_118	[p7l782t1841r1060b1917],
17	.	.	O	.	_	0	SENT_118	[p7l782t1841r1060b1917],

1	N	NN	O	n	nn	3	SENT_119	[p7l1079t1847r1136b1901],
2	Engll	NNP	O	Engll	nn	3	SENT_119	[p7l1151t1842r1331b1917],
3	Med	NNP	O	Med	_	0	SENT_119	[p7l1345t1842r1483b1901],
4	2004	CD	DATE	2004	num	3	SENT_119	[p7l1500t1846r2088b1913],
5	;	:	O	;	_	0	SENT_119	[p7l1500t1846r2088b1913],
6	350:2129	CD	NUMBER	350:2129	number	7	SENT_119	[p7l1500t1846r2088b1913],
7	—	CD	NUMBER	—	dep	3	SENT_119	[p7l1500t1846r2088b1913],
8	39	CD	NUMBER	39	dep	7	SENT_119	[p7l1500t1846r2088b1913],
9	.	.	O	.	_	0	SENT_119	[p7l1500t1846r2088b1913],

1	10	CD	NUMBER	10	_	0	SENT_120	[p7l16t1944r102b1997],
2	.	.	O	.	_	0	SENT_120	[p7l16t1944r102b1997],

1	Schrag	NNP	PERSON	Schrag	nn	5	SENT_121	[p7l144t1938r361b2013],
2	D.	NNP	O	D.	nn	5	SENT_121	[p7l379t1943r445b1997],
3	The	NNP	O	The	nn	5	SENT_121	[p7l468t1938r588b1996],
4	price	NN	O	price	nn	5	SENT_121	[p7l608t1939r765b2013],
5	tag	NN	O	tag	_	0	SENT_121	[p7l786t1951r886b2013],
6	on	IN	O	on	_	0	SENT_121	[p7l904t1957r984b1997],
7	progress	NN	O	progress	nn	9	SENT_121	[p7l1004t1957r1279b2013],
8	—	CD	NUMBER	—	num	9	SENT_121	[p7l1298t1972r1379b1977],
9	chemotherapy	NN	O	chemotherapy	prep_on	5	SENT_121	[p7l1398t1938r1853b2013],
10	for	IN	O	for	_	0	SENT_121	[p7l1870t1937r1962b1997],
11	colorectal	JJ	O	colorectal	amod	12	SENT_121	[p7l1981t1938r2139b1997, p7l13t2034r188b2092],
12	cancer	NN	O	cancer	prep_for	5	SENT_121	[p7l207t2053r425b2093],
13	.	.	O	.	_	0	SENT_121	[p7l207t2053r425b2093],

1	N	NN	O	n	nn	3	SENT_122	[p7l446t2039r503b2094],
2	Engll	NNP	O	Engll	nn	3	SENT_122	[p7l519t2034r704b2109],
3	Med	NNP	O	Med	_	0	SENT_122	[p7l718t2034r859b2093],
4	2004	CD	DATE	2004	num	3	SENT_122	[p7l878t2038r1398b2105],
5	;	:	O	;	_	0	SENT_122	[p7l878t2038r1398b2105],
6	351:317	CD	NUMBER	351:317	number	7	SENT_122	[p7l878t2038r1398b2105],
7	—	CD	NUMBER	—	dep	3	SENT_122	[p7l878t2038r1398b2105],
8	9	CD	NUMBER	9	dep	7	SENT_122	[p7l878t2038r1398b2105],
9	.	.	O	.	_	0	SENT_122	[p7l878t2038r1398b2105],

1	1	CD	NUMBER	1	num	2	SENT_123	[p7l16t2137r44b2188],
2	1	CD	NUMBER	1	_	0	SENT_123	[p7l54t2137r102b2188],
3	.	.	O	.	_	0	SENT_123	[p7l54t2137r102b2188],

1	Saltz	NNP	PERSON	Saltz	nn	2	SENT_124	[p7l144t2130r294b2189],
2	L	NNP	O	L	_	0	SENT_124	[p7l308t2135r363b2201],
3	,	,	O	,	_	0	SENT_124	[p7l308t2135r363b2201],
4	Rubin	NNP	PERSON	Rubin	nn	5	SENT_124	[p7l382t2130r576b2192],
5	M	NNP	O	M	appos	2	SENT_124	[p7l589t2135r671b2201],
6	,	,	O	,	_	0	SENT_124	[p7l589t2135r671b2201],
7	Hochster	NNP	PERSON	Hochster	nn	8	SENT_124	[p7l691t2130r984b2189],
8	H	NNP	O	H	appos	2	SENT_124	[p7l998t2135r1070b2201],
9	,	,	O	,	_	0	SENT_124	[p7l998t2135r1070b2201],
10	et	FW	O	et	nn	11	SENT_124	[p7l1091t2142r1149b2188],
11	al.	FW	O	al.	appos	2	SENT_124	[p7l1160t2130r1231b2189],
12	.	.	O	.	_	0	SENT_124	[p7l1160t2130r1231b2189],

1	Cetuximab	NNP	O	Cetuximab	_	0	SENT_125	[p7l1251t2130r1593b2190],
2	(	CD	NUMBER	(	num	1	SENT_125	[p7l1613t2134r1987b2198],
3	IMC	NNP	O	IMC	dep	1	SENT_125	[p7l1613t2134r1987b2198],
4	.	.	O	.	_	0	SENT_125	[p7l1613t2134r1987b2198],

1	—	NN	O	—	_	0	SENT_126	[p7l1613t2134r1987b2198],
2	.	.	O	.	_	0	SENT_126	[p7l1613t2134r1987b2198],

1	C225	CD	NUMBER	c225	num	2	SENT_127	[p7l1613t2134r1987b2198],
2	)	NN	O	)	nsubj	11	SENT_127	[p7l1613t2134r1987b2198],
3	plus	CC	O	plus	prep	2	SENT_127	[p7l2006t2130r2139b2205],
4	irinotecan	NN	O	irinotecan	nn	6	SENT_127	[p7l12t2227r334b2285],
5	(	CD	NUMBER	(	num	6	SENT_127	[p7l359t2230r634b2294],
6	CPT	NNP	O	CPT	dep	3	SENT_127	[p7l359t2230r634b2294],
7	—	CD	NUMBER	—	number	8	SENT_127	[p7l359t2230r634b2294],
8	11	CD	NUMBER	11	num	9	SENT_127	[p7l359t2230r634b2294],
9	)	NN	O	)	dep	6	SENT_127	[p7l359t2230r634b2294],
10	is	VBZ	O	be	cop	11	SENT_127	[p7l660t2227r709b2284],
11	active	JJ	O	active	_	0	SENT_127	[p7l732t2227r909b2286],
12	in	IN	O	in	_	0	SENT_127	[p7l931t2227r992b2284],
13	CPT	NNP	O	CPT	prep_in	11	SENT_127	[p7l1013t2225r1583b2301],
14	—	CD	NUMBER	—	num	20	SENT_127	[p7l1013t2225r1583b2301],
15	11-refractory	JJ	O	11-refractory	amod	20	SENT_127	[p7l1013t2225r1583b2301],
16	colorectal	JJ	O	colorectal	amod	20	SENT_127	[p7l1602t2226r1912b2285],
17	cancer	NN	O	cancer	nn	20	SENT_127	[p7l1934t2245r2141b2285],
18	(	CD	NUMBER	(	num	20	SENT_127	[p7l17t2326r201b2391],
19	CRC	NN	ORGANIZATION	crc	nn	20	SENT_127	[p7l17t2326r201b2391],
20	)	NN	O	)	attr	11	SENT_127	[p7l17t2326r201b2391],
21	that	WDT	O	that	nsubj	22	SENT_127	[p7l242t2322r367b2380],
22	expresses	VBZ	O	express	rcmod	20	SENT_127	[p7l402t2341r703b2397],
23	epidermal	JJ	O	epidermal	amod	25	SENT_127	[p7l741t2322r1061b2397],
24	growth	NN	O	growth	nn	25	SENT_127	[p7l1097t2322r1326b2397],
25	factor	NN	O	factor	dobj	22	SENT_127	[p7l1362t2321r1547b2381],
26	receptor	NN	O	receptor	nn	29	SENT_127	[p7l1582t2335r1846b2397],
27	(	CD	NUMBER	(	num	29	SENT_127	[p7l1884t2326r2136b2390],
28	EGFR	NN	ORGANIZATION	egfr	nn	29	SENT_127	[p7l1884t2326r2136b2390],
29	)	NN	O	)	dep	25	SENT_127	[p7l1884t2326r2136b2390],
30	.	.	O	.	_	0	SENT_127	[p7l1884t2326r2136b2390],

1	Prog	NN	O	prog	dep	6	SENT_128	[p7l12t2423r162b2493],
2	Proc	NNP	O	Proc	nn	6	SENT_128	[p7l177t2423r318b2477],
3	Am	NNP	O	Am	nn	6	SENT_128	[p7l333t2423r446b2476],
4	Soc	NNP	O	Soc	nn	6	SENT_128	[p7l466t2422r576b2477],
5	Clin	NNP	O	Clin	nn	6	SENT_128	[p7l594t2418r724b2477],
6	Oncol	NNP	O	Oncol	_	0	SENT_128	[p7l743t2418r934b2477],
7	2001	CD	DATE	2001	num	6	SENT_128	[p7l952t2422r1323b2489],
8	;	:	O	;	_	0	SENT_128	[p7l952t2422r1323b2489],
9	20:3	CD	NUMBER	20:3	num	10	SENT_128	[p7l952t2422r1323b2489],
10	a.	NN	O	a.	dep	11	SENT_128	[p7l952t2422r1323b2489],
11	abstract	JJ	O	abstract	parataxis	6	SENT_128	[p7l1345t2418r1614b2477],
12	.	.	O	.	_	0	SENT_128	[p7l1345t2418r1614b2477],

1	12	CD	NUMBER	12	_	0	SENT_129	[p7l16t2521r102b2572],
2	.	.	O	.	_	0	SENT_129	[p7l16t2521r102b2572],

1	Saltz	NNP	PERSON	Saltz	nn	2	SENT_130	[p7l144t2514r294b2573],
2	LB	NNP	O	LB	_	0	SENT_130	[p7l313t2519r414b2585],
3	,	,	O	,	_	0	SENT_130	[p7l313t2519r414b2585],
4	Meropol	NNP	O	Meropol	nn	6	SENT_130	[p7l436t2514r708b2589],
5	N	NNP	O	N	nn	6	SENT_130	[p7l726t2519r821b2585],
6	]	NN	O	]	appos	2	SENT_130	[p7l726t2519r821b2585],
7	,	,	O	,	_	0	SENT_130	[p7l726t2519r821b2585],
8	Loehrer	NNP	O	Loehrer	nn	10	SENT_130	[p7l845t2514r1094b2573],
9	PJ	NNP	O	PJ	nn	10	SENT_130	[p7l1110t2519r1172b2583],
10	Sr	NNP	O	Sr	appos	2	SENT_130	[p7l1193t2518r1268b2585],
11	,	,	O	,	_	0	SENT_130	[p7l1193t2518r1268b2585],
12	Needle	NNP	O	Needle	nn	13	SENT_130	[p7l1291t2514r1512b2574],
13	MN	NN	O	mn	appos	2	SENT_130	[p7l1531t2519r1667b2585],
14	,	,	O	,	_	0	SENT_130	[p7l1531t2519r1667b2585],
15	K	NNP	O	K	appos	2	SENT_130	[p7l1691t2515r1922b2589],
16	(	CD	NUMBER	(	number	17	SENT_130	[p7l1691t2515r1922b2589],
17	)	CD	NUMBER	)	num	18	SENT_130	[p7l1691t2515r1922b2589],
18	pitJ	NN	O	pitj	dep	15	SENT_130	[p7l1691t2515r1922b2589],
19	,	,	O	,	_	0	SENT_130	[p7l1691t2515r1922b2589],
20	Mayer	NNP	PERSON	Mayer	nn	21	SENT_130	[p7l1945t2519r2141b2589],
21	R	NNP	O	R	appos	2	SENT_130	[p7l12t2615r99b2678],
22	]	NN	O	]	dep	21	SENT_130	[p7l12t2615r99b2678],
23	.	.	O	.	_	0	SENT_130	[p7l12t2615r99b2678],

1	Phase	NN	O	phase	nn	3	SENT_131	[p7l125t2610r308b2668],
2	II	CD	NUMBER	ii	num	3	SENT_131	[p7l330t2615r378b2668],
3	trial	NN	O	trial	_	0	SENT_131	[p7l400t2610r525b2668],
4	of	IN	O	of	_	0	SENT_131	[p7l548t2609r623b2669],
5	cetuximab	NN	O	cetuximab	prep_of	3	SENT_131	[p7l633t2610r959b2670],
6	in	IN	O	in	_	0	SENT_131	[p7l982t2611r1043b2668],
7	patients	NNS	O	patient	prep_in	5	SENT_131	[p7l1065t2611r1316b2685],
8	with	IN	O	with	_	0	SENT_131	[p7l1336t2610r1479b2670],
9	refractory	JJ	O	refractory	amod	11	SENT_131	[p7l1501t2609r1810b2685],
10	colorectal	JJ	O	colorectal	amod	11	SENT_131	[p7l1830t2610r2139b2669],
11	cancer	NN	O	cancer	prep_with	7	SENT_131	[p7l14t2725r220b2764],
12	that	WDT	O	that	nsubj	13	SENT_131	[p7l245t2706r370b2764],
13	expresses	VBZ	O	express	rcmod	11	SENT_131	[p7l394t2725r695b2781],
14	the	DT	O	the	det	18	SENT_131	[p7l723t2706r820b2765],
15	epidermal	JJ	O	epidermal	amod	18	SENT_131	[p7l848t2706r1167b2781],
16	growth	NN	O	growth	nn	18	SENT_131	[p7l1194t2706r1421b2781],
17	factor	NN	O	factor	nn	18	SENT_131	[p7l1448t2705r1633b2765],
18	receptor	NN	O	receptor	dobj	13	SENT_131	[p7l1657t2719r1932b2781],
19	.	.	O	.	_	0	SENT_131	[p7l1657t2719r1932b2781],

1	J	NNP	O	J	nn	3	SENT_132	[p7l1955t2711r1984b2774],
2	Clin	NNP	O	Clin	nn	3	SENT_132	[p7l2008t2706r2139b2765],
3	Oncol	NNP	O	Oncol	_	0	SENT_132	[p7l13t2802r204b2861],
4	2004	CD	DATE	2004	num	3	SENT_132	[p7l222t2806r743b2873],
5	;	:	O	;	_	0	SENT_132	[p7l222t2806r743b2873],
6	22:1201	CD	NUMBER	22:1201	number	7	SENT_132	[p7l222t2806r743b2873],
7	—	CD	NUMBER	—	dep	3	SENT_132	[p7l222t2806r743b2873],
8	8	CD	NUMBER	8	dep	7	SENT_132	[p7l222t2806r743b2873],
9	.	.	O	.	_	0	SENT_132	[p7l222t2806r743b2873],

1	13	CD	NUMBER	13	_	0	SENT_133	[p7l16t2905r102b2957],
2	.	.	O	.	_	0	SENT_133	[p7l16t2905r102b2957],

1	Randal	NNP	PERSON	Randal	nn	4	SENT_134	[p7l141t2898r365b2960],
2	J.	NNP	PERSON	J.	nn	4	SENT_134	[p7l385t2903r430b2967],
3	Erbitux	NNP	PERSON	Erbitux	nn	4	SENT_134	[p7l462t2898r695b2958],
4	trial	NN	O	trial	nsubj	5	SENT_134	[p7l723t2898r847b2956],
5	ﬂawed	VBD	O	ﬂawed	_	0	SENT_134	[p7l877t2897r1085b2958],
6	from	IN	O	from	_	0	SENT_134	[p7l1114t2897r1269b2957],
7	the	DT	O	the	det	8	SENT_134	[p7l1299t2898r1396b2956],
8	beginning	NN	O	beginning	prep_from	5	SENT_134	[p7l1426t2898r1768b2973],
9	,	,	O	,	_	0	SENT_134	[p7l1426t2898r1768b2973],
10	committee	NN	O	committee	nn	11	SENT_134	[p7l1802t2899r2140b2957],
11	ﬁnds	NNS	O	ﬁnds	appos	8	SENT_134	[p7l13t2992r190b3052],
12	.	.	O	.	_	0	SENT_134	[p7l13t2992r190b3052],

1	J	NNP	O	J	nn	4	SENT_135	[p7l206t2998r233b3061],
2	Natl	NNP	O	Natl	nn	4	SENT_135	[p7l249t2993r384b3052],
3	Cancer	NNP	O	Cancer	nn	4	SENT_135	[p7l402t2997r624b3052],
4	Inst	NNP	O	Inst	_	0	SENT_135	[p7l640t2998r766b3051],
5	2002	CD	DATE	2002	num	4	SENT_135	[p7l780t2997r1301b3064],
6	;	:	O	;	_	0	SENT_135	[p7l780t2997r1301b3064],
7	94:1824	CD	NUMBER	94:1824	number	8	SENT_135	[p7l780t2997r1301b3064],
8	—	CD	NUMBER	—	dep	4	SENT_135	[p7l780t2997r1301b3064],
9	5	CD	NUMBER	5	dep	8	SENT_135	[p7l780t2997r1301b3064],
10	.	.	O	.	_	0	SENT_135	[p7l780t2997r1301b3064],

1	Copyright	NN	O	copyright	_	0	SENT_136	[p7l15t3082r254b3147],
2	©	CD	NUMBER	©	num	6	SENT_136	[p7l275t3088r329b3142],
3	2004	CD	DATE	2004	num	6	SENT_136	[p7l353t3086r478b3132],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_136	[p7l499t3083r860b3132],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_136	[p7l881t3082r1080b3132],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_136	[p7l1097t3084r1280b3147],
7	.	.	O	.	_	0	SENT_136	[p7l1097t3084r1280b3147],

1	392	CD	NUMBER	392	num	4	SENT_137	[p7l149t3216r206b3238],
2	N	NN	O	n	nn	4	SENT_137	[p7l917t3218r930b3233],
3	ENGLJ	NN	O	englj	nn	4	SENT_137	[p7l946t3217r1030b3239],
4	MED	NN	O	med	_	0	SENT_137	[p7l1045t3218r1097b3233],
5	351	CD	NUMBER	351	num	7	SENT_137	[p7l1110t3217r1174b3239],
6	;	:	O	;	_	0	SENT_137	[p7l1110t3217r1174b3239],
7	4	CD	NUMBER	4	dep	4	SENT_137	[p7l1110t3217r1174b3239],
8	WWW.NEJM.ORG	NNP	O	WWW.NEJM.ORG	nn	9	SENT_137	[p7l1208t3217r1420b3239],
9	JULY	NNP	DATE	JULY	dep	4	SENT_137	[p7l1453t3218r1513b3239],
10	22	CD	DATE	22	num	9	SENT_137	[p7l1525t3217r1562b3237],
11	,	,	O	,	_	0	SENT_137	[p7l1525t3217r1562b3237],
12	2oo4	CD	NUMBER	2oo4	num	9	SENT_137	[p7l1575t3217r1643b3239],

1	The	DT	O	the	det	4	SENT_138	[p7l936t3250r987b3274],
2	New	NNP	O	New	nn	4	SENT_138	[p7l996t3251r1058b3274],
3	England	NNP	O	England	nn	4	SENT_138	[p7l1067t3250r1178b3281],
4	Journal	NNP	O	Journal	_	0	SENT_138	[p7l1187t3250r1284b3274],
5	of	IN	O	of	_	0	SENT_138	[p7l1294t3250r1323b3274],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_138	[p7l1330t3250r1455b3274],

1	Downloaded	VBN	O	download	_	0	SENT_139	[p7l378t3291r548b3314],
2	from	IN	O	from	_	0	SENT_139	[p7l557t3291r621b3314],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_139	[p7l630t3291r748b3321],
4	at	IN	O	at	_	0	SENT_139	[p7l759t3295r782b3314],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_139	[p7l790t3291r973b3314],
6	on	IN	O	on	_	0	SENT_139	[p7l982t3298r1015b3314],
7	January	NNP	DATE	January	prep_on	1	SENT_139	[p7l1023t3291r1126b3321],
8	5	CD	DATE	5	num	7	SENT_139	[p7l1136t3291r1159b3318],
9	,	,	DATE	,	_	0	SENT_139	[p7l1136t3291r1159b3318],
10	2014	CD	DATE	2014	num	7	SENT_139	[p7l1170t3291r1242b3314],
11	.	.	O	.	_	0	SENT_139	[p7l1170t3291r1242b3314],

1	For	IN	O	for	_	0	SENT_140	[p7l1252t3291r1299b3314],
2	personal	JJ	O	personal	amod	3	SENT_140	[p7l1307t3291r1419b3321],
3	use	NN	O	use	pobj	1	SENT_140	[p7l1428t3298r1472b3314],
4	only	RB	O	only	advmod	3	SENT_140	[p7l1482t3291r1546b3321],
5	.	.	O	.	_	0	SENT_140	[p7l1482t3291r1546b3321],

1	No	DT	O	no	det	3	SENT_141	[p7l1557t3291r1597b3314],
2	other	JJ	O	other	amod	3	SENT_141	[p7l1607t3291r1675b3314],
3	uses	NNS	O	use	_	0	SENT_141	[p7l1683t3298r1739b3314],
4	without	IN	O	without	_	0	SENT_141	[p7l1749t3291r1850b3314],
5	permission	NN	O	permission	prep_without	3	SENT_141	[p7l1859t3291r2011b3321],
6	.	.	O	.	_	0	SENT_141	[p7l1859t3291r2011b3321],

1	Copyright	NN	O	copyright	_	0	SENT_142	[p7l728t3332r863b3363],
2	©	CD	NUMBER	©	num	6	SENT_142	[p7l872t3332r896b3356],
3	2004	CD	DATE	2004	num	6	SENT_142	[p7l906t3332r971b3356],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_142	[p7l980t3332r1171b3356],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_142	[p7l1181t3332r1289b3356],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_142	[p7l1300t3332r1405b3363],
7	.	.	O	.	_	0	SENT_142	[p7l1300t3332r1405b3363],

1	All	DT	O	all	det	2	SENT_143	[p7l1416t3332r1457b3356],
2	rights	NNS	O	rights	nsubj	3	SENT_143	[p7l1466t3332r1541b3363],
3	reserved	VBN	O	reserve	_	0	SENT_143	[p7l1551t3332r1670b3356],
4	.	.	O	.	_	0	SENT_143	[p7l1551t3332r1670b3356],

